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 11 General introduction 
Introduction 
 
Eyes are immunologically privileged, which means that the immune system behaves in a different 
way than elsewhere in the body: the ocular environment tends to suppress immune reactions. This 
immune privilege is the main reason behind the success of allogeneic eg. corneal transplantations, as 
it leads to inhibition of the rejection of transplants. 
With regard to intraocular tumors, the ocular immune system places us for a paradigm: uveal 
melanoma (UM) is a tumor that develops inside the eye, but while the environment limits 
inflammation, tumors may contain a lot of infiltrating cells. However, in contrast with what one 
would expect in cancer, increased levels of infiltrating immune cells are associated with shorter 
instead of longer survival rates. In this case, a local immune response does not lead to tumor 
destruction, but local inflammation contributes to angiogenesis and is associated with the formation 
of metastases. 
Several different factors determine the effectiveness of immune responses. Human leukocyte 
antigens (HLAs) for instance play a central role in most immune responses by presenting antigens, 
which may be derived from a transplant or from tumor cells, to the immune system. It may well be 
that the HLA levels are differentially regulated in different tissues and that this will provide us with an 
answer how the environment influences the behaviour of the immune system. In this thesis, I will 
discuss relevant immunological, environmental and other factors, first by summarizing the aspects 
that are critical for biocompatibility and acceptance of corneal implants, and secondly by discussing 
the way the immune system and the environment are involved in UM.  
 
1. Immunology 
1.1 Immune responses 
The immune system protects the body against diseases by killing pathogens and tumor cells.  
The innate immune system is the first active line of defense once our body’s mechanical barriers 
have been breached. It reacts quickly, is non specific, and recruits immune cells to the site of danger 
using cytokines. The innate immune system subsequently activates the adaptive immune system by 
presenting antigens in the lymph nodes. The subsequent adaptive immune response is antigen-
specific and has immunological memory, specific for each pathogen: when a pathogen enters the 
body a second time, specific immune cells will eliminate it faster than the first time. This adaptive 
immune system is the second active line of defense and consists of two groups of immune cells: B-
cells and T-cells, both of which carry receptor molecules that recognize specific targets. The B-cell 
receptor is an antibody molecule that can recognize the pathogen in its free and generic form, while 
the T-cell receptor only recognizes processed pathogens presented as peptides by the HLA molecules 
of other cells.  
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1.2 Human Leukocyte Antigens (HLA) 
HLA antigens are necessary for the induction of immune responses, as well as for the immunological 
effector phase, as they present target peptides to helper as well as effector T cells. HLA antigens are 
divided into two classes: HLA Class I and Class II. HLA Class I antigens are derived from the three 
classical loci HLA-A, -B and -C and the non-classical loci HLA-E, -F, -G, -H, -I and -J. HLA molecules are 
expressed on platelets and almost all nucleated cells, except most cells of the central nervous 
system. The HLA Class I molecules present intracellular peptides to cytotoxic CD8-positive T cells 
during the effector phase. HLA Class II consists of three main genetic loci: HLA-DR, -DQ and -DP. 
eClass II molecules are expressed on some immune cells such as B cells and activated T cells, and 
especially on antigen-presenting cells such as the DCs, macrophages, and monocytes, as well on 
endothelial cells and thymic epithelial cells. The Class II molecules present peptides from exogenous 
antigens to the CD4+ helper T cells in order to start the induction of an immune response. Cytokines 
can modify the level of expression of Class I and II molecules. The HLA genes are the most 
polymorphic genes in the human genome, providing a great diversity of HLA alleles, with each 
specific allele having the ability to present certain antigens better or worse than other alleles. 
 
1.3 Immune privilege and corneal immune response 
The immune privilege of the eye is caused by an immunological threshold, which is due to a variety of 
immuno-evasive and immuno-suppressive mechanisms. Because many tissues in the eye are amitotic 
and therefore incapable of regeneration, the eye is very sensitive to injury, including damage caused 
by inflammation. The eye deploys several tactics to reduce damage, affecting the innate and adaptive 
immune system.1-6  Many blood vessels within the eye are non-fenestrated and contain tight 
junctions, restricting passage of inflammatory cells and macromolecules into the eye.7  Membrane-
bound molecules on the cells lining the interior of the eye induce apoptosis of invading activated T-
cells.8, 9  
In addition to these passive defenses against damage, an active system has been identified, known as 
Anterior Chamber-Associated Immune Deviation (ACAID): the aqueous humor of the eye contains 
soluble immunosuppressive and anti-inflammatory factors, such as TGF-β2, α-melanocyte-
stimulating hormone (α-MSH) and vasoactive intestinal peptide (VIP). (1, 10, 11 Exposure of antigen-
carrying macrophages to these factors and their subsequent migration to the spleen leads to the 
induction of regulator T cells (Tregs) that suppress both the afferent and efferent arms of the 
immune response.12  α-MSH inhibits delayed-type hypersensitivity, macrophages, and neutrophils 
and induces Tregs. VIP inhibits T-cell activation and proliferation, and inhibits the delayed-type 
hypersensitivity as well. 
The human cornea consists of five layers: from the front to the back they are the epithelium, 
Bowman’s membrane, stroma (containing the keratocytes), Descemet’s membrane, and the 
endothelium. The cornea serves as the window of our eye. The function of the epithelium is to 
protect the cornea from the outside world, while the stroma provides the cornea with strength and 
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elasticity to withstand pressure and trauma. The endothelium serves to pump fluid out of the cornea; 
failure to do so results in corneal swelling and haze and severely-reduced vision. This makes the 
endothelium a very sensitive part of the cornea, especially because endothelial cells hardly 
regenerate. 
The cornea exhibits some specific features which strenghten its immune-privileged status:  
1) Absence of corneal lymph and blood vessels and blockade of lymph vessel formation, 
together with a relative lack of lymphatic drainage from the eye, ensures that antigens can 
only leave the eye via the aqueous drainage system into the bloodstream.13  The aqueous 
outflow will carry antigens to the spleen, rather than the draining lymph nodes, which will 
then act as the primary lymphoid tissue.14  
2) The compact architecture of the corneal stroma is believed to inhibit the infiltration of 
immune cells, while the blood-aqueous barrier prevents immunologically-active cells and 
factors from entering the ocular tissue.14  Although functional antigen-presenting cells (APCs) 
are present in the peripheral and paracentral cornea, they are scarce and mostly immature in 
the healthy central cornea, resulting in weak local antigen presentation.15  
3) Corneal tissue by itself is able to produce cytokines that inhibit T cell responses.16   
4) Angiogenesis can occur, but several factors inhibit this. Endostatin is present and reduces 
VEGF receptor signaling. Intact epithelium expresses VEGF-receptor-3, which inhibits 
angiogenesis, possibly by catching the free VEGF molecules. Soluble VEGF receptor-1 in the 
extracellular matrix performs in the same way by binding VEGF-A before it can induse 
angiogenesis.17   
5) The epithelium and endothelium express Fas-ligand, which can induce apoptosis of T-cells 
and neutrophils,18 and Programmed Death-Ligand 1 (PD-L1) which inhibits T-cell 
proliferation, interferon-gamma (IFNG) secretion and induses apoptosis.19  
In the clinical setting, a local immune response elicited for example by surgery, is further tempered 
by topical corticosteroids applied to the cornea post-operatively or by oral immunosuppressives.20   
 
1.4 Human cornea allograft transplantation 
Due to its immune privilege, cornea allograft transplantation is one of the most successful types of 
solid organ transplantation, with one-year graft survival rates above 90%.21, 22  However, the 15-year 
graft acceptance rate is around 55%, which equals survival rates of other forms of solid organ 
transplantation.21  Graft failure is defined as the irreversible loss of a graft’s clarity. This can be due to 
immunological rejection, endothelial dysfunction, surgical trauma, infection or secondary 
glaucoma.23  The most common cause of transplant failure is rejection, accounting for 30% of the 
failures.21, 22  Rejection occurs because the host’s immune system attacks and gradually destroys the 
transplant. Several approaches can be exploited to reduce the rate of immune rejection, which are 
described in Chapter 1. 
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1.5 Alternatives for human cornea transplantation 
There is a worldwide shortage of human donor corneas, especially in developing countries.24, 25  
Furthermore, human donor corneas are expensive (around 3000 American dollars 26 ) and not suited 
for a hostile host environment, such as inflamed or severely neovascularized corneas. Therefore, 
research has taken place for over 100 years to discover alternatives for human donor corneas,27 and 
several alternatives exist. I will discuss the most well-known of these alternatives, which are either 
currently in use, or under investigation. 
 
1.6 Boston Keratoprosthesis 
The Boston Keratoprosthesis (BKpro), FDA approved since 1992, is a corneal implant, consisting of a 
front plate containing an optical cylinder and a plastic or titanium back plate that locks the optical 
cylinder in place. Between the front and back plate, a human donor cornea is inserted.28  Indications 
for use of the BKpro are cases of corneal blindness with failed grafts, significant corneal 
neovascularization, limbal stem cell deficiency, autoimmune disease or chemical injury.28  These 
patients should however have a healthy ocular surface in order to retain a bandage lens 
postoperatively.29  The BKpro still needs a human donor cornea, with its risk of rejection, and is 
rather expensive, although the developers of the BKpro are working towards cost reduction.30  
 
1.7 Osteo-Odonto-Keratoprosthesis  
The Osteo-Odonto-Keratoprosthesis (OOKP), described first in 1963,31 uses a tooth root and alveolar 
bone to support a centrally-implanted optical cylinder. For this, a labor-intensive, two-stage surgery 
is performed.32  First, the ocular surface (epithelium of the cornea and conjunctiva) is removed and 
replaced with buccal mucosa. During the same surgical procedure, the tooth is harvested and the 
optical cylinder is placed in its center, after which the tooth-optic is placed subcutaneously or 
submuscularly in the orbito-zygomatic area on the contralateral side to attain a fibrovascular coating. 
Secondly, the implant is explanted 2-4 months later, and sutured in place over the cornea, with the 
posterior optic protruding into the corneal opening, and the anterior optical cylinder protruding 
through the buccal mucosa covering the bulbus.  
Indications are bilateral corneal blindness due to several ocular and systemic pathologies such as end 
stage Stevens-Johnson Syndrome. The surgery however is performed usually only in one eye, keeping 
the other eye as a spare.32  
Although being the most successful and well-retained keratoprosthesis,33 the complexity of the 
surgery, its high cost, and it being indicated only for high risk patients, make it no real alternative to 
human donor cornea transplantation. 
 
1.8 Collagen-based cornea 
Collagen-based artificial corneas form another alternative for human corneal transplantation. They 
are largely three-dimensional scaffolds made from biomaterial, mimicking as well as possible the 
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human corneal stroma, which should upon grafting ultimately be repopulated by the host’s corneal 
cells.34-36  For anterior lamellar approaches, an acellular scaffold can be used, thereby reducing the 
chance of rejection. The most promising of these is the synthesized recombinant human collagen 
type III scaffold of Fagerholm, et al.35  A drawback of this synthesized scaffold is the difficult 
fabrication process;37  another one is the need for better tensile strength in order to be able to 
perform continuous suturing instead of overlaying sutures. 
Other fabricated constructs for regenerating the human cornea have not yet reached the clinical 
stage. Collagen-based alternatives for posterior lamellar or full-thickness approaches need viable 
endothelial cells on the posterior side in order to prevent stromal swelling,38, 39  or other means to 
prevent this swelling. The alternative posterior approaches will not be discussed here. 
 
1.9 Decullarized cornea 
Decellularized human corneas are basically also collagen-based scaffolds but, as one still needs a 
human donor cornea, their use does not decrease the lack of need for human tissues. A 
decellularized porcine corneal stroma is another option that is being explored 40 , but porcine tissue 
confers a risk of transmitting animal diseases.41  Screening may reduce that risk, but would come at a 
price.41  
 
1.10 Stem cell-based approaches 
Stem cell-based approaches are being explored to regenerate part of or even the whole cornea. The 
biggest challenge is to have the human cornea stromal cells, the keratocytes, secrete specific types of 
collagen as the orthogonally-arranged multilayered lamellae are needed for the corneal transparency 
and strength. For this, human corneal stromal stem cells (hCSSCs) are being used, which under 
specific culture conditions can differentiate into cells similar to keratocytes, which secrete an 
extracellular matrix that mimics the corneal stroma.42, 43  These hCSSCs may also have potency to 
restore the disrupted collagen fiber organization of scarred corneal stroma,44  or can induce stromal 
healing without scar formation when implanted directly after damage.45  
 
1.11 Other scaffold materials 
Asides from the keratoprosthesis, collagen scaffolds and stem cell approach, other materials are also 
being explored as scaffolds for corneal cells in order to regenerate the human cornea. Among these 
materials is the electrospun gelatin nanofiber scaffold of Tonsomboon et al.,46  a two-component 
scaffold with a central core of poly(ethylene glycol)/poly(acrylic acid) (PEG/PAA) covered with 
collagen type I and a microperforated poly(hydroxyethyl acrylate) (PHEA) hydrogel skirt with the 
surface covered with collagen type I.47  Also, scaffolds made from silk are being developed.48  
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1.12 Requirements of an artificial cornea 
As described above, the cornea consists of five main layers. The layer that is in contact with air is the 
epithelium, which is gradually replaced every 7-14 days by proliferation and subsequent 
differentiation of the basal cells. The basal cells themselves are also constantly replaced by cells 
origination from the limbal stem cell niche, and migrate from the peripheral cornea towards the 
center.49-51  The stroma makes up 90% of the total corneal thickness, which measures around 520-
540 um at the center,52, 53  and up to around 610 um at the periphery.53, 54  It is a mainly acellular 
layer with only 3-10% of its volume consisting of quiescent keratocytes.55  The cornea’s transparency 
and its strength are due to the specific arrangement and uniformity of its collagen fibers and the 
dehydration state.56-59  The collagen fibers are mostly type I, but type V, VI and XII are also present.60  
The diameter of these fibers is a uniform 31-34 nm,55, 61, 62  and their diameter is around 22.7 nm ± 
1.8 nm in a study of corneas immediately fixid after surgery,59 with an interfibril spacing of around 20 
nm, maintained by collagens and proteoglycans.59 This, together with the cornea being the window 
of the eye, brings us to the requirements of an artificial cornea based on a collagen scaffold, as 
shown in Table 1.  
We decided to focus on an anterior approach, leaving the endothelium intact. In Chapter 2, we focus 
on the first results of a fish-scale derived collagen matrix (FSCM), a scaffold with high water content 
and a good oxygen permeability as the basis for corneal regeneration.63  
We describe the results of light scatter and transmission, and the first short-term in vivo experiments 
in rats. 
 
Table 1 Requirements of an artificial cornea 
Light transmission  ± 91% 64  
Forward light scatter range 0.9 (healthy young) - 1.5 (old) log(s)65  
Water content ± 78% 66  
Oxygen permeability ± 29 x 10-11 (cm2 x ml O2)/(sec x ml x mmHg)
67
  
Glucose permeability ± 2.5 - 3.0 x10-6 68  
Albumin permeability albumin permeability ± 2.1 - 4.1 x10-8 69  
Young’s Modulus (elasticity) ± 3-13 MPa 70  
Tensile strength ± 3.8 MPa 71  
Suturable  
Not immunogenic  
No immune sensitization  
Facilitates reepithelialization on anterior side  
Allows tissue incorporation or tissue attachment  
Facilitates endothelium attachment on posterior side *In case of penetrating keratoplasty 
 
 17 General introduction 
In this paper, we put emphasis on the implantation technique and immune responses. In Chapter 3, 
we describe the in vitro results of co-cultures between cornea cells and the FSCM, and additional in 
vivo experiments with longer follow up. Using in vivo experiments, we analyze the behavior, immune 
response and possibility of sensitization against the FSCM, and compare the results to another matrix 
already used in ocular surgery, and to sham surgery. Additionally, we determine the tensile strength 
and glucose permeability of the fish scale collagen matrix.  
A review of the role of the immune system and matching for the major histocompatibility antigens in 
corneal transplantation follows in Chapter 4. 
 
2. Uveal melanoma 
While local immune privilege allows acceptance of corneal transplants, lack of an effective immune 
response against tumor cells may play a role in the outgrowth of malignant melanoma cells inside the 
eye. UM is the most common intraocular tumor in adults with an incidence that ranges from 4.3 to 
10.9 per million,72-75  with the higher incidence being in areas populated by whites.76  Up to 50% of 
the patients with large tumors that need enucleation may develop metastases which are almost 
always fatal.77  The 5-year survival of all cases remains around 69-78%, death is usually due to 
metastasis.72, 78  Over the last decades, survival has not improved.73  
UM has its origin in the melanocytes of the uveal tract, which consists of the choroid, ciliary body and 
the iris. Most tumors are located in the choroid (86%).76  
Risk factors for developing UM are congenital ocular and oculodermal melanocytosis (nevus of Ota) 
with a lifetime risk of developing UM of 1 in 400.79  Other risk factors for the development of UM are 
light eye color, fair skin, and inability to tan, 80 , and the presence of a veal nevus. Uveal nevi occur in 
5-8% of whites, but only 1 in 8845 nevi transform into UM.79  However, 18% of extraordinarily large 
nevi (≥10mm in diameter) progresses into melanoma over 10 years.81   
Once a patient has been diagnosed with primary UM, the chance to develop metastasis can be 
calculated using several parameters. UM metastasises haematogenously unless it invades the 
conjunctiva, in which case it can spread to regional lymph nodes; this is extremely rare.82  
Prognostic factors include largest basal diameter, thickness of the tumor, ciliary body involvement 
and extrascleral extension.82  Other prognostic factors are cell type (epithelioid or spindle), non-
random chromosomal aberrations or the gene-expression profile of the tumor. A shorter survival is 
seen in patients with epithelioid cell type, loss of the whole chromosome 3, gain of the long arm of 
chromosome 8, and the gene-expression profile class 2 (as based on 15 genes).83-85  Several factors 
are combined into the TNM-classification which is based on the size of the primary tumor, 
involvement of the ciliary body, extraocular extension, and the presence of metastases.86  Adding 
chromosome status to the TNM class adds precision.87   
Local treatment of the primary tumor, in case of absent metastasis, has good results, but it seems to 
have no impact on the metastasis rate. Possible treatments of the primary tumor include 
brachytherapy (for tumors ≤ 10 mm thickness) and proton-beam radiation, which carry equal 
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outcomes with enucleation.88-90  When the tumor is too large for radiation, enucleation remains the 
treatment of choice.90  
There is no effective treatment of metastasized disease, although several modalities have been tried 
and are still under investigation. 
 
2.1 Link between HLA, inflammation and UM 
It is an intriguing finding that in UM, the presence of an increased level of infiltrating immune cells 
does not prevent, but seems to stimulate tumor progression. If we solve the mechanism behind this 
phenomenon, we may find therapies to attack and destroy the metastasis and be able to prevent 
progression and subsequently, the patients’ death. 
It is known that cancer cells can use immune evasion in order to survive.91  It has been assumed that 
the most common method a tumor deploys to escape from T-cells is reducing its antigen expression 
by down-regulating the expression of its HLA molecules.91, 92  This is certainly not the case in UM, as a 
higher death rate is associated with an increased HLA expression.93-95  
However, other mechanisms exist, such as alterations in the expressed subtypes of HLA molecules, 
or, for example, expression of non-classical instead of classical HLA molecules. Natural Killer (NK) 
cells specifically attack cells without HLA Class I, and tumor cells with a high HLA Class I can evade NK-
cell-mediated killing while coursing through the blood. Other escape mechanisms are immune 
evasion through defect death receptor signaling, lack of co-stimulation or the secretion of 
immunosuppressive cytokines and attraction of immunosuppressive T-cells.91  An example of creating 
a favorable immune microenvironment for tumor growth is the attraction of tumor-associated 
macrophages (TAMs), of which the M2 type is known to play a role in promoting angiogenesis and 
inhibiting immune responses.96   
In UM, important immunological parameters associated with prognosis are lymphocyte (97  and 
macrophage infiltration.98 High numbers of tumor-infiltrating CD68+ and CD163+ (M2) macrophages 
are associated with an unfavorable prognosis,96, 98, 99  and CD68+ (M1) macrophages have been 
associated with increased HLA Class I and II expression.100  
 
2.2 HLA genotype and UM 
We have focused mainly on the role and function of HLA in UM. We already know that in UM, tumors 
which metastasize have an increased expression of HLA molecules compared to those which do 
not.100  Other studies have shown that HLA polymorphisms may mediate susceptibility to certain 
cancers,101, 102  and a possible connection between HLA-B40 or B44 with metastasis in UM has been 
suggested.103, 104  There are also several specific associations between HLA antigens and ocular 
diseases, of which especially those in which pigment is somehow involved are of interest. Birdshot 
Chorioretinopathy (BCR), which is characterized by multiple hypopigmented chorioretinal lesions, is 
associated with HLA-A29.105  Vogt-Koyanagi-Harada syndrome (VKH), a bilateral, chronic, diffuse 
panuveitis in which late stage depigmentation of the fundus occurs, has a genetic association with 
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HLA-DR4.106 Using this as a starting point, we set out to investigate, whether a person’s specific HLA 
genotype may predict the amount of HLA expression in UM or may be indicative for the level of 
inflammation in this malignancy. 
 
2.3 HLA regulation, prognostic factors and UM 
The genes encoding the HLA Class I and Class II antigens are located on chromosome 6p. Generally, 
chromosomal gain leads to an increased expression of the genes on that chromosome in tumors.107, 
108  This places us for an intriguing paradox in UM, as gain of chromosome 6p in tumor cells is 
associated with a good prognosis, while an increase in HLA Class I and II expression is associated with 
a poor prognosis.  
Several other factors beyond gene dosage influence the level of HLA expression. First of all, to be 
functional, the HLA molecules should reach the cell surface. This requires a properly-functioning 
peptide-loading system.109  Second, transcription of the HLA genes is regulated by several genes, such 
as NLRC5 and CIITA. NLRC5 plays a crucial role in the transcriptional regulation of HLA Class I genes,110 
and CIITA in the transcriptional regulation of the HLA Class II genes,111  while it is also involved in HLA 
Class I transcriptional activation.112  The promoters NLRC5 and CIITA are in turn influenced by, 
amongst others, the interferon-regulatory factor 1 (IRF1).113  CIITA is silenced by EZH2 (Enhancer of 
Zeste Homologue 2, a Polycomb Repressive Complex 2 subunit; chr7q).114  
Not only these transcriptional regulators influence HLA Class I and Class II expression, but also 
external influences. Interferon-gamma (IFNG) stimulation is known to increase the level of HLA Class I 
and Class II in UM cell lines.114, 115  Down-regulation of HLA expression on cell lines may be induced by 
tumor growth factor beta (TGFB).115, 116   
Without HLA molecules, T-cells cannot react to and subsequently destroy their target cells.117  This 
underlines the importance of determining whether HLA expression in UM cells functions properly, 
and how it is regulated. We therefore investigated in primary enucleated tumors, instead of cell 
lines, whether chromosomal dose effects or specific known regulators influence HLA gene or protein 
expression in UM. The outcome is described in Chapter 6. We also analyzed the influence of the 
genes encoding for the peptide-loading system molecules. Lastly, we assessed the possible influence 
of the microenvironment on HLA gene expression by comparing expression levels in human primary 
or metastatic UM with their corresponding xenografts placed in mice, which lack tumor-infiltrating 
leukocytes. 
 
2.4  M1 and M2 macrophages 
As said earlier, UM creates a tumor promoting microenvironment, in which M2 macrophages play a 
important role. TAM promote tumor growth, angiogenesis, metastasis and induce 
immunosuppression. These functions contrast with the M1 macrophages which are known to have 
anti-tumoral activity. 
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The microenvironment in which the macrophages reside induces the polarization towards either an 
M1 or M2 type. The M2 macrophages are induced by interleukin-4 (IL-4), IL-10 and IL-13,118 ( as well 
as macrophage colony-stimulating factor (M-CSF) and CC chemokine ligand-2 (CCL2).119, 120  M2 
macrophages express HLA Class II at a lower level than M1 macrophages, 121  and are insufficient for 
antigen presentation.122 . They produce also IL-10 themselves as wel as TGF-β, and help to maintain 
the tumor promoting environment.  
The tumor promoting environment is a result of the complex interplay between tumor cells, 
regulatory T-cells and macrophages, which possibly can be influenced for example by 
immunotherapy. This may skew the polarization towards the proinflammatory M1 type.123  
 
2.5 BAP1 and UM 
To broaden our scope, we looked at new prognostic factors for UM. This could provide us with new 
clues of how UM evade destruction by the immune cells. Harbour et al. demonstrated that loss of 
one copy of chromosome 3 in combination with inactivating mutations in the gene encoding BAP1 
(BRCA1-associated protein 1) on the remaining copy of chromosome 3, is associated with 
metastasis.124  BAP1 exerts a tumor suppression function, and is a deubiquitinating enzyme of the 
polycomp-group proteins of transcriptional repressors.125-127  We determined how expression of 
BAP1 at the mRNA or protein level was related to prognosis (chapter 7). A subsequent study has 
shown that loss of BAP1 is strongly associated with tumor infiltration with lymphocytes, suggesting 
that BAP1 is an immune response regulator.128   
 
3. This thesis 
This thesis looks at the effect of the ocular environment on two important areas: can we develop a 
new biocornea that may be used to replace a damaged human cornea, and can we find out how to 
modulate the cells of UM to find ways to prevent or treat metastases? The link between the two is 
the role of HLA antigens in rejection and inflammation, as these are essential for inducing an immune 
response as well as for the effector phase. 
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Abstract 
 
Purpose: A fish scale–derived collagen matrix (FSCM) is proposed as an alternative for human donor 
corneal tissue. Light scatter and light transmission of the FSCM were measured and compared with 
human cornea, and its short-term biocompatibility was tested in a rat model. 
 
Methods: Light scatter was determined with a straylight measuring device, whereas light 
transmission was measured using a broadband absorption spectrometer. For evaluation of the 
biocompatibiliy, three approaches were used: the FSCM was implanted as an anterior lamellar 
keratoplasty (ALK), placed in an interlamellar corneal pocket (IL), and placed subconjunctivally (SC). 
Transparency, neovascularization, and epithelial damage were followed for 21 days. Morphology and 
cellular infiltration were assessed histologically. 
 
Results: The amount of scattered light was comparable to that seen in early cataract and the 
percentage of light transmission was similar to the transmission through the human cornea. 
Implantation of the FSCM as an ALK led to mild haziness only, not obscuring the pupil, despite the 
development of neovascularization around the sutures; IL placement led to a moderate haze, partly 
obscuring the pupil, and to (partial) melting of the anterior corneal lamella. The SC group exhibited 
local swelling and induration, which decreased over time. Histology showed a chronic inflammation 
varying from mild and moderate in the ALK and IL group, to severe in the SC group. 
 
Conclusions: In spite of technical difficulties, it was feasible to use the FSCM for ALK, whereas IL 
placement led to melting of the anterior lamella. Further studies are necessary for better 
understanding of its immunogenicity. The light scatter and transmission data show that the first 
version of this FSCM is comparable to human cornea tissue in this respect. 
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Introduction 
 
Corneal disease is a major cause of blindness worldwide, second only to cataract. Globally, more than 
10 million individuals are bilaterally blind due to corneal pathology and even more unilaterally.1 
Corneal transplantation is presently the only option to restore vision in these patients. Full-thickness 
corneal transplantation is one of the most successful forms of tissue transplantation and has been 
performed since 1905. One year after transplantation, the success rate is excellent in low-risk cases 
(avascular corneas). However, at longer follow-up, the overall acceptance of the grafts declines, 
particularly in high-risk cases.2–5 The worldwide demand for human donor corneas, however, exceeds 
the world’s supply, especially in developing countries.6 Artificial corneal substitutes have emerged to 
counter this shortage and overcome the disadvantages of human donor corneas, including immune 
rejection. These corneal substitutes range from completely synthetic prostheses, which primarily aim 
to restore the cornea’s refractive function,7,8 and tissue-engineered cell-based constructs,9 to 
hydrogels and scaffolds that facilitate the regeneration of the host tissue.10–12 
Although much progress has been realized, keratoprostheses have not reached widespread use.8 At 
the moment, they are too expensive and complex for routine use in developing countries, where the 
need for implants is highest. Alternatively, biological explants are being developed and tissue-
engineered corneal epithelial cell sheets have been successfully transplanted in patients.13–15 As 
corneal pathology often extends beyond the epithelium and affects the corneal stroma as well, 
replacement of the corneal stroma is usually necessary. To replace the corneal stroma, a cell-based 
construct or polymer scaffold of sufficient thickness is needed. 
Ideally, such a scaffold for corneal regeneration allows reepithelialization, endothelialization, and 
repopulation with interstitial cells and nerves, preferably all of the patient’s own origin. However, 
human corneal endothelium hardly regenerates. For many corneal opacities without endothelial 
involvement, procedures that preserve the recipient’s endothelium are used, such as anterior 
lamellar keratoplasty (ALK) and deep ALK (DALK). These anterior keratoplasties result in much better 
graft survival than the full-thickness grafts in penetrating keratoplasty (PK).16–18 The anterior lamellar 
approach is therefore a logical starting point for scaffold-based corneal regeneration. In 2010, this 
approach was studied with a biosynthetic implant in a phase I clinical trial with 10 patients. Corneal 
regeneration with restored vision and sensitivity was found after 24 months of follow-up,19 proving 
potential of this concept. The biosynthetic implant was synthesized from human recombined 
collagen type I, which is an elaborate and rather expensive procedure, and despite the claimed 
success in this study, no new trials have started so far. Collagen scaffolds that already exist in nature 
may reduce the cost of fabrication and promise a sufficient resource for clinical transplantation even 
in developing countries. A decellularized porcine corneal matrix as a xenographic scaffold for corneal 
regeneration has been studied for several years by several research groups, as it closely resembles 
the human corneal stromal organization.12,20,21 Indeed, such porcine matrices may offer a relative 
inexpensive and widely available alternative to human donor corneas. Results from clinical trials are 
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not yet available, but a first phase I clinical trial is currently running.22 Collagen matrices that are even 
more widely available, easier to harvest, and at lower expense, therefore definitely offer an 
interesting alternative, and this is the topic of our study. 
Here we present the results of a matrix made from naturally occurring collagen type I and obtained 
from scales of the tilapia fish. Tilapia (Oreochromis mossambicus) are farmed for consumption under 
controlled circumstances23 and the specific size of the fish can be selected on harvesting. Their scales 
consist of parallel-arranged collagen fibers packed in layers oriented approximately 90 degrees,24 
mimicking the human corneal stroma. This scaffold supports the growth of corneal cells and is highly 
permeable for oxygen.25 Moreover, collagen sponges fabricated from reconstituted collagen fibers 
from tilapia scales produce only rare inflammatory responses in vivo.26 
To investigate the suitability of this fish scale–derived collagen matrix (FSCM) for use as an artificial 
cornea, the light-scatter and light-transmission properties were examined. Also, in vivo studies were 
performed, using the rat keratoplasty model, widely employed for corneal transplantation studies.27 
We investigated the short-term biocompatibility and handling of the FSCM in three different surgical 




Fish Scale-Derived Artificial Cornea 
A ±250 µm-thick decellularized and decalcified fish scale–derived extracellular matrix (ECM), 
consisting of collagen type I, was used for implantation (7-mm diameter, 0.2–0.3 mm thickness, 
P09011001; Aeon Astron Europe, Leiden, The Netherlands) (Fig. 1).25 In short, fresh tilapia scales 
were cleaned in distilled water and cellular components were removed using a four-step detergent 
and enzymatic extraction process as developed by Courtman et al.28 Acetic acid was used to increase 
pore size and porosity and nitric acid to decalcify the fish scales. The decellularized and decalcified 
scales were rinsed with 70% ethanol and stored until use in sterilized PBS at 48C. 
 
Figure 1. The fish scale–derived collagen matrix. 
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Top Pattern, Light Scatter, and Transmission 
Phase-contrast images (Axio Observer.A1; Carl Zeiss AG, Jena, Germany) were taken of the prepared 
fish scale–derived collagen scaffold and used to create a composition photograph in Adobe 
Photoshop (CS3 Extended, version 10.0; Adobe Systems Incorporated, San Jose, CA) to visualize the 
whole top surface. Scanning electron microscope images were taken of the cutting edge of the 
prepared FSCM and of the micro pattern on the top surface. 
To measure forward light scatter, we chose a similar approach as is used clinically to assess the 
functional effect of forward light scatter in patients.29 This way, the ex vivo results can directly be 
compared with clinical in vivo results. We applied a psychophysical technique known as 
‘‘compensation comparison’’ and the outcome value is the straylight parameter‘s.30 This technique is 
implemented in a commercial instrument (C-Quant; Oculus GmbH, Wetzlar, Germany) for clinical 
use, measuring the light scatter between 5 and 10 degrees, which has proved representative for the 
total amount of straylight (light scatter ≥1). We used this instrument, with a slight adaption, to assess 
forward light scatter from physical samples.31 In short, two stimuli of the compensation comparison 
method, straylight flicker and comparison flicker, are presented to and compared by the subject 
simultaneously. To exclude the influence of light scatter provoked by the observer’s eye and to 
measure only the light scatter caused by the matrix, the straylight flicker source itself was shielded in 
such a way that it illuminated only the tested sample.31 Three FSCMs (P11251101; 8.0 ± 0.8 mm 
[diameter], 0.25–0.35 mm [thickness]) were put on a test glass, one drop of PBS was used to prevent 
dehydration, and a cover glass was put on top. A black, opaque disk, with a central hole of 6.5-mm 
diameter, was mounted over the test glass, leaving only the FSCM visible. The test glass, with the 
FSCM and black opaque disk, was put in the ocular of the C-Quant device to measure the light 
scatter. Three measurements per FSCM were performed. A holder containing PBS without an FSCM 
acted as a control experiment. 
To measure light transmission, three FSCMs (P11251101; 8.0 ± 0.8 mm [diameter], 0.25–0.35 mm 
[thickness]), placed in a sample holder and kept hydrated with PBS, were studied by a broadband 
absorption spectrometer, covering the visible and near infrared spectrum with a spectral resolution 
of 0.55 nm. Details are available from Bouwman et al.32 The setup comprised a light source (LOT Oriel 
Xe-arc; 300 µm filament; LOT-QuantumDesign GmbH, Darmstadt, Germany) and spectrometer 
(Andor Shamrock SR-303i; Andor Technology PLC, Belfast, UK). The light source emitted white light 
with a homogeneous intensity pattern in the 200- to 760-nm region, fully covering the wavelength 
domain relevant to the human eye. This light was guided via a diaphragm through the center of the 
FSCM, which was placed 15 cm from the 10 µm wide inlet of the spectrometer. The sensor of the 
spectrometer measured light only in the horizontal plane. The maximum angle at which light could 
enter the spectrometer was 0.004 degrees. The spectrometer measured the direct light transmission, 
as straylight is defined as light being scattered at 1 or more degrees. All measurements were taken 
relative to atmospheric air and normalized for background light. Normalization and measurement of 
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transmission values for empty space were performed directly before each individual measurement. A 
holder containing only PBS was used to correct for light absorption or scatter caused by the holder 
itself. The light transmission of the visible spectrum was measured in steps of 0.56-nm wavelength 
and compared with the total light transmission of the human cornea, using the formula of van den 
Berg and Tan.33 
 
Suturing 
Two human donor eyes, obtained from the Euro Cornea Bank (Beverwijk, The Netherlands), were 
used to test the suturability of the scaffolds with nylon 10/0 sutures (nr. 8065 198001; Alcon B.V., 
Gorinchem, The Netherlands). In short, two FSCMs of 6-mm diameter were sutured into human 
corneas, 1 day postmortem, by placing 12 interrupted sutures in one case and continuous suture in 




Eighteen male Fischer 344/DuCrl albino rats (Charles River Laboratory, L’Arbresle Cedex, France), 
each weighing between 280 and 336 g, were used for ocular implantation with permission of the 
Animal Ethics Committee of the Leiden University Medical Center. All animals were treated in 
accordance with the ARVO Statement for Use of Animals in Ophthalmic and Vision Research. They 
were given 1 week to acclimatize. 
 
Implantation 
The rats were divided into three groups of six animals, and in order to determine biocompatibility, 
scaffolds were placed in the anterior eye. In the first group, the FSCM, with the pattern on top, was 
placed as an ALK. In the second group, the FSCM was placed in an intralamellar pocket (IL), and in the 
last group it was inserted subconjunctivally (SC). The rats were anesthetized with isoflurane, with the 
addition of a topical drop of oxybuprocain and a subconjunctival injection of 20 µL bupivacain. Prior 
to implantation, the FSCM was soaked for 5 minutes in antibiotics (polyspectran containing 
gramicidine, neomycine, and polymyxine B). 
ALK was performed by trephination of the right eye using a 3-mm trephine. The anterior tissue was 
removed using an air bubble, lamellar dissector, and scissors. The FSCM was cut to a diameter of 3.2 
mm, inserted, and attached with eight nylon 10/0 sutures (nr. 8065 198001; Alcon B.V.). The surface 
of the FSCM was carefully leveled to line up with the native epithelium. 
For the IL group, a nonpenetrating incision was made with a 158 stab knife and a pocket was created 
using an air bubble and a lamellar dissector. An FSCM with a diameter of 2.7 mm was inserted and 
the pocket was closed with two 10/0 nylon sutures. 
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SC implantation was performed by making an incision with a 158 stab knife. A blunt spatula was used 
to create a subconjunctival pocket, into which an FSCM with a diameter of 2.7 mm was inserted; the 
pocket was closed with two 10/0 nylon sutures. 
Dehydration of the eye during surgery was prevented by regular wetting of the eye with special eye 
washings (balanced salt solution, 907553; Pharmacy LUMC, Leiden, The Netherlands). Directly after 
surgery, 1% chloramphenicol ointment (Chloramphenicol-POS 1%, 10 mg/g; Ursapharm Benelux B.V., 
Helmond, The Netherlands) was applied. In all cases, the unoperated left eye served as a control and 
was kept hydrated with gel (Vidisic Carbogel, carbomer 2 mg/g; Tramedico B.V., Weesp, The 
Netherlands) to prevent dryness during surgery. 
 
In Vivo Observation 
The animals were observed in the 3 weeks following implantation. Ocular drops with corticosteroids 
and antibiotics (Tobradex, containing dexamethasone and tobramycine; Alcon Cusi SA, Barcelona, 
Spain) were applied in the ALK and IL groups, once daily during the first week and every other day 
during the second week. All drops were stopped at the 2-week follow-up. The SC group did not 
receive any drops postoperatively. 
At 2, 7, 13, and 21 days after implantation, all animals were examined with a microscope to judge 
neovascularization, transparency, and clinical signs of inflammation, such as conjunctival redness or 
purulent secretion. Corneal neovascularization was numerically scored from 0 to 5, with 0 no vessels, 
1 growth of vessels at the limbus, 2 vessels reaching the sutures/FSCM, 3 vessels present underneath 
the FSCM, 4 vessels entering the FSCM, and 5 vessels present throughout the whole FSCM. 
Transparency of the cornea was assessed using a grading scale as previously used by Hackett et al.,34 
with 0 = transparent, 1 = a mild haze not obscuring the pupil, 2 = a moderate haze partially obscuring 
the pupil, and 3 = an opaque area totally obscuring the pupil. 
 
Histopathological Evaluation 
After euthanizing the 16 rats with carbon dioxide, the eyes were enucleated and fixated with 
Davidson solution (composed of glacial acetic acid, ethyl alcohol, and buffered formalin) and then 
dehydrated and embedded in paraffin. Sections were cut on a microtome (Leica RM2165; Leica 
Microsystems GmbH, Wetzlar, Germany) at 5 lm and stained with hematoxylin and eosin (HE) for 
histological examination. All eyes were analyzed for the organization of the epithelium, stroma, and 
endothelium, and scored semiquantitatively for infiltration of immune cells and ingrowth of corneal 
cells into the FSCM. The immune infiltrate was characterized based on morphology. 
 
Statistical Analysis 
All statistical analyses were performed using a statistical software program (SPSS for Microsoft 
Windows, version 17.0.2; IBM SPSS Statistics, IBM Corporation, Chicago, IL). The χ2 trend test was 
used for assessing differences between the groups regarding corneal neovascularization and 
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opacification, and leukocyte infiltration. Statistical significance was assumed for resulting P values 




Top Pattern, Light Scatter, and Light Transmission 
The whole top surface of the FSCM was visualized with a composed phase-contrast image. The micro 
pattern on top of the FSCM differed per area, with roughly one quarter having a spider-web 
appearance with micro ridges and channels, two quarters exhibiting circular running ridges and 
channels, but without intersecting lines, and the last quarter consisting of spikes (Fig. 2a). SEM 
images of the FSCM confirmed these findings (Figs. 2b–d). The micro ridges were wavelike in shape, 





Figure 2. Composition of several phase-contrast images showing the distribution of the micro pattern with the spokes and 
interconnecting channels in one quadrant (a-1), the spikes in the opposite quarter (a-2), and the circular running lines in the 
area (a-3) between those two quadrants. Detailed SEM-images depict the transitional area between the circular lines and 
spikes (b), between the lines and spokes (d), and a cross section showing the multiple layers (c). 
 
 
The amount of straylight was measured for three FSCMs using the compensation comparison 
method. Log values for forward light scatter caused by the holding device were beyond the lowest 
measurable value for the C-Quant device (log [s] < 0.40) and were considered to be negligible. The 
mean light scatter of the three FSCMs was log (s) = 1.62. All results are listed in Table 1.  
Direct light transmission of the visible spectrum was measured on another three FSCMs. The mean 
direct light transmission of the three measured FSCMs, corrected for reduction of light transmission 
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Figure 3. Cross section of the FSCM showing the dimensions of the circular running ridges on the surface. 
 
 
caused by the PBS-filled holder, amounted to 89%, 97%, and 85% and showed corresponding curved 
graphs (Fig. 4a). The three measurements were grouped and compared with the total light-
transmission curve of the human cornea (Fig. 4b). The human corneal light transmission values were 
within the SEM of the FSCM light-transmission values. The mean direct light transmission of the 
FSCM was 90%, whereas the total light transmission of the human cornea was 91%.33 
 
 
Table 1. Forward Light Scatter Results in Log(s) With Oculus (C-Quant) 
Measurements First Second Third Mean 
FSCM 1 1.50 1.53 1.46 1.50 
FSCM 2 1.66 1.69 1.74 1.70 
FSCM 3 1.62 1.65 1.63 1.63 




Suturing tests with the two FSCMs revealed in both methods no tearing at the suture points and the 
knots could be buried. On bringing in the suture needle, confined cracking occurred. Micro-shearing 
at the suture points of the FSCM (and not of the human cornea) was observed on tightening some of 
the knots. 
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Short-Term Biocompatibility 
To determine the scaffold’s biocompatibility, FSCMs were placed in the cornea as ALKs, placed 
intracorneally (intralamellar pockets) and placed subconjunctivally. 
One week following transplantation, all six rats that underwent ALK had a clear and quiet cornea, 
with minimal neovascularization in maximally one quadrant. After 2 weeks, the scaffolds remained in 
place, while neovascularization was reaching the FSCM. In five cases, a mild haze at the edge of the 
FSCM, not obscuring the pupil, was observed, and in the sixth animal, the haze partially obscured the 
pupil. Sutures started to loosen slightly in all cases. At the 3-week end point, the neovascularization 
extended underneath the FSCM with vessels aimed at the sutures, but not penetrating the FSCM. 
The haze increased slightly, not obscuring the pupil. Gradual loosening of the sutures resulted in loss 
of the FSCM in two cases at day 18 and 21, as the rats were allowed to move freely and touch their 
eyes. These cases were excluded from further analysis. 
During follow-up, the eyes were stained with fluorescein to analyze epithelialization. In the ALK 
group, the total area of the FSCM stained positively, indicating the absence of reepithelialization of 
the FSCM surface after 3 weeks. 
Implantation in an intralamellar pocket was performed in six rats. The results were less uniform than 
found for the ALK implants. After 1 week, two cases showed no haze, two cases exhibited a mild haze 
that did not obscure the pupil, and the remaining two rats showed a moderate haze, partially 
obscuring the pupil. In four cases, blood vessels approached the sutures located near the limbus. All 
sutures were removed after 1 week. After 2 weeks, superficial vessels reached the FSCM. The 
amount of haze remained stable, while some melting of the anterior lamella in front of the FSCM was 
noticed in five animals. Two animals were killed at 13 and 19 days postimplantation due to too much 
weight loss. When the 3-week end point was reached, blood vessels reached the FSCM in the 
remaining four animals, with some vessels starting to invade the over-or underlying stroma. Vessels 
did not invade the matrix and were less dense than in the ALK group. 
 
 
Figure 4. Direct light-transmission curves for the visible spectrum of three FSCMs (a), and the mean direct light transmission 
of the FSCM compared with the total light transmission of the human cornea (b). HC, human cornea. 
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After 3 weeks, the corneal haziness had slightly increased in three animals, ranging from a mild haze 
to an opaque area totally obscuring the pupil. In one case, however, the neovascularization had 
diminished and remained present only in the limbal area and a moderate corneal haze was observed. 
Corneal fluorescein staining revealed melted areas of the anterior lamella of variable size in all four 
remaining cases. 
The six rats receiving an SC implant showed slight SC swelling postoperatively at the implantation 
site. The swelling disappeared after 2 weeks in four rats and lasted until the end point in two rats. 
Local conjunctival hyperemia was present at a low degree until the end point. Sutures were not 
removed, as within 1 week the sutures were overgrown by the conjunctiva and removal without 
damaging the surrounding area proved to be difficult. 
 
Overall 
Except for the two cases mentioned, all implanted animals were in good health, kept their weight, 
and showed no symptoms of any ocular infection or noticeable irritation. The FSCM flattened the 
recipient rat cornea due to a curvature disassociation. End point neovascularization and opacification 
(Figs. 5a, 5b) did not differ significantly (P = 0.46 and P = 0.19, respectively) between the ALK and IL 
groups. Typical cases of each implantation model are depicted in Figure 6. An overview of in vivo and 
histological characteristics is given in Table 2. 
 
Histopathological Evaluation 
To visualize the clinically observed changes with histology, sections of the four scaffold-containing 
corneas in the ALK group were cut, stained with HE, and compared with the control lateral eye (Figs. 
7a, 7b). HE staining showed mild corneal edema with blood vessels and infiltrating leukocytes in the 
stroma around the sutures and at a lower degree under the FSCM (Figs. 7c, 7d). A few leukocytes 
were seen within the FSCM. The leukocytes showed a typically chronic inflammatory reaction with 
mainly macrophages and lymphocytes and some neutrophils. Epithelial downgrowth occurred in all 
cases at the border of the FSCM. At the location of the sutures and at the border of the FSCM, the 
epithelium showed hyperplasia and metaplasia. 
HE staining of the four cases of the IL group showed infiltration of immune cells, which consisted of 
the typical mixture with macrophages, lymphocytes, and some neutrophils. A few leukocytes were 
found within the FSCM (Fig. 7e). Local edema, metaplasia, and necrotic cells of the epithelium 
overlying the FSCM were observed in three of the four cases (Figs. 7e, 7f). However, one of the 
implants had no leukocytes or blood vessels infiltrating the stroma (Fig. 7f) and the other only a few 
(not shown). This corresponded with the in vivo observations (Figs. 6f–j). Infiltration of immune cells 
was not significantly different between the ALK and IL groups (P = 0.57) (Fig. 8). 
The SC implants were completely surrounded by leukocytes in all six cases, with several leukocytes 
invading the FSCM. The leukocyte infiltration was limited to the adjacent surrounding tissue, again   
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representing chronic inflammation. The SC group showed significantly more infiltration than the ALK 
group (P = 0.04) and the IL group (P = 0.02) (Fig. 8). The tissue surrounding the implant showed 




Pattern and Light Scatter and Transmission 
The composed phase-contrast image of the FSCM shows that the pattern that contains the micro 
channels covers only a quarter and not the full surface. This is in accordance with the natural pattern 
of the so-called ctenoid fish scales.35 Nevertheless, this nonhomogeneity of the pattern does not 
prevent corneal stromal cells from populating the scaffold’s surface, and is perhaps even stimulating 
cell spread.25 The circular running ridges had a height and width much larger than the visible 
wavelengths, thereby provoking light scatter. This is in accordance with the observations that the 
pattern was clearly visible under the phase-contrast microscope. The latter visualizes differences in 





Figure 5. Scoring of corneal neovascularization (a) and opacification (b) at different time points during follow-up of the ALK 
and IL groups. Vessel score and opacity score did not differ significantly at the 21-day end point (respectively P = 0.46 and P 
= 0.19; χ2 trend test). Greatest difference of vessel score between the two groups at day 13 was not significant either (P = 
0.14). Error bars represent SEM. Vessel score: 0 = none; 1 = at limbus; 2 = reaching sutures/FSCM; 3 = under FSCM; 4 = 
entering FSCM; 5 = whole FSCM. Opacity score: 0 = transparent; 1 = mild haze, not obscuring the pupil; 2 = moderate haze 
partially obscuring the pupil; 3 = opaque area totally obscuring the pupil. 
 
 
The FSCM had a forward light scattering of log(s) 1.62, comparable to the amount of scattering 
caused by early cataract.30,36 The direct light transmission was 90%. 
Even though this value reflects the direct transmission and not the total light transmission, which 
includes forward-scattered light as well, it is very close to the total light transmission of 91% found 
for the human cornea. 
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Figure 6. Typical cases of each implantation model are shown. The IL group has been separated in best result and average 
result, due to high variability. All groups showed good transparency of the corneal implants on microscopic examination 
directly postoperatively (first column: [a, f, k, p]) and up to 7 days (second column: [b, g, l, q]). Neovascularization and 
opacification were visible at 13 days (third column: [c, h, m, r]) and gradually increased until day 21 (fourth column: [d, i, n, 
s]). Neovascularization is seen even more clearly postmortem (last column: [e, j, o, t]). 
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The light-transmission curves of the FSCM and human cornea are also very similar in shape, 
indicating corresponding values of Rayleigh scatter (i.e., light scatter caused by particles much 
smaller than the wavelength of light such as molecules). The displacement along the y-axis of the 
light-transmission curves for the different FSCMs can be attributed to a wavelength-independent 
scatter, plausibly caused by the micro pattern that roughens the surface of the FSCM with ridges 
larger in size than the wavelength of visible light. Although special care was taken for optimum 
position, it could not be prohibited that each FSCM was slightly differently positioned relative to the 
spectrometer and therefore caused different amounts of scatter. Removal of the micro pattern from 
the FSCM surface will improve light transmission and especially light-scatter values, which in turn will 
result in better visual acuity when implanted. 
 
Suturing 
The suturing test demonstrated that the FSCM can be sutured successfully into the cornea, when 
handled with care. The scaffold was brisker and had less mechanical strength than the human cornea 
(or rat cornea), indicated by the confined cracking and shearing. Increasing the elasticity and strength 
likely will improve the ease of handling and this may be needed to make the FSCM applicable for full-
thickness transplantation in humans. 
 
In Vivo Biocompatibility 
The rat keratoplasty model has been used to study corneal transplantation for more than 25 years.27 
Our findings of this first in vivo study with the FSCM correspond to the results seen with allogeneic 
corneal transplantations in rats.37–39 All corneal implants showed good acceptance up to 1 week 
postoperatively with neovascularization limited to one quadrant of the limbal rim, no opacity at all in 
the ALK group, and mild opacity in the IL group. After 3 weeks, neovascularization had increased until 
it reached the FSCM and sutures, but vessels failed to penetrate the FSCM. The opacity gradually 
increased to a mild haze (stage 1) in the ALK group and a moderate haze (stage 2) in the IL group. 
Total opacification (stage 3) of the FSCM, indicative for a complete rejection, was observed in only 
one animal of the IL group. It is important to note that in humans with a nonvascularized cornea, a 
non-HLA–matched allogeneic corneal transplantation has a high acceptance rate, whereas in rats, 
this situation leads to rejection after 5 to 15 days.37–39 A rejected graft is recognized by complete 
corneal opacification and infiltrating T cells on histology. The main finding of this study on the short-
term biocompatibility and handling of the FSCM to obtain a first impression of its use as a 
replacement of human donor material, is that the FSCM may have potential for corneal applications 
in humans. 
The local abnormalities that occurred in the corneal epithelium are largely explained by mechanical 
irritation induced by the FSCM. The edges were standing out due to a relative mismatch in curve and 
thickness and insufficient elasticity. This led to compression of the overlaying stroma and epithelium 
and created a tear meniscus in the IL group. These characteristics also explain the development of 
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epithelial downgrowth that occurred in the ALK group. The dense structure and thickness of the 
FSCM may have put pressure on the remaining corneal tissue in the IL group, prohibiting adequate 
flow of nutrients from the anterior chamber toward the overlaying anterior cornea. This mechanism, 
together with a too shallow implantation, is thought to be responsible for the observed melting. 
Histology confirmed that the cases with lesser melting were indeed implanted at a greater depth. 
The amount of neovascularization was comparable to that seen in allogeneic corneal 
transplantations in rats38,40 and provoked by the sutures.41 This explains the higher degree of 
neovascularization in the ALK group, in which more sutures were used and not removed, in contrast 
to the IL group, in which two sutures were used and removed after 2 weeks. In both groups, vessels 
failed to invade the FSCM, perhaps due to the fibril density of the FSCM or by yet to be identified 
antiangiogenic properties. 
Corneal opacification, which indicates swelling or an ongoing immune reaction, reached levels 
compatible with a complete rejection in 2 of the 12 corneal implants. The observed opacification may 
be due to the mentioned mechanical irritation, which leads to corneal damage and subsequent 
leukocyte infiltration. 
The infiltration of leukocytes was mild to moderate and consisted predominantly of macrophages, 
lymphocytes, and some neutrophils, indicative of a chronic immune reaction. The leukocytic 
infiltration was primarily aimed at the sutures in the ALK group and surrounded the scaffold in the SC 
group and partly in the IL group. The SC group showed the presence of fibroblasts aligned around the 
scaffold, similar to a mild foreign body reaction.42 It is unlikely that this infiltration and swelling is 
caused by pathogens present on the FSCM prior to implantation, as FSCMs from the same batch 
were tested and found to be negative for bacteria and fungi. Furthermore, a more severe reaction is 
expected in case of infection. Type 1 collagen of fish is similar to that of humans43 and reconstituted 
tilapia collagen sponges caused only rare inflammatory responses.26 Still, the collagen of the FSCM or 
residues of chemicals used for decellularization and decalcification could have provoked the immune 
response. A strong argument to support the notion that the inflammation was due to surgical trauma 
and mechanical irritation is the complete absence of inflammation in one case. If the inflammation 
had been due to a heterologous protein, one would have expected an immune response in all cases. 
The gradual tearing of the sutures through the FSCM, as noticed after 2 weeks, was aggravated by 
the outstanding edges and additional external mechanical forces caused by blinking and eye 
movements. Placing a contact lens or increasing the elasticity or curvature of the FSCM may offer a 
pathway to prevent this.44 The increased cellular infiltration and swelling on the histology of the SC 
group is well explained by the less immune privilege of the conjunctiva compared with the cornea. 
Other collagen matrices used for corneal regeneration, such as the biosynthetic artificial cornea,19 
are already being used in clinical studies, following a decennium of preclinical research.45 The novelty 
and advantage of the FSCMs are its wide availability, its low cost, and simple manufacturing process. 
However, we are at an early phase in our research, and working on overcoming technical challenges 
so as to develop a useful prototype. 
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Figure 7. HE stainings. Examples of control corneas are shown (a, b). The ALK group had mild to moderate infiltrationof 
leukocytes, epithelial hyper- and metaplasia, and epithelial downgrowth due to mismatch in shape (c, d). The IL group had a 
mild to moderate infiltration in two cases (e) and almost no infiltration in two other cases (f); all IL cases showed local 
atrophy and metaplasia of the epithelium (e, f). The SC group showed moderate infiltration (g, h), with fibrous capsule 
formation and some leukocytes infiltrating between the layers (h). *Leukocyte infiltration and concomitant edema. 
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Figure 8. Semiquantitative scoring of stroma infiltrating leukocytes (0 = none; 1 =+; 2 = ++ 3 = +++). Error bars represent 





This systemic study of the physical and biomedical short-term effects of the FSCM as corneal 
replacement, demonstrates its potential for future use. The availability of an easy obtainable and 
biocompatible FSCM can have a high impact on decreasing the shortage of donor corneas and make 
lifelong use of immunosuppressive medication redundant. The potential of this FSCM is 
demonstrated for the first time by an adequate light transmission, reasonable light-scattering values, 
and ability to be used in keratoplasty. Future studies with a curved and thinner FSCM are necessary 
to prevent mechanical irritation and increase the understanding of its immunogenicity. Long-term in 
vivo studies and studies on modified FSCMs, for instance with the top pattern removed, are needed 
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Abstract 
 
Purpose: To determine whether a fish scale-derived collagen matrix (FSCM) meets the basic criteria 
to serve as an artificial cornea, as determined with in vitro and in vivo tests. 
 
Methods: Primary corneal epithelial and stromal cells were obtained from human donor corneas and 
used to examine the (in)direct cytotoxicity effects of the scaffold. Cytotoxicity was assessed by an 
MTT assay, while cellular proliferation, corneal cell phenotype and adhesion markers were assessed 
using an EdU-assay and immunofluorescence. For in vivo-testing, FSCMs were implanted 
subcutaneously in rats. Ologen® Collagen Matrices were used as controls. A second implant was 
implanted as an immunological challenge. The FSCM was implanted in a corneal pocket of seven New 
Zealand White rabbits, and compared to sham surgery.  
 
Results: The FSCM was used as a scaffold to grow corneal epithelial and stromal cells, and displayed 
no cytotoxicity to these cells. Corneal epithelial cells displayed their normal phenotypical markers 
(CK3/12 and E-cadherin), as well as cell-matrix adhesion molecules: integrin-a6 and b4, laminin 332, 
and hemi-desmosomes. Corneal stromal cells similarly expressed adhesion molecules (integrin-a6 
and b1). A subcutaneous implant of the FSCM in rats did not induce inflammation or sensitization; 
the response was comparable to the response against the Ologen®Collagen Matrix. Implantation of 
the FSCM in a corneal stromal pocket in rabbits led to a transparent cornea, healthy epithelium, and, 
on histology, hardly any infiltrating immune cells. 
 
Conclusion: The FSCM allows excellent cell growth, is not immunogenic and is well-tolerated in the 
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Introduction 
 
Of the 39 million people worldwide who suffer from corneal blindness, approximately 12% are 
affected bilaterally, with the developing countries having the highest percentages of corneal 
blindness.1-3 Corneal blindness may be caused by corneal opacities, trachoma, and childhood 
blindness.3 There are multiple barriers that prevent restoration of vision in these patients through 
corneal transplantation, and these problems are especially common in developing countries: lack of 
access to drugs such as steroids and antibiotics, and lack of trained surgeons, but the most important 
one is lack of corneal donor tissue and the availability of those corneas at an affordable price.3,4 Even 
in the developed countries the cost of a donor cornea remains high, for example the cost of a donor 
cornea in the United States is approximately 3000 US dollars.5  
The shortage of donor corneas may be reduced by using keratoprostheses as artificial corneas, as 
these keratoprostheses, such as the Boston Keratoprosthesis (B-Kpro) and Osteo-Odonto-
Keratoprosthesis (OOKP), are viable solutions.6,7 However, due to potential complications and high 
surgical demands, such implants are currently only used in high risk patients. Furthermore, the B-
Kpro still has the risk of rejection as it uses a donor cornea, while the OOKP has a complex 
implantation procedure, and both are rather expensive, although the developers of the B-Kpro are 
working towards cost reduction.8 Three-dimensional scaffolds made from biomaterial, mimicking the 
corneal stroma, may be repopulated by the patient's own corneal cells, and those cells may in turn 
regenerate corneal tissue.9-11 The use of biomaterials would reduce the chance of immune rejection. 
Three-dimensional scaffolds can be fabricated,10 or harvested in an almost ready state from, for 
example, porcine corneas,12 or a porcine cornea may be modified before use.13 
Different biomaterials can be used and indeed are being explored as the basis for scaffolds.4,14-17 The 
human corneal stroma consists primarily of type I collagen, arranged in orthogonal lamellae, which 
give the cornea its enormous tensile strength.18 This makes collagen a logical material for use as an 
artificial corneal scaffold.15,19 Indeed, one synthesized collagen (recombinant human collagen type III) 
scaffold has reached the clinical phase I, but a drawback is the complicated fabrication process;20 
another one is achieving enough tensile strength of the construct to allow interrupted or continuous 
suturing. 
Decellularized human corneas can also be regarded as collagen-based scaffolds but use of these 
scaffolds will not decrease the lack of need for tissues. Decellularized porcine corneal stroma is 
another option, but this confers a risk of transmitting animal disease.15 Screening for pathogens may 
reduce that risk.15 
Another source for three-dimensional collagen scaffolds are fish scales.21-23 Scales from the Tilapia 
fish, farmed under controlled conditions,24 are composed of collagen type I, arranged in a similar way 
as in human corneas.25 Such scaffolds may offer a cheap alternative and facilitate corneal 
regeneration. 
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Previous studies showed that a collagen scaffold, made of the scales of the Tilapia fish (Oreochromis 
niloticas) by decellularization and decalcification, facilitates repopulation by rabbit corneal stromal 
cells and has a high oxygen permeability.23 Our previous experiments showed that this scaffold has 
adequate light transmission values and is suitable for use in keratoplasty, using intermittent 
sutures.26 
As we hypothesized that the fish scale-derived collagen matrix (FSCM) can be used as an implant for 
corneal reconstruction, we set out to perform an in depth investigation into the suitability of this 
implant for corneal reconstruction. We measured the tensile strength and glucose permeability of 
the FSCM-derived scaffolds, cultured primary human corneal epithelial and stromal cells together 
with the scaffold to assess the scaffold's cytotoxicity, and determined its effect on the proliferation, 
phenotype and adhesion of corneal cells in vitro; finally, we studied the body's response upon 




Fish-scale derived collagen matrix 
The collagen matrices were prepared from the scales of Tilapia (Oreochromis Niloticas), bred under 
controlled conditions as previously described.23,24,26 Decellularized, decalcified and gamma-irradiated 
FSCM were provided by Aeon Astron Europe BV (Leiden, the Netherlands) and stored in sterilized 
phosphate-buffered saline (PBS) containing 1% penicillin/streptomycin (15140-122; Gibco by Life 
Technologies, Bleiswijk, the Netherlands) at 4° Celsius until use. The matrices were 8.0 ± 1.0 mm in 
diameter, 0.25 ± 0.05 mm in thickness, and had no curvature, except the ones used for the rabbit 
experiment. 
 
Tensile strength and glucose permeability 
The tensile strength of the matrices was determined using a universal testing machine (Instron 3365, 
UK) with a gauge length of 10 mm. The test was performed at a crosshead speed of 6 mm/min at 
room temperature. Measurements were performed on four independent samples. 
Glucose permeability was assessed with the USP <1724> Vertical Diffusion Cell Test using the Franz 
cell system. Matrices (n = 4) were fixed between a donor chamber containing 50 mg/ml glucose 
solution and a receptor chamber with distilled water. After 1, 6, and18 h, water from the receptor 
chamber was removed for glucose measurement, for which a glucose assay kit was used (Cat no. 
GAGO20-1KT; SigmaeAldrich, Diegem, Belgium). 
Primary human corneal cells 
Human cadaveric eyes were obtained from the EuroCorneabank, Beverwijk, the Netherlands. Corneal 
epithelial cells were harvested by cutting the cornea into four equal quadrants, washing the corneal 
pieces three times in PBS (phosphate-buffered saline) and incubating the tissue overnight at 4 °C in 
2.4 U/ml dispase II (04 942078 001; Roche Applied Science, Mannheim, Germany) in PBS. The corneal 
 55 Biocompatibility of a fish scale-derived artificial cornea 
epithelium was manually separated as a sheet from the underlying tissue by gentle use of forceps 
and a spatula, centrifuged (5 min at 1000 rpm), and incubated in 80 ml TrypLE (TrypLE Select 126050-
10; Life Technologies Europe BV, Bleiswijk, the Netherlands) for 10-15 min at 37 °C to create a single 
cell suspension, which was cultured in CnT-20 medium (CnT-20; Bio-connect BV, Huissen, the 
Netherlands) with 1% penicillin/streptomycin. 
The cornea was cut into small pieces of about 1 1 mm to isolate corneal stromal cells. The corneal 
parts were placed in a 0.1% collagenase type II solution (17101-015; Life Technologies Europe BV) 
and incubated overnight at 37 °C. The obtained cell solution was put through a 70 mm cell strainer, 
subsequently centrifuged (5 min at 850 rpm) and cultured in DMEM/HAM F12 medium with stable 
glutamin (FG4815; Biochrom AG, Berlin, Germany), supplemented with 5% fetal calf serum (758093; 
Greiner Bio-one GmbH, Frickenhausen, Germany) and 1% penicillin/streptomycin. 
 
Cytotoxicity and proliferation 
Cytotoxicity was analyzed using an MTT viability assay, where epithelial and stromal cells were 
directly and indirectly exposed to the FSCM (P12261201/P12041201) for 24 h. In order to determine 
cytotoxicity through direct cell contact, the cells were seeded and the scaffold was added to the 
culture. To assess any indirect cytotoxicity, the cells were cultured in the presence of FSCM extract 
(cell culture medium that had been incubated with the scaffold for 24 h at 37 °C) and a dilution series 
of the extract (1:2 and 1:4). As a positive control, cells were treated with 1% sodium dodecyl sulfate, 
while untreated cells served as a negative control. For the MTT assay, 1 mg/ml 3-(4.5-
dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) (M2128-5G, lot: 046K5304; 
SigmaeAldrich, Diegem, Belgium) was added to the cell cultures and the cells were incubated for 2 h 
at 37 °C. Metabolically active cells reduce MTT to formazan and after formazan extraction using 
isopropanol, the optical density was measured using a spectrophotometer (at 570 nm). This assay 
was performed in triplicate. 
To assess proliferation, the two-donor mixes of epithelial (40,000 cells) and two-donor mixes of 
stromal cells (25,000 cells) were seeded onto the smooth side of the FSCM (P12261201) and on 
plastic discs, which served as controls. Experiments were carried out in duplicates. After 24, 48, and 
72 h, cells were incubated with1% of 5-ethynyl-2’-deoxyuridine (EdU) (Click-It® EdU Alexa Fluor® 594 
Imaging Kit; C10339; Life Technologies Europe BV) for 16 h, and, after being washed with PBS, cells 
were fixed with 4% form-aldehyde in PBS, and permeabilized by 0.5% Triton® X-100 EdU was 
visualized using Alexa Fluor® 594. DAPI counterstaining served to identify cell nuclei. EdU-positive 
cells, indicating actively dividing cells, were manually counted by two different observers in three 
randomly-selected areas on the FSCM, using a confocal microscope. 
 
Immunofluorescence, SEM and TEM 
Corneal epithelial cells were seeded on the patterned side of four FSCMs (15,000-50,000 cells/FSCM), 
and on the smooth side of two FSCMs (P06271201), and cultured until sub-confluence (11-12 days), 
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at which time the FSCMs were prepared for whole mount immunofluorescence to assess cell 
phenotype and adhesion. For this, the scaffolds were fixed in 4% formaldehyde, and antibodies were 
applied against CK3/12 (1:50; bs-2369R-Cy7; Bio-Connect BV, Huissen, The Netherlands), a marker of 
differentiated corneal epithelium, and the cell-matrix adhesion molecules integrin α6 (1:1000; 
ab20142; Abcam; Cambridge, UK) and β4 (1:1000; ab110167; Abcam; Cambridge, UK). After 
incubation with fluorochrome-labeled secondary antibodies, counterstaining was performed with 
DAPI (cell nuclei) and Alexa Fluor 488 Phalloidin (F-actin filaments) (1:100; A12379; Life Technologies 
Europe BV; Bleiswijk, the Netherlands). 
The experiments with the corneal epithelial cells were repeated at another location (University of 
Antwerp, Antwerp, Belgium) using corneal limbal explants from one human donor cornea. Each 
limbal explant was placed on top of four different non-curved FSCMs (P12261201), and additionally 
on top of two dome-shaped FSCMs (P08081304; diameter curvature 7.4 ± 0.2 mm) and cultured in 
Corneal Epithelial Culture Medium27 (supplemented with collagen and fibronectin) for 22 days for 
immunofluorescence and 20 days for analysis with Transmission Electron Microscopy (TEM) and 
Scanning Electron Microscopy (SEM). Whole mount immunofluorescence was performed on the four 
non-curved FSCMs, that were cut in halves, for CK3/12 (1:100; ab68260; Abcam, Cambridge, UK), E-
cadherin (1:400; ab53033), integrin α6 (1:1000; ab20142), laminin-332 (1:25; ab11575; Abcam; 
Cambridge, UK), and additionally with ΔN P63 (1:300; sc-8609; Santa Cruz Biotechnology; CA, USA), a 
determinant for stemness. Corneal stromal cells were also cultured on the smooth side of FSCMs 
(P12261201), coated with and without rat tail collagen type I. The cells were stained for whole mount 
immunofluorescence with antibodies against the transmembrane receptors integrin-α6 (1:1000; 
ab20142) and integrin-β1 (1:50; ab52971; Abcam, Cambridge, UK), involved in cell-matrix adhesion, 
and counterstained for F-actin (Alexa Fluor 488 Phalloidin; A12379) to depict the cytoskeleton, and 
with DAPI for cell nuclei. 
 
Post-modifications 
FSCMs (P04201201)23,24,26 were treated with femto second laser to create FSCMs with vertical non-
penetrating pores only, or in combination with 1x890 mm (HxW) horizontal tunnels. Additionally, 
two scaffolds were incubated for 3 h at 37 °C in PBS with 4.8 U/ml dispase II to detach the collagen 
layers. Corneal stromal cells were cultured on these manipulated FSCMs (200,000 cells/FSCM). When 
complete confluence over the FSCM (2-3 weeks) was obtained, the samples were fixated in 4% 
formaldehyde and hematoxylin-eosin (HE) staining and immunofluorescence with F-actin and DAPI 
was performed to visualize the effect on the FSCMs and on the behavior of the cells. 
 
Subcutaneous implantation 
Forty male Fischer 344 albino rats (Charles River Laboratories, France), weighing between 280 and 
336 g, were used for subcutaneous implantation of the FSCM. Ethical approval was given by the 
Animal Experiments Committee of the Leiden University Medical Center (Leiden, the Netherlands), 
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and all animals were treated according to the ARVO statement for use of animals in ophthalmic and 
vision research. Animals were given at least one week for acclimatization. 
Prophylactic pain reduction was started pre-operatively with acetaminophen infusion solution (50 
mg/ml) added to the drinking water at 1 mg/ml, which was continued during seven days. The rats 
were anesthetized with isoflurane and a subcutaneous injection of 50 ml bupivacaine (5 mg/ml) at 
the site of implantation. A 2 cm long incision was made in the right, high dorsal flank, where a 
subcutaneous space was created, and the matrix inserted. Twenty animals received the FSCM 
(P09151101) and twenty other animals another matrix, the Ologen® Collagen Matrix (Aeon Astron 
Europe, Leiden, The Netherlands; 12 mm in diameter, 1 mm in thickness; porcine collagen type I) as a 
control; Ologen® Collagen Matrix is used for bleb filtration in trabeculectomy surgery in humans.28 
All matrices were cut in half and soaked in antibiotics for 5 min (Polyspectran®containing 
Gramicidine, neomycine and poly-myxine B) prior to insertion. The incision was closed with 6/0 
absorbable sutures (Safil REF 1048734, B. Braun Medical BV, Oss, The Netherlands). Seven animals of 
the twenty with an FSCM, and eight animals of the twenty with an Ologen® implant, additionally 
underwent sham surgery on the contralateral dorsal flank, which served as a control (n = 15) to 
determine whether the surgery itself influenced local inflammation in the rat subcutaneous tissue. 
At 1, 6, and 11 weeks post implantation, five animals with an FSCM and five with an Ologen® implant 
were sacrificed. Three weeks after the first implant, a second FSCM was implanted in the 
contralateral dorsal flank of five animals of the FSCM group and a second Ologen®implant in five 
animals of the Ologen® group to study immune sensitization; these animals were sacrificed one week 
after the second implant. After the animals were sacrificed, the subcutaneous tissues were 
harvested, formalin fixed and embedded in paraffin. Sections were cut and stained with HE. Based on 
the HE staining, three representative cases were selected out of the five per group per time point, 
which were additionally stained with antibodies to identify granulocytes (MPO staining; 1:1000; 
ab45977; Abcam), macrophages (ED-1 staining; 1:300; MAB1435; Millipore BV, Amsterdam, The 
Netherlands), T cells (CD3 staining; 1:500; MCA772GA; Sanbio BV, Uden, The Netherlands), and 
immunoglobulins (Polyclonal Rabbit Anti-Rat Immunoglobulins/HRP, mainly IgG; 1:100; P0162; Dako 
BV, Heverlee, Belgium). 
For automatic scoring with a computer program (ImageJ;29 W.S. Rasband, ImageJ, U.S. National 
Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997e2014), three images 
were made of two subsequent sections per matrix at standard locations (left end, middle, and right 
end of the matrices), and the percentage positively-staining area per view was calculated for each 
staining. An independent pathologist graded the amount of immune response as: minimal, mild, 
moderate, and severe, based on the HE staining. 
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Intrastromal implantation 
Fourteen female New Zealand White rabbits (Charles River Laboratories, France), ranging from 2 to 3 
kg, underwent intra-stromal surgery, with seven animals receiving a curved FSCM (P08081304; 120 ± 
20 mm in thickness, curvature 7.4 ± 0.2 mm in diameter) in their right eye, while seven other animals 
received no implant (while undergoing the same surgical procedure), serving as controls. Ethical 
approval was given by the Animal Experimentation Committee of the University of Utrecht (Utrecht, 
the Netherlands) where the experiment was conducted, and all animals were treated according to 
the ARVO statement for use of animals in ophthalmic and vision research. All rabbits underwent at 
least one week of acclimatization. 
Prophylactic painkilling was started preoperatively with a subcutaneous injection of Carprofen (4-5 
mg/kg) and this was given postoperatively once daily for six days. The anesthetic regimen consisted 
of intramuscular injections of Ketanest-S® (ketamine 15 mg/kg/h) and Dexdomitor® 
(dexmedetomidine 0.125 mg/kg/h), and local administration of one drop oxybuprocaine 0.4% every 
15 min. 
A corneal incision was made with a precision depth knife set at approximately 80% of the corneal 
thickness, and the corneal layers were dissected horizontally with a blunt spatula until a pocket was 
formed of at least 4 mm width and 5 mm length. An FSCM was trephined to 3.8 mm and inserted 
into this corneal pocket, and the incision was closed with 10/0 nylon sutures. Sutures were removed 
at 3.5 weeks follow-up. 
The eyes were treated postoperatively with tobramycin/dexamethasone eye drops twice daily for 
eleven days. When symptoms of ocular irritation arose, tobramycin/dexamethason treatment was 
restarted for all animals, together with artificial tears (Visidic Carbogel; Tramedico BV, Weesp, the 
Netherlands), until the symptoms subsided, after which the treatment was reduced, but continued 
until euthanasia after 6 weeks of follow-up. 
Eyes were checked with a surgical microscope at 1, 2, 3.5, and 6 weeks for conjunctival hyperemia, 
corneal haze and neovascularization, and ocular discharge. At 6 weeks, the eyes were additionally 
observed through a slit-lamp, and the animals were euthanized. The corneas were harvested, fixated 
in formaldehyde and embedded in paraffin. HE staining was performed as well as an 
immunohistochemical staining with an antibody against RAM11 (1:25; M063301; Dako BV) to identify 
macrophages. 
 
Long-term intra-stromal implantation 
Two other New Zealand White rabbits were used for long-term follow-up. In these animals a partial 
depth corneal incision was made to create an intrastromal pocket of 6.5 mm in diameter using a 
crescent 2.0 mm knife. An FSCM was trephined down to 6 mm in diameter and inserted to the 
pocket. The incision opening was closed with 10-0 nylon sutures. Postoperatively daily drops of 
Levofloxacin 0.5% and Prednisolone acetate 1% (Pred Forte) were administred during the first 4 
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weeks. Follow up was performed at week 1, 2, 3, 4 and 54 with optical coherence tomography (OCT) 




Tensile strength and glucose permeability 
Four FSCM's were used to measure the tensile strength and glucose permeability. The Young's 
modulus for tensile strength was calculated from the stress-strain curve and was 11.7 ± 0.92 MPa. 
The glucose diffusion flux was maximal after 1 h (24.9 ± 6.8 x 10-6 cm2/s). The diffusion flux decreased 
to 6.0 ± 0.5 and 2. 6 ± 0.3 x 10-6 cm2/s at 6 and 18 h. 
 
Cytotoxicity 
Human corneal epithelial and stromal cells were co-cultured with the FSCM to test for any cytotoxic 
effects using an MTT assay. Cell viability was assessed and compared to unexposed controls (Fig. 1). 
For the direct contact test, an FSCM was added to the culture, while for the indirect contact test, the 
cells were cultured in the presence of FSCM extract (cell culture medium that had been incubated 
with the scaffold for 24 h at 37°C) and a dilution series of the supernatant was tested. Using two 
FSCM, corneal epithelial and stromal cell viability in the direct contact test was 79.6% and 83.4%, and 
for the indirect contact test 83.7% and 89.3%. This was higher than the threshold for cytotoxicity, 
which has been set at 70% according to the ISO-standard (ISO: 10993-5:2009(9)). 
 
Proliferation 
Next, we determined whether the FSCM influenced cell proliferation. Human corneal epithelial and 
stromal cells were seeded on an FSCM and on plastic, and dividing cells were counted after 24, 48, 
and 72 h of culture using EdU staining. The percentage of actively-dividing (EdU positive) epithelial or 
stromal cells on the FSCM was similar to the number of EdU-positive epithelial or stromal cells 
cultured on plastic discs (Fig. 2A and B). 
 
Phenotype and adhesion 
After having assessed cytotoxicity and cell proliferation, we determined if there might also be an 
effect on morphogenesis or on adhesion molecules. Therefore, primary human corneal epithelial 
cells were cultured on FSCMs and assessed using immunofluorescence for the presence of different 
markers. The cells proliferated on both the anterior as well as the posterior side of the FSCM, and we 
observed no difference in cell growth with regard to the different micropatterns present on the 
FSCM (spokes, ridges, and spikes on the anterior side, and no pattern (smooth) on the posterior side 
(Fig. 3). The seemingly black, unpopulated areas (Fig. 3B) were out of focus: changing the focus of the 
confocal microscope showed that these areas were populated as well. 
 




Figure 1. Effect of fish scale-derived collagen matrix (FSCM) on cellular viability. Primary human corneal epithelial cells (A) 
or primary human stromal cells (B) were cultured in indirect and direct contact with the fish scale-derived collagen matrix 
(FSCM), and the cytotoxicity was tested using a viability assay (MTT test). As a positive control for minimal MTT staining 
(toxicity) we used cells killed with SDS. 
 
 
Primary human corneal epithelial cells were grown until confluence on the FSCM in two different 
laboratories and assessed for phenotype and adhesion markers with immunofluorescence staining 
(Fig. 4A). The epithelial cells were CK3/12-positive, and displayed cell-cell adhesion and cell-matrix 
adhesion molecules (E-cadherin, integrin-α6, integrin-β4, and laminin 332). The primary human 
stromal cells, the keratocytes, cultured on the FSCM, were positive for integrin-α6, and integrin-β1 
(Fig. 4B). No difference in expression was observed when FSCM's were coated with rat tail collagen 
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Figure 2. Cell proliferation of human corneal epithelial and stromal cells cultured on FSCM or plastic. Primary human 
corneal epithelial cells (A) or primary human stromal cells (B), were cultured on the fish scale-derived collagen matrix 
(FSCM) or on plastic control discs and proliferation was determined in a three-day proliferation assay, in which actively 
dividing cells were stained with 1% 5-ethynyl-2’-deoxyuridine (EdU). There were no significant differences between the 
percentage EdU positive and EdU negative epithelial and stromal cells grown on the FSCM and on the control discs 
(ManneWhitney U test). 
 
 
The TEM images revealed that stratified primary epithelial cells grown on top of the FSCM developed 
a stratified layer, which had approximately six cell layers, and that desmosomes were present 
between the epithelial cells, while hemidesmosomes were seen between the basal epithelial cells 
and the underlying FSCM (Fig. 4C). 
 
Post-modifications to stimulate cellular ingrowth 
We wondered whether it was possible to post-modify the FSCM to stimulate cell ingrowth into the 
scaffold, and to test this, the FSCM was incubated in dispase and modified by femto-second laser 
(Fig. 5A). Incubating the FSCM in 2.4 U/ml dispase II for 4 h resulted in a space between the dense 
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a femto-second laser and cultured primary corneal stromal cells on top of this modified FSCM. 
Confocal immunofluorescence images depicted cells that filled up the pore of the FSCM, as well as 
the small spaces created between the dense collagen layers (Fig. 5C). When a FSCM was used that 
had been modified with pores and horizontal tunnels of approximately 1 mm in height, corneal 
stromal cells were found to protrude their cytoskeleton into those tunnels (Fig. 5D). 
 
Immunogenicity 
To determine the immunogenicity of the FSCM, a classical challenge test was performed in rats. The 
FSCM was implanted subcutaneously in the dorsal flank of rats (n = 20) and the tissue response was 
compared to a matrix used in human bleb filtration for trabeculectomy (n = 20), as well as to sham 




Figure 3. In vitro human corneal epithelial cell growth on the FSCM. The anterior surface of the FSCM has three 
distinguishable patterns: spokes, ridges, and spikes, as clearly seen with a phase-contrast microscope, while the posterior 
surface is smooth, as demonstrated by a SEM (A). The primary human corneal epithelial cells grew equally on each surface 
(B). Blue: DAPI, staining cell nuclei; Green: Alexa Fluor 488 Phalloidin, staining F-actin; Red: CK3/12, staining differentiated 
corneal epithelium.  
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amount and composition of infiltrating cells existed and one animal, at the end point, showed fibrous 
capsule formation. Fig. 6A shows the HE staining of the FSCM and surrounding subcutaneous tissue 




Figure 4. In vitro characteristics of primary human corneal epithelial cells grown on FSCM. A. Primary human corneal 
epithelial cells cultured on the FSCM stained positive for CK3/12 (red) (indicating differentiated epithelium), for the cellecell 
adhesion marker E-cadherin (green), for the cell-matrix/cellecell adhesion markers integrin-α6 (red), integrin-β4 (red), and 
basement membrane marker laminin 332 (green), and most cells stained positive for the stem cell marker p63 (red) (A; blue 
= cell nuclei; green = F-actin, unless otherwise stated). B. Primary human corneal stromal cells, the keratocytes, displayed 
the adhesion molecules integrin-α6 and integrin-β1, whether the FSCM was coated with collagen type I or not (B; blue = cell 
nuclei, green = F-actin, red = integrins). C. Desmosomes were present (arrows) between the epithelial cells cultured on the 
FSCM, and stratification occurred (C; numbers indicate cell layers).  
 
 
Immunostaining for granulocytes, macrophages, T cells, and immunoglobulins showed more 
variation at 1 week postoperatively than after 6 and 11 weeks postoperatively. The composition of 
infiltrating immune cells one week after implantation was dominated by granulocytes, but also 
contained macrophages in all groups (Fig. 6B). The immune response at 1 week was graded as 
moderate and was not significantly different from the two control groups (Fig. 6C). The immune 
response diminished to mild and minimal over time until the end point at 11 weeks, for each of the 
four immunomarkers, and the response to the FSCM was again not different from that seen with the 
Integrin-β4 





Figure 5. Modification of the FSCM by generating pores to increase cell ingrowth. The FSCM can be manipulated with the 
femto-second laser to create pores and horizontal tunnels in the FSCM (A), as well as with dispase II to create a small space 
between the naturally present horizontal collagen layers at the outer edge of the FSCM (B). Primary human corneal stromal 
cells are shown to interact with these alterations by filling up the small spaces (see arrows) thus created by dispase II in 
FSCMs with laser made pores (C), and in FSCMs in which horizontal tunnels were created subsequently (D). The white 
dotted lines indicate the borders of the pores (C) and of the pores and tunnels (D) created in the FSCM, and the side views 
represent digital cross sections. 
 
 
control matrix (Ologen® Collagen Matrix), and sham surgery (Fig. 6C). Microscopic analyses revealed 
that the increased amount of macrophages present in the FSCM group at 1 week, and of 
granulocytes at 11 weeks, were due to false-positive counting of the folds on the sections for which 
the ImageJ software could not correct, thereby creating high error-bars. These samples were not 
excluded from the analysis. A subcutaneous immunological challenge with an FSCM, three weeks 
after the first exposure to the FSCM, elicited no increased immune response after 1 week (Fig. 6D). 
 
Corneal compatibility 
Finally, we evaluated the in vivo compatibility of the FSCM: curved FSCMs were implanted 
intrastromally in rabbit corneas to assess the corneal tissue response to the FSCMs. Rabbits that 
underwent sham surgery served as controls. The animals were observed for six weeks, and the 
corneas were subsequently analyzed histologically. Sutures were removed after 3.5 weeks as they 
gave rise to ocular irritation in both groups, which disappeared upon removal of the sutures. The 
cornea stayed clear throughout the follow up, and no epithelial defects or signs of melting were 
observed (Fig. 7A). Some corneal vascularization was present in the superior limbal area in both 
groups, but this was similar to the situation in the non-operated contralateral eyes (Fig. 7B). The  
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corneal stroma showed a normal arrangement of its fibers around the FSCM. A few infiltrating cells 
were noticed around the edge of the FSCM (Fig. 7C). The infiltrate contained a mix of corneal stromal 
cells (keratocytes) and macrophages (Fig. 7D and E). No granulocytes were seen throughout the 
sections and in a few sections, a single T cell was observed. The activated cells were not seen to 
invade the FSCM, but appeared to deposit new extracellular matrix at the edges (Fig. 7D and E). The 
FSCM slightly pushed up the overlaying corneal stroma, resulting in a slight atrophy of the otherwise 
healthy epithelium covering the area positioned above some of the more superficially-implanted 
FSCMs, while showing normal epithelial morphology in the ones with deeper implants which caused 





Figure 7. In vivo tolerance to FSCMs in rabbit corneas. A. Intrastromally implanted FSCMs (small arrow) in rabbits stayed 
clear during follow-up, and do not differ from the image of the rabbits that received sham surgery (big arrows indicate site 
of incision). B. Neovascularization was physiological and was equal in eyes with an FSCM to eyes after sham surgery or 
contralateral eyes. C. The overlaying epithelium appeared viable on the HE-staining, and a few infiltrating cells, depending 
on the location at the FSCM's edge (D), were present. E. Macrophages (RAM11 staining) were seen in the scarce infiltrate 
(dark brown is immunopositive).  
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The two rabbits implanted intrastromally with 6 mm diameter FSCM's for long-term follow up 
revealed no significant immune response as based on the in vivo follow up and the OCT images. The 
OCT revealed that there were no signs of extrusion of the implanted FSCM and that the thickness of 




Our data show that the FSCM is suitable for use as basic material to develop an artificial cornea. It 
facilitates adequate epithelial regrowth and adhesion, is not immunogenic, and can be stably 
implanted in the cornea. 11.7 ± 0.9 MPa. 
The glucose diffusion flux was maximal after 1 h (24.89 ± 6.78 x 10-6 cm2/s). The glucose diffusion rate 
of the FSCM (24.9 ± 6.8 x 10-6 cm2/s) is more than adequate, when compared to the human cornea 
(2.5-3.0 x 10-6 cm2/s) [30]. The tensile strength (11.7 ± 0.9 MPa) is also nearly identical to that of the 
human cornea (3-9 MPa).31  
It is of paramount that any material used as a basis to develop an artificial cornea has no unwanted 
effects that interfere with its purpose: to replace a damaged cornea for a given period of time. The 
material should be non-toxic to surrounding cells and not have a major influence on a cell's 
proliferative capacity. Our data illustrate clearly that the FSCM is neither cytotoxic nor has a major 
influence on epithelial proliferation. As the FSCM is being developed as a stromal replacement 
device, it should facilitate regrowth and adhesion of stable and healthy corneal epithelium. Our in 
vitro studies show that primary human corneal epithelial cells that grow on the FSCM are of the 
correct phenotype, i.e. expressing CK3/12, E-cadherin and desmosomes, the latter of which are both 
involved in cell-cell contact and communication between epithelial cells). Intact cell-cell contact and 
communication is very important in epithelial tissues to fulfill their barrier function.32,33 
The presence of hemi-desmosomes and one of its components, the heterodimer integrin-α6 and 
integrin-β4,34,35 shows that these cell-matrix adhesion molecules are produced by the epithelial cells, 
and indicates that cell-matrix adhesion is indeed present; this is essential for firm adhesion of newly-
formed corneal epithelium to the FSCM. We also show the presence of laminin-322, as integrin-α6β4 
preferentially binds to this protein, which is produced by epithelial cells and is part of the basal 
membrane, and strengthens the connection with the underlying collagen.36 The finding that primary 
human epithelial cells are able to stratify when grown in specific medium on top of the FSCM greatly 
supports the use of this scaffold as a replacement therapy for corneal stroma. 
Once the FSCM is implanted in the cornea, its border is adherent to the surrounding corneal stromal 
tissue. When the FSCM is sutured into place, the sutures should provide enough strength to hold it in 
situ. For long term use, the FSCM should become attached to the surrounding recipient's corneal 
tissue. In this adhesion process, the corneal stromal cells play a pivotal role, and our in vitro studies 
with primary corneal keratocytes show that they grow on the FSCM and express the cell-matrix 
adhesion molecules needed by keratocytes (Fig. 4B): integrins α6 and β1.37 
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Figure 8. Long-term follow up of intrastromal FSCM's. The intrastromally placed FSCM remained stable in situ during a total 
of 54 weeks (54 W) without eliciting an immune response. The first column shows the rabbit eye in vivo, the second column 
shows a cross section made by OCT of the lateral area of the FSCM and the third column shows a cross section of the medial 




In order to improve the physical interaction between the FSCM and the keratocytes, the FSCM can be 
modified using several techniques. We manipulated the FSCM with a femto second laser and dispase 
II, which led to additional attachment points for keratocytes. Additionally, cross-linking may be 
applied, a technique used to produce the curved FSCM, which was used for intrastromal implantation 
in rabbit corneas. That this FSCM is suited for post modification makes it ideal to adjust it as needed 
during its development towards an artificial cornea. 
Implantation of the FSCM subcutaneously in rats allowed us to compare the immune response 
against the FSCM with the response against a collagen matrix that is already safely used in humans as 
well as with sham surgery: we demonstrated that the FSCM is not immunogenic, as there was no 
specific immune response, and there were no signs of sensitization upon reintroducing the FSCM 
subcutaneously in the same animal. This confirms our hypothesis as posed in our previous work,26 
namely that the inflammation following corneal placement in a pocket or as an anterior laminar graft 
was largely due to mechanical irritation. The loose rat skin still allowed some shifting of the FSCM, 
which is denser and harder than the spongy Ologen® Collagen Matrix, and in one case elicited fibrous 
encapsulation. Despite the possibility of movement of the matrix, and despite that the skin is 
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vascularized and not immunosuppressed, only a few immune cells and no specific immune responses 
were observed. 
Our focus in the rabbit experiment, with intrastromal implantation of the FSCM, was to test whether 
the FSCM could have a negative effect on the cornea, i.e. melting of the overlying epithelium or 
eliciting an unwanted immune response during a longer follow up period (six instead of three weeks). 
For that reason we implanted a thinner and curved FSCM, thereby minimizing mechanical irritation. 
We used intrastromal implantation instead of an anterior lamellar keratoplasty, as we intended to 
determine the potential response elicited by the FSCM, and not by sutures or mechanical irritation. 
Using this model, we were able to place the sutures far away from the FSCM, which helped in 
distinguishing between a response elicited by and towards the sutures versus one elicited by the 
FSCM. We observed that all corneas stayed transparent, the overlaying epithelium remained healthy 
and stable during 6 weeks of follow-up, and on histology, a few infiltrating macrophages were 
observed; we can thus conclude that there were no unwanted adverse effects. Keratocytes were 
located near the skirt of the FSCM and appeared to interact with the exposed edges and we 
hypothesize that these keratocytes may be slowly replacing the FSCM's collagen type I by extra-
cellular matrix deposition. The observed empty spaces between the layers at the FSCM's edge are 
considered to be due to the trephination. Long-term follow-up suggests that the FSCM will remain 
stable without extrusion, degradation or rejection for at least up to one year. Some scarring around 
the FSCM was visible however, which is something we should address. 
When looking into the literature, there are several other solutions for corneal restoration. In contrast 
with the Boston Keratoprostheses, the FSCM does not need a donor cornea.38 The OOKP is a complex 
but well researched solution as all other options for corneal restoration have failed.39 The FSCM may 
offer an alternative. 
A synthetic transparent scaffold (ACTO TexKPRO; polyvinylidene difluoride fibers and silicone) has 
successfully been implanted as preliminary treatment in six patients for 6-40 months after which a 
keratoplasty was performed. This ACTO TexKPRO is currently being developed as a solution for cases 
where the ocular surface has been destroyed.40 A recent publication evaluated a hydrogel 
(polyethylene glycol/polyacrylic acid) designed as artificial cornea, also by intrastromal implantation 
in rabbits.41 Fifty percent of the rabbits followed for 2 months (n = 6) kept clear corneas without 
inflammation. However, after up to 16 months follow up, there was a high rate of complications, 
such as epithelial defects, corneal thinning and even extrusion. Yet in a previous study, this hydrogel 
showed clear corneas up to around 6 months.42 Our two rabbits had no extrusion or notable corneal 
thinning at 1 year follow up. 
A clinically-used biosynthetic artificial cornea that is made from carbodiimide cross-linked 
recombinant human collagen, has been shown to be stable for up to 4 years of follow-up in 10 
patients, although it resulted in thinner corneas (358 ± 101 mm).16 This material is quite costly, and 
seems to be the closest to our material. 
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We showed previously that the FSCM has identical direct light transmission as the human cornea 
(although its light scatter values can be further optimized), and that it has a low immunogenicity. In 
our current study, we show that the FSCM is a scaffold that has no adverse effects to corneal cells in 
vitro, or to the cornea in vivo in the short term, and most likely also not in the long term. This clears 
the road for initiating larger longer follow-up experiments and to optimize its suturability. Further 
work will focus on the use of the FSCM as a corneal replacement strategy when no human material is 
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Abstract  
 
As many patients with severe corneal disease are not even considered as candidates for a human 
graft due to their high risk of rejection, it is essential to find ways to reduce the chance of rejection. 
One of the options is proper matching of the cornea donor and recipient for the Human Leukocyte 
Antigens (HLA), a subject of much debate. Currently, patients receiving their first corneal allograft are 
hardly ever matched for HLA and even patients undergoing a regraft usually do not receive an HLA-
matched graft. While anterior and posterior lamellar grafts are not immune to rejection, they are 
usually performed in low risk, non-vascularized cases. These are the cases in which the immune 
privilege due to the avascular status and active immune inhibition is still intact. Once broken due to 
infection, sensitization or trauma, rejection will occur. There is enough data to show that when 
proper DNA-based typing techniques are being used, even low risk perforating corneal 
transplantations benefit from matching for HLA Class I, and high risk cases from HLA Class I and 
probably Class II matching. Combining HLA class I and class II matching, or using the HLAMatchmaker 
could further improve the effect of HLA matching. However, new techniques could be applied to 
reduce the chance of rejection. Options are the local or systemic use of biologics, or gene therapy, 
aiming at preventing or suppressing immune responses. The goal of all these approaches should be 
to prevent a first rejection, as secondary grafts are usually at higher risk of complications including 
rejections than first grafts. 
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1. Introduction 
 
Cornea transplantations are performed frequently, and results are often excellent. However, many 
cases are not eligible for a transplantation as the chance of rejection is considered too high. Rejection 
may even occur in low risk cases and in lamellar grafts, and one wonders whether matching for the 
HLA antigens may contribute to better graft survival. We review the evidence for this, especially 
focusing on studies in humans, and we looked which potential new approaches may be available to 
clinicians in the near future. 
Since the first successful corneal transplantation in 1905,(Zirm, 1989) many improvements have been 
made that significantly increased graft survival. The development of microsurgery and the operating 
microscope allowed more precise corneal transplantations, and the recognition of the function of 
corticosteroids in the 1950s helped to reduce inflammation and fight potential rejection episodes. In 
1982, a major textbook on immunology mentioned that “The cornea, the transparent membrane of 
the eye, is normally not perfused with blood and does not contain lymphatics, so it is not easily 
accessible to immune cells; when transplanted, it enjoys the status of a privileged graft. However, 
even in this favorable situation, graft rejection sometimes occurs, presumably because of damage to 
the grafting site inflicted by surgery”.(Klein, 1982) It is clear that immunological theory and animal 
experiments led to the idea that corneas were hardly susceptible to rejection. Indeed, when looking 
nowadays at all cases, corneal allografting is one of the most successful forms of solid organ 
transplantation. Still, in spite of the great results in experimental corneal transplantation in rats, and 
the excellent results in certain groups of patients and types of corneal transplants, immune- 
mediated graft rejection remains the single most important cause of short- and long-term corneal 
graft failure. This is also the case when a cornea is implanted in normal- or low-risk patients.(Coster and 
Williams, 2005; Kuchle et al., 2002; Qu and Xie, 2010; Wilson and Kaufman, 1990) While overall survival rates for full thickness 
grafts are close to 90% one year after transplantation, they subsequently steadily decline.(Ing et al., 1998; 
Williams et al., 2006) At ten years, in random transplants, the overall graft survival rate is 60%-80%,(Coster and 
Williams, 2005; Ing et al., 1998; Inoue et al., 2000a; Thompson et al., 2003; Williams et al., 1997) with an immunological rejection rate 
after fifteen-years ranging from 21% to 29%.(Patel et al., 2004) Due to changes in surgical techniques, we 
now see fewer full thickness grafts, and anterior and posterior corneal replacements are gaining 
popularity, but rejection has been reported as still having a major impact, also in lamellar 
keratoplasties.(Allan et al., 2007; Mashor et al., 2010; Reinhart et al., 2011) 
One assumed that matching of donor and recipient for HLA (human leukocyte) antigens was not 
necessary in corneal grafting due to the already protective ocular immune privilege; it is therefore 
not surprising that HLA matching studies were performed for kidney transplantation soon after the 
identification of the HLA antigens as a potential transplantation antigen system, but that HLA 
matching was only sporadically analysed for corneal transplants. When these studies were 
performed, the outcomes led to controversial results regarding the benefit of HLA matching to 
reduce corneal allograft rejection.(Baggesen et al., 1991; Beekhuis et al., 1991; Ehlers and Kissmeyer-Nielsen, 1979; Foulks et al., 1983; 
 79 Matching for Human Leukocyte Antigens (HLA) in corneal transplantation - To do or not to do 
Hargrave et al., 2004; Hoffmann and Pahlitzsch, 1989; Reinhard et al., 2003; Stark et al., 1978; The Collaborative Corneal Transplantation Studies Research 
Group, 1992; Vail et al., 1997; Vannas, 1975) A difference is especially observed between most European studies and 
the main study performed in the USA, the CCTS study. Subsequently, a long-term discussion on the 
benefit of HLA typing and matching and the strong opinions of some leaders in the field have 
discouraged research in this field, and one wonders whether that is correct. As every immune 
rejection starts with direct or indirect recognition of donor major or minor HLA-antigens as being 
foreign, there are still good reasons to unravel and not directly to disregard the role of HLA matching 
in corneal transplantation, and to properly evaluate the existing data. 
It is essential to find ways to improve cornea graft survival in high risk cases, especially as a large 
group of patients with severe corneal disease is not even being considered for a human graft due the 
high risk of rejection, such as cases with severe burns or Stevens Johnson's disease. Limbal 
transplantation is not discussed in this review, but its application is severely limited due to the very 
high frequency of graft rejection.(Fernandes et al., 2004) 
We will therefore address 1) the role of transplantation immunology in corneal transplantation, and 
specifically the role of HLA antigens in antigen presentation; 2) the influence of HLA matching in 
corneal graft survival, for both the major and minor histocompatibility antigens, and 3) discuss 
immunological approaches that may increase graft survival. We will focus on studies that may be 
clinically relevant in the near future, and will therefore limit the description of new basic research 
data in mice. 
 
2. Corneal transplantation immunology 
 
2.1. High and low risk cases 
The cornea is the most-commonly transplanted tissue in humans, with over 65,000 transplants being 
performed worldwide each year.(Williams et al., 2009) Part of the success of corneal transplantations is 
based on the immune privilege of the cornea, and hence, corneal grafts have a survival benefit over 
organ allografts.(Niederkorn, 2001; Niederkorn and Stein-Streilein, 2010; Niederkorn, 2006; Skelsey et al., 2001; Streilein, 2003) 
Notwithstanding the irrefutable role that the immune privilege plays in the success of corneal 
grafting, it will not completely protect the unmatched graft from immune rejection, but only curtail 
the effect of immune responses. Graft survival is related to the status of the recipient bed, such as 
the amount of vascularization, and the underlying disease, and not so much to the recipient's age in 
the Australian data (Figs. 2-6). The latter finding is in contrast with other reports, such as Vail et al. 
(1997), who in a cohort of 2777 grafts studied in the UK Corneal Transplant Follow up Study observed 
less rejection with advancing age. While other causes of failure increased with age, graft survival did 
not differ. Vail's study showed that the risk of rejection was associated with the presence of 
glaucoma, inflammation, regrafting and large graft size. These associations point to the importance 
of the recipient bed: analyses of human corneas and animal studies have shown that the number of 
antigen-presenting cells in the receiving cornea play an important role: low- or normal-risk patients 
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have an avascular cornea, no inflammation and thus only a few antigen-presenting cells, and have 
long-term graft survival rates ranging from 62 to 96% after 10 years.(Williams et al., 1997) On the other 
hand, high risk patients with corneal vascularization in several quadrants of the cornea, active 
herpetic infection, and high densities of Langerhans' cells, have 10-year graft survival rates of 35%-
41% (Thompson et al., 2003; Williams et al., 1997) Thompson et al. (2003) studied 3992 consecutive eyes that 
underwent a penetrating keratoplasty at a large tertiary care center, and reported that the most 
common causes of graft failure were endothelial failure and immunologic endothelial rejection. 
Keratoconus had the best 10-year survival, at 92%, while first regrafts had only 41% graft survival at 
10 years. The presence of deep vessels at more than 3 clock hours led to 65% 10-year overall graft 
survival versus 82% in non-vascularized cases. As already mentioned, patients with highly-
vascularized corneas are often not considered candidates for grafting, as their chances of developing 
rejection are too high. It is noteworthy that the transplants in the most successful cases, i.e. in 
keratoconus and primary endothelial dystrophy of Fuchs, are the conditions with the least amount of 
vascularization.(Jager et al., 1988) Retransplants are often placed in vascularized recipient beds, and every 
subsequent regraft has a lower chance of surviving.(Thompson et al., 2003; Williams et al., 1997) 
If one also takes into account that upon failure of the primary graft, often a re-graft is performed, 
(Bersudsky et al., 2001; George and Larkin, 2004; Qu and Xie, 2010; Williams et al., 1997; Yahalom et al., 2005) it is obvious that reducing the 
risk of immunologic primary allograft rejection and understanding its mechanism is of vital 
importance to improve vision, to reduce graft loss and to prevent retransplantations. 
 
2.2. Immune privilege 
The immune privilege of corneal allografts is based on at least six physiological mechanisms, which 
either block the induction of the immune response, deviate the immune response towards a 
tolerogenic pathway or help to escape the immune attack:(Niederkorn and Larkin, 2010) 
 
1) Absence of corneal lymph and blood vessels and blockade of lymph vessel formation, together 
with a relative lack of lymphatic drainage from the eye, ensures that antigens can only leave the 
eye via the aqueous draining system into the blood-stream.(Albuquerque et al., 2009) The aqueous 
outflow will carry antigens to the spleen, rather then the draining lymph nodes, which will then 
act as the primary lymphoid tissue.(Streilein, 1995) 
2) Inducement of regulatory T cells by the allograft, which inhibits the induction and function of the 
alloimmune T cells.(Chauhan et al., 2009; Yamada et al., 2005) 
3) Protection from complement-mediated cytolysis.(Bora et al., 1993; Hargrave et al., 2003; Hegde et al., 2002; Lass et al., 
1990) 
4) Induced apoptosis of neutrophils and T cells at the graftehost interface.(Stuart et al., 1997; Yamagami et al., 
1997) 
5) Diminished corneal T-cell proliferation(Hori et al., 2006; Jager et al., 1995; Shen et al., 2007) and, 
6) Diminished NK cell activation.(Apte et al., 1998; Apte and Niederkorn, 1996) 
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Corneal immunosuppression is not a passive system based on the absence of antigen recognition, as 
was originally thought, but consists of active immunological interactions with many different players. 
The combined effect of these active mechanisms that inhibit immune response after introduction of 
antigen in the anterior chamber is known as anterior chamber-associated immune deviation.(Niederkorn, 
2006; Stein-Streilein and Streilein, 2002; Streilein, 2003) Antigens placed into the anterior chamber of murine eyes are 
taken up by specific macrophages in the iris, which subsequently migrate to the spleen. The presence 
of TGF beta in the anterior chamber modifies the antigen-loaded macrophages in such a way that 
they develop immunosuppressive characteristics.(Wilbanks and Streilein, 1992) Leakage of donor corneal 
proteins into the anterior chamber of the eye may thus induce anterior chamber-associated immune 
deviation. Additionally, the compact architecture of the corneal stroma is believed to inhibit the 
infiltration of immune cells and the blood-aqueous barrier prevents immunologically-active cells and 
factors from entering the ocular tissue.(Streilein, 1995) Although functional antigen-presenting cells (APCs) 
are present in the peripheral and paracentral cornea, they are scarce and mostly immature in the 
healthy central cornea, resulting in weak local antigen presentation.(Mayer et al., 2007) As grafts are usually 
placed centrally, they encounter only a few APCs. This may of course be different when inflammation 
is present, bringing in massive numbers of APCs, as is the case e.g. in herpetic corneal 
infections.(Williams et al., 1989) Corneal tissue by itself is able to produce cytokines to inhibit T cell 
responses;(Jager et al.,1995) the nature of the factors that are involved has not yet been elucidated. In the 
clinical setting, a local immune response, elicited by the corneal transplantation, is further tempered 
by topical corticosteroids applied to the cornea post-operatively, supported (when needed) by oral 
immunosuppressive agents.(The Collaborative Corneal Transplantation Studies Research Group,1992) Mucosal tolerance can 
also be induced by conjunctiva-associated lymphoid tissue.(Dua et al., 1995) 
 
2.3. Histocompatibility antigens 
The first descriptions, of what is now known as the Human Leukocyte Antigen (HLA) system, the 
major histocompatibility complex (MHC) in humans, date from 1958.(Dausset, 1958; Payne and Rolfs, 1958; van Rood et 
al., 1959) As many ophthalmologists who perform corneal transplantations are not immunologists, we 
will include a description of the development of the HLA system, which explains its weird 
nomenclature. 
In 1936, Peter A. Gorer, studying allogeneic tumor transplantation in mice, discovered the presence 
of an antigen (antigen II) responsible for rejection (Gorer, 1936); additionally, he found that the sera 
of mice, that had received an allogeneic tumor, contained antibodies against this tumor.(Gorer, 1937) In 
1944-45, Peter Medawar confirmed that an immune response against the graft was responsible for 
rejection of allogeneic transplants.(Medawar, 1944, 1945) After the Second World War, Gorer continued his 
work, together with George D. Snell, and found that his antigen II was encoded by a gene on the H 
locus in mice.(Gorer et al., 1948) In 1958, Dausset (1958), van Rood et al. (1959), and Payne and Rolfs (1958) 
laid the foundation of what is now known as the HLA complex. They studied human sera obtained 
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from multi-transfused patients or multiparous women and noted that antibodies in these sera 
reacted with leukocytes from many other individuals, but not all, thus demonstrating the existence of 
a polymorphic system. The first named antigen was H2, for which Dausset gets the credits.(Dausset, 1958) 
Van Rood noticed that serum from a multiparous woman who developed a blood transfusion 
reaction contained antibodies against white blood cells instead of erythrocytes, and using sera from 
many women and a leukocyte agglutination assay, he identified a series of antigens. Van Rood 
reported the existence of a bi-allelic system of leukocyte antigens, which he called 4a and 4b (now 
known as HLA-Bw4 and -Bw6).(van Rood, 1962) Other researchers identified other leukocyte antigens, and 
when the International Histocompatibility Workshops were established, different researchers were 
able to compare their work. This led to the discovery that most of these leukocyte antigens were 
genetically closely linked, and inherited at one chromosomal region, which was originally called HL-A 
(Human Leukocyte, locus A),(Thorsby and Lie, 2005) with the letters forming also a combination of the H of 
Dausset's H2 locus, and Rose Payne's LA antigens.(Terasaki, 1990; van Rood, 1969) The chromosomal region that 
codes for the HLA antigens is located on the short arm of chromosome 6 and responsible for the 
polymorphic HLA complex. At the time it was discovered that there were different Class I loci,(Kissmeyer-
Nielsen et al., 1968) many antigens had already been identified and given a number, and this explains the 
strange numbering of A's and B's (A1, A2, A3, Bw4, B5, Bw6, B7, B8, A9, etc). The terms Class I for 
HLA-A, -B and -C and Class II for HLA-DR, -DQ and -DP were introduced by Klein (1977) and Thorsby 
and Lie (2005). 
The primary biological role of these HLA antigens is not to impede tissue matching (although the 
name histocompatibility antigens seems to suggest that this is the most important function of these 
antigens), but to present all kind of antigens to the immune system. Antigen presentation is 
important in the recognition of environmental pathogens such as viruses, bacteria and fungi, to 
which the direct innate immune system and subsequently the adaptive immune system must 
develop an adequate response. HLA antigens contribute to the induction of immune responses, as 
well as to the effector phase, by presenting target peptides to helper and effector T cells. 
As already mentioned, HLA antigens are divided into two classes, HLA Class I and Class II. HLA Class I 
antigens are derived from the three classical loci HLA-A, -B and -C and the non-classical loci HLA- E, -
F, -G, -H, -I and -J, and are expressed on platelets and almost all nucleated cells, except most cells of 
the central nervous system. The HLA Class I molecules present peptides, derived from proteins that 
are broken down inside the cell, to cytotoxic CD8- positive T cells. HLA Class II consists of three main 
genetic loci, HLA-DR, -DQ and -DP, and these molecules are expressed on some immunological cells 
such as B cells and activated T cells, and especially on antigen-presenting cells such as dendritic cells, 
macrophages, and monocytes, and on endothelial cells and thymic epithelial cells. The Class II 
molecules present peptides from exogenous antigens to the CD4-positive helper T cells. Cytokines 
can modify the level of expression of Class I and II molecules. The HLA genes are the most 
polymorphic genes in the human genome, providing a great diversity of HLA alleles, with each 
specific allele having the ability to present certain antigens better or worse than other alleles. 
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Transplanting tissue from one individual into another introduces a new set of donor HLA antigens 
into the recipient. The peptides that are derived from the foreign HLA molecules can either be 
presented by the patient's own HLA molecules, or by the donor's that are present in the graft (Fig. 1). 




Figure 1. Pathways of recognition of HLA antigens (MHC) and mechanisms of graft rejection. 
 
 
the donor tissue as foreign, and this may induce an immune response that ultimately ends in 
irreversible graft rejection. Reducing the differences in HLA antigens between donor and host by HLA 
matching should reduce the risk of rejection. HLA matching as a method to reduce graft rejection in 
living-related kidney transplantation came in use in the 1970s, when it was widely acknowledged that 
transplantation between HLA-identical living-related individuals was superior to other methods to 
improve graft survival.(Singal and Skinnider, 1970; Thorsby and Lie, 2005) Matching was first started using the HLA Class 
I antigens, but it took until 1978, after the identification of HLA-DR, before HLA-matching for 
cadaveric kidney transplantation showed beneficial results.(Albrechtsen et al., 1978a, 1978b; Opelz, 1985; Persijn et al., 1978; 
Ting and Morris, 1978) 
In spite of all the mechanisms that are involved in the immune privilege of the eye, corneal graft 
rejection can occur and is caused by the immune response generated by recognition of host antigens. 
In spite of the early assumption that transplanted corneas would enjoy immunological privilege and 
could not be rejected, clinical data and early animal experiments demonstrated that especially grafts 
in vascularized recipients can be rejected.(Maumenee, 1951) Rejection can take place in all three distinctive 
corneal cell layers or in one layer only: the epithelium, stroma and endothelium. (Khodadoust and Silverstein, 
1969) Knowledge about the distribution of the HLA antigens is therefore important to comprehend the 
rejection process. As graft rejection occurs most commonly in the endothelium,(Chong and Dana, 2008) one 
would expect this cell layer to have the highest expression of HLA antigens. This is not the case. HLA-
A, -B and -C (Class I) are present at high levels on epithelial cells, especially near the limbus, at lower 
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levels on the stromal keratocytes and even less on the endothelium, although conflicting reports 
exist regarding the latter.(Baudouin et al., 1988; Pepose and Benevento, 1991; Treseler et al., 1984; Whitsett and Stulting, 1984; Williams et al., 
1985) 
HLA-C is expressed at 10e35% of the levels of HLA-A or –B,(Bunce and Welsh, 1994; McCutcheon et al., 1995) and is 
considered a weak transplantation antigen with no known role in matching for allografts. (Ferrara et al., 
1978) The Class II antigens HLA-DR, -DQ and -DP (Class II) are not expressed by the three corneal layers 
in the healthy eye; however, Class II positive epithelial dendritic cells are present, mainly in the 
peripheral corneal epithelium.(Baudouin et al., 1988; Pels and van der Gaag, 1984; Pepose and Benevento, 1991; Treseler et al., 1984; 
Whitsett and Stulting, 1984; Williams et al., 1985) Studies on rejected human corneas show that inflammation leads to 
expression of HLA Class II in all cell layers.(Donnelly et al., 1985; Dreizen et al., 1988) 
Of the 'non-classical' HLA antigens (HLA-E, -F, -G, -H, -I and -J), only HLA-E (four alleles) and -G (three 
alleles) are known to be polymorphic and little is known about their expression and phys- iological 
role in the cornea. They have no known relevance to clinical corneal transplantation,(Taylor and Dyer, 1995) 
although HLA-G is expressed in all three corneal layers.(Le et al., 2003) Histocompatibility antigen 
expression is higher in corneas of younger persons compared with older persons.(Whitsett and Stulting, 1984) 
Indeed corneal rejection risk is higher for grafts from young (0-5 years) than from older persons (40-
70 years).(Palay et al., 1997) 
Aside from the major histocompatibility antigens, minor histocompatibility antigens (minor H 
antigens) exist. Minor H antigens are peptides presented by the HLA complex, and are derived from 
polymorphic proteins. A donor can have a different variant of the same protein as the host, which 
upon presentation of its peptides by HLA Class II molecules on donor or host APCs, will be recognized 
as foreign and can induce a strong immune reaction against the graft; this has been well documented 
in HLA-identical stem cell transplantations.(Dickinson et al., 2002; Goulmy et al., 1996; Goulmy, 2006) 
Known minor H antigens expressed on corneal tissue are HY, the male-specific minor H antigen, and 
HA-3.(de Bueger et al., 1992; Goulmy et al., 1995; Peeler et al., 1988; Ross et al., 1991; Sonoda and Streilein, 1992) Animal studies have 
demonstrated that minor antigens can be an important target for immune responses in corneal 
transplantations. (Haskova et al., 2003; Sano et al., 1996, 1999) 
 
2.4. Immune rejection 
Once a recipient's immune system recognizes the allograft as foreign, rejection will occur. In general, 
rejection can be defined as hyperacute, acute or chronic.(Bush, 1999) Hyperacute rejection is the most 
rapid and aggressive form and takes place immediately after implantation. This type of rejection has 
been described in solid organ transplantation and is mediated by circulating antibodies, directed 
against ABO-blood group or HLA antigens or both; such antibodies may have developed as the result 
of a previous antigen exposure, such as a blood transfusion or pregnancy.(Wood and Goto, 2012) With regard 
to corneal allografts, early studies found an influence of ABO incompatibility in high risk patients,(Inoue 
and Tsuru, 1999; Maguire et al., 1994) but more recent studies did not confirm this. (Dunn et al., 2009; Soma et al., 2004; Stulting et 
al., 2012) In contrast to the clear role which anti-HLA alloantibodies have in solid organ transplantation, 
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their role is not entirely clear in corneal transplantation. Although they can exacerbate a rejection, 
alloantibodies are not believed to be by themselves capable of acutely rejecting corneal grafts, most 
likely due to the lack of blood vessels in low risk grafts.(George and Larkin, 2004; Goslings et al., 1998; Stein-Streilein and 
Streilein, 2002) This minor influence of alloantibodies, together with the avascularity of the cornea, 
explains that hyperacute corneal rejection, if at all, seldom occurs. However, it should not be ignored 
that allosensitization as the result of previous antigen exposure still has an important influence on 
corneal transplant survival, even if it does not lead to acute rejection. The negative effects of 
immunization were found to be independent of the degree of vascularization.(Roy et al., 1992) Regrafting is 
undesirable as it leads to a higher chance of rejection and moreover, the fast occurrence of graft 
failure after a re-transplantation indicates the importance of absent prior allosensitization before 
grafting (Fig. 2).(Coster and Williams, 2005; Niederkorn and Larkin, 2010; Williams et al., 2012) The role of allo-antibodies in any 




Figure 2. Kaplan-Meier survival plot for corneal graft survival according to the number of previously-rejected ipsilateral 
transplants. Regrafts have significant worse graft survival (log-rank test). Used with permission from Department of 
Ophthalmology, Adelaide: The Australian Corneal Graft Registry 2012 Report; KA Williams, MT Lowe, MC Keane, VJ Jones, 
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Acute rejection manifests within days to months and is initiated by the recognition of new foreign 
antigens by the immune system: this type of rejection is antibody as well as cell-mediated.(Game and 
Lechler, 2002) With adequate and timely treatment, acute rejection can be resolved, although it can still 
predispose the host to chronic rejection.  
Chronic rejection develops slowly and usually occurs after months or years and is believed to be 
mediated by antibody and cell-mediated immune responses with macrophage involvement.(Game and 
Lechler, 2002) Despite improvements in immunosuppressive therapies which can prevent and control 
acute rejection, chronic rejection is still a major problem, and has become the major cause of solid 
organ.(Bush, 1999; Racusen, 2003), and corneal allograft failure (Coster and Williams, 2005; Ing et al., 1998; Inoue et al., 2000a; Patel et al., 2004; 
Thompson et al., 2003; Williams et al., 1997, 2006) 
With regard to the different corneal cell layers, epithelial rejection is, although probably common, 
generally quiet, asymptomatic, transient and usually does not affect graft survival.(George and Larkin, 2004; 
Khodadoust and Silverstein, 1969; Prendergast and Easty, 1991) Stromal rejection is relatively common, can progress to 
endothelial rejection if not treated, and can be acute or chronic,(George and Larkin, 2004; Khodadoust and Silverstein, 
1969; Panda et al., 2007; Prendergast and Easty, 1991) as infiltrating stromal cells may persist for several years in the 
allograft.(Macdonald et al., 2010) Endothelial rejection can be acute or chronic, and is the most symptomatic 
and serious one of the three types of rejection.(Khodadoust and Silverstein, 1969) Endothelial cells persist for life 
as they are hardly proliferative. Therefore cell loss due to recurrent reversible rejection episodes may 
lead to graft failure due to endothelial decompensation.(Bourne, 2001; George and Larkin, 2004; Joyce et al., 1996; 
Prendergast and Easty, 1991) 
Once the immune privilege of the anterior chamber and cornea has been compromised, a local 
immune response may lead to graft rejection. The loss of immune privilege may either be due to 
inflammation caused by the allograft itself, or to other causes of inflammation, corneal 
vascularization, or ocular surface diseases. A well-known trigger of rejection is a loose suture, which 
will attract mucous and bacteria and become a focus for leukocyte accumulation (macrophages, 
Langerhans' cells, T cells) inducing local upregulation of HLA antigens.(Jonas et al., 2002) Immune rejection 
involves both the innate and adaptive immune response. Major and minor H antigens can be 
recognized indirectly via presentation through the innate immune system and directly via the 
adaptive immune system as illustrated in Fig. 1.(Game and Lechler, 2002; Sayegh and Turka, 1998) The innate immune 
response (neutrophils, macrophages) on its own is not capable of rejecting the graft and the 
involvement of the adaptive immune response (T cells) is required.(Krensky et al., 1990; Niederkorn, 2007) The 
major bridge between the two is the interaction between APCs of the innate immune system and T 
cells of the adaptive system. APCs, of both the donor and host, are able to pick up material shed from 
the graft and activate the adaptive immune system by presenting these antigens to the CD4+ T 
helper cells. These CD4+ T helper cells play a central role in recruiting effector cells into the graft, as 
they are able to activate CD8+ cytotoxic T cells which subsequently attack the donor cells, and B cells 
which start producing antibodies against donor antigens. Furthermore, CD4+ T cells recruit 
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macrophages, granulocytes, and NK cells, and activate the complement system. All of these players 




Figure 3. KaplaneMeier survival plot for corneal graft survival according to the recipient age (keratoconus excluded). Age at 
time of grafting had no significant effect on graft survival (log-rank test). Reprinted with permission from: Department of 
Ophthalmology, Adelaide: The Australian Corneal Graft Registry 2012 Report; KA Williams, MT Lowe, MC Keane, VJ Jones, 
RS Loh, DJ Coster (Eds); 2012, pp. 1-246. URL: http://hdl.handle.net/2328/25859. 
 
Number at Risk 
  Identity Initially 3 years 6 years 9 years 12 years 15 years 18 years 21 years 
≤49 years 2060 868 454 235 142 73 26 5 
50 - 59 years 1235 529 273 144 77 30 7 n/a 
60 - 69 years 2102 907 471 224 109 34 5 1 
70 - 79 years 3548 1316 541 176 62 14 2 1 
≥80 years 2467 558 156 32 4 1 n/a n/a 
 
 
In the adaptive immune system, CD4+ T cells of the host respond directly to donor HLA Class II 
antigens, which are expressed on APCs, while CD8+ T cells of the host recognize donor HLA Class I 
antigens, present on the cell surface of donor corneal cells.(Game and Lechler, 2002; Sayegh and Turka, 1998; Wood and 
Goto, 2012) 
Direct recognition plays a major role in acute rejection, while indirect recognition is additionally 
involved in acute and chronic rejection.(Auchincloss et al., 1993; Lee et al., 2001; Sayegh and Turka, 1998) Involvement of the 
adaptive immune response and especially of the T cells is required for corneal graft rejection,(Krensky et 
al., 1990; Niederkorn, 2007) but not necessarily simultaneously.(Hegde and Niederkorn, 2000) While studies in mice 
showed that minor H antigens may even have a more important role in rejection than major MHC 
antigens, very few studies have been performed to determine the presence of T cells directed against 
minor antigens in human corneal transplant rejections. 
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2.5. Cellular and humoral anti-corneal immune responses in humans 
Once antigen presentation has occurred, immune responses against the graft may be 
induced.(Maumenee, 1951) It is possible that previous sensitization through an earlier graft or pregnancy 
has occurred, which has induced either an antibody or cellular immune response against the cornea, 
against minor antigens or against the HLA antigens. Many studies about the role of such immune 
responses have been performed in rabbits or mice, but only some studies regarding T cell or antibody 
responses are available regarding humans. In Leiden, crossmatches between recipient serum and 
cornea donor leukocytes have been performed since 1968, as antibodies were considered a risk 
factor for corneal graft rejection. Additionally, screening was performed in potentially-sensitized 
individuals to determine the presence of antibodies against a panel of leukocyte donors.(van Rood et al., 
1976) This was initiated after early studies had shown that anti-leukocyte antibodies are present in 
cornea recipients. While one study showed the presence of directly lympho-cytotoxic T cells in the 
blood of corneal transplant recipients but hardly of any antibody,(Grunnet et al., 1976) a second study from 
the same group on one case correlated graft rejection with the presence of an antibody-dependent 




Figure 4. Kaplan-Meier survival plot for penetrating corneal graft survival according to the pre-graft vascularization status. 
Graft survival was shorter when more quadrants were vascularized (log rank test). Reprinted with permission from: 
Department of Ophthalmology, Adelaide: The Australian Corneal Graft Registry 2012 Report; KA Williams, MT Lowe, MC 
Keane, VJ Jones, RS Loh, DJ Coster (Eds); 2012, pp. 1-246. URL: http://hdl.handle.net/2328/25859. 
 
Number at Risk 
Identity Initially 3 years 6 years 9 years 12 years 15 years 18 years 21 years 
Not vascularized 11168 4871 2488 1266 703 336 123 34 
1 quadrant 1158 417 182 60 22 7 n/a n/a 
2 quadrants 1721 614 267 136 71 25 4 n/a 
3 quadrants 844 312 153 67 34 18 5 2 
4 quadrants 1400 386 162 63 30 14 4 n/a 
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In the U.S.A., Stark collaborated with Terasaki, one of the first experts in identifying anti-HLA 
antibodies, to investigate the development of lymphocytotoxic antibodies in corneal transplant 
patients.(Stark et al., 1973) The presence of allo-antibodies was determined on a panel of leukocytes from 
90 to 100 individuals in the microlymphocyte cytotoxicity test. Three cases had antibodies prior to 
transplantation, and all three developed a rejection.Five out of six patients who were negative prior 
to transplantation and developed a corneal graft rejection developed such antibodies, versus only 
one of eight patients who did not reject and had a successful transplant.(Stark et al., 1973) As this study 




Figure 5. Kaplan-Meier survival plot for corneal graft survival according to main indications for penetrating grafts. The 
variation in survival across the main indications was significant (log rank test); keratoconus had the longest survival, and 
corneal ulcers the shortest. Reprinted with permission from: Department of Ophthalmology, Adelaide: The Australian 
Corneal Graft Registry 2012 Report; KA Williams, MT Lowe, MC Keane, VJ Jones, RS Loh, DJ Coster (Eds); 2012, pp. 1-246. 
URL: http://hdl.handle.net/2328/25859. 
 
Number at Risk 
 Identity Initially 3 years 6 years 9 years 12 years 15 years 18 years 21 years 
Corneal scars & opacities 314 118 68 22 13 2 n/a n/a 
Corneal ulcers (not HSV) 349 71 32 15 6 1 n/a n/a 
Bullous keratopathy 3814 1236 475 168 62 20 4 1 
Corneal dystrophies 1806 872 429 188 96 35 7 2 
Non-herpetic infections 221 60 32 12 7 3 n/a n/a 
Herpetic eye disease 692 287 151 87 50 26 4 2 
Trauma 266 103 54 21 9 3 n/a n/a 
Keratoconus 4930 2444 1367 781 471 251 98 27 
Interstitial keratitis 151 81 41 19 11 n/a n/a n/a 
Corneal degeneration 117 33 16 7 3 1 n/a n/a 
Congenital abnormalities 67 25 15 10 10 5 3 n/a 
Failed previous graft 3277 1152 522 225 105 40 17 4 
Other 287 112 56 30 17 11 3 n/a 
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led to a clear advice regarding testing of corneal transplant patients for the presence of cytotoxic 
antibodies: patients should be screened when there is a history of pregnancy, blood transfusion, or 
previous corneal transplant failure, upon which a cross-match test between the serum of the 
sensitized patient and cells from the potential donor should be performed, and mismatches of the 
same specificity as the cytotoxic antibodies of the recipient should be avoided. These criteria were 
not all based on scientific data from this study, but were similar to the screening advise given on the 
basis of data on kidney transplants.(Opelz et al., 1973)  
Another study described that even in patients with 100% panel reactivity, acceptable mismatches 
could still be found and could be defined in 80% of these patients.(Vannas et al., 1976) 
The Collaborative Corneal Transplantation Studies Research Group (1992) included a prospective 
study to compare donor-recipient pairs with (37 cases) and without (419 cases) a positive serological 
crossmatch (lymphocytotoxic anti-HLA antibodies): a higher frequency of graft failure due to 
rejection was seen in the cross-match positive group than in the crossmatch negative group.(Hahn et al., 
1995) In another cohort, Des Marchais observed a negative influence of a positive crossmatch only in 
patients who had previously undergone a transplant or already rejected a cornea graft.(Des et al., 1998) In 
a study on 1681 consecutive keratoplasties, Volker-Dieben et al. reported that a panel reactivity of 
more than 10% led to a significantly-increased chance of rejection in moderately to severely 
vascularized recipients.(Volker-Dieben et al., 2000) When looking at an IgM crossmatch between patient serum 
and corneal donor rims, antibodies were found in 28% versus 25% of the recipients with preformed 
anti-HLA antibodies.(Sel et al., 2012) Although these studies provide some evidence that the presence of 
anti-HLA antibodies has an adverse effect on penetrating corneal transplants, too few studies have 
reported on their importance in different types of corneal diseases, or their importance for re- 
transplants after rejection. Recently, Sel et al. studied the impact of pre-existing donor-specific allo-
antibodies against donor HLA Class I or II prospectively using a novel ELISA-based crossmatch 
procedure: in a short-term follow-up study, they found a 50% lower rejection rate in patients without 
allo-antibodies.(Sel et al., 2012) This is in accordance with the finding in solid organ transplantation that 
allo-antibody formation is related to acute and especially chronic allograft rejection.(Doxiadis, 2012; Terasaki, 
2003) 
Antibodies can be directed against major and minor HLA antigens or against corneal antigens. Nelken 
analyzed whether a corneal transplantation induced the development of antibodies that bound to 
corneal antigens, and indeed, in 15/33 cases such antibodies were observed.(Nelken and Nelken, 1965) Some 
studies analyzed responses against a specific soluble corneal protein, known as BCP 54 (Bovine 
cornea protein 54),(Jager et al., 1991) which has been identified to correspond to corneal aldehyde 
dehydrogenase (ADH).(Verjans et al., 1990) Antibodies against this antigen occur in healthy controls, but also 
in patients with Fuchs' heterochromic cyclitis or uveitis,(Kruit et al., 1985; van der Gaag et al., 1989) and such 
antibodies were found to be present in over 40% of cornea transplantation patients. Similarly, 
patients often displayed a T-cell mediated reactivity against this antigen.(Jager et al., 1994) No prognostic 
value could be attributed to the presence of a humoral or cellular anti-BCP 54 immune response, but 
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it was interesting that five of the six patients who had a rejection episode during the study period 
had anti-BCP antibodies prior to transplantation and changed from a negative to a positive cellular 
anti-BCP 54 response.(Jager et al., 1991) These studies suggest an increase in T cell reactivity against 
corneal antigens as the result of local inflammation, not necessarily as the cause of rejection. 
Furthermore, there may be a subgroup of patients who tend to develop any type of immune 
response.  
Earlier, Stark et al. had used the leukocyte migration inhibition test to determine the presence of a 
cellular immune response in corneal graft recipients.(Stark, 1980) Only patients who had rejected a graft 
at the time of testing showed a positive response. 
Roelen et al. determined the presence of cytotoxic T lymphocytes (CTLs) against mismatched donor 
Class I antigens in patients 
 
 
Figure 6. Kaplan-Meier survival plot for corneal graft survival according to the main indications for lamellar grafts. The 
variation in survival across the main indications was significant (log rank test); pterygium had the longest survival, and 
bullous keratopathy the shortest. Reprinted with permission from: Department of Ophthalmology, Adelaide: The Australian 
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with and without a corneal graft rejection. CTLs were divided into naïve and primed CTLs based on 
their sensitivity or resistance to anti-CD8 or cyclosporine A in vitro. Rejections were strongly 
associated with the presence of primed donor-specific CTLs.(Roelen et al., 1995) 
All the different types of corneal transplantation and not only penetrating corneal transplants can 
lead to rejection as shown by data of the Australian Corneal Graft Registry for anterior (Figs. 7 and 8) 
and posterior keratoplasties (Fig. 9). Tan describes that in penetrating keratoplasty (PK), acute 
endothelial rejection occurs in 20% of the cases during 5-year follow up. While in anterior lamellar 
keratoplasty (ALK) there is no risk of endothelial rejection as the endothelium is not transplanted, 
stromal rejection occurs only in 1-2%. This lack of rejections is probably not directly related to the 
tissue characteristics, but to the disease, as ALK are mostly performed for keratoconus, a type of 
corneal disease that is not associated with corneal angiogenesis, and leads to infrequent rejection 
even in PKs. In endothelial keratoplasty (EK), endothelial rejection rates are probably similar as in PK. 




Figure 7. Kaplan-Meier survival plot for corneal graft survival according to type of keratoplasty (irregardless of indication). 
Penetrating grafts survived longer than the lamellar grafts (log rank test). Reprinted with permission from: Department of 
Ophthalmology, Adelaide: The Australian Corneal Graft Registry 2012 Report; KA Williams, MT Lowe, MC Keane, VJ Jones, 
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Figure 8. Kaplan-Meier survival plots of observed penetrating corneal grafts(penetrating) and deep anterior lamellar 
keratoplasty (DALK) procedures performed from 1996 through 2013 for keratoconus. The numbers on the plot represent 
the number of grafts at risk in each stratum. The differences between the curves are significant at P < 0.001 (log-rank test). 
Penetrating grafts for keratoconus fared significantly better than DALK procedures for the same indication over the same 
era. Reprinted from Ophthalmology, Vol. 121/5, DJ Coster, MT Lowe, MC Keane, KA Williams, A comparison of lamellar and 
penetrating keratoplasty outcomes: a registry study, pp. 979-987, Copyright 2014, with permission from Elsevier.  
 
 
3. Matching major histocompatibility antigens 
 
Data from the European Eye Bank Association in 1995 indicate that over time, HLA matching has 
been performed less and less, although some confounding factors are present. In 1991, matching for 
HLA Class I was performed in 24% and for Class II in 19% of the transplanted corneas, compared to 
9.5% for both Class I and II in 1995.(Maas-Reijs et al., 1997) This trend continued and in 2008, HLA-Class II 
matching in corneal allografting was performed in only 3.3% of the transplanted corneas reported to 
the European Eye Bank Association.(European Eye Bank Association, 2010) However, a report by BISLIFE, based in 
the Netherlands, reported that 22% of the implanted corneas from centers they are collaborating 
with, were being HLA matched in 2009.(BIS Foundation, 2009) In the Australian Corneal Graft Registry Report 
of 2012, and the Cornea Donor Study published in 2012,(Stulting et al., 2012) HLA-matching rates and 
methods are not mentioned at all and are supposed to be performed rarely, even for corneal 
regrafts, while graft failure as an indication for corneal transplantation is increasing and immune 
rejection remains the main reason of graft failure. The Dutch Organ Transplantation Registry report 
of 2013 mentioned that of the 1286 transplanted corneas, only 46 were HLA-typed.(Leiden van et al., 2014)  
Currently, graft failure is the third or fourth indication for keratoplasty (both penetrating and 
lamellar), depending on the country, and ranges from 12 to 21%, while the percentage is gradually 
increasing overall, (Keenan et al., 2012; Konijn-Janssen et al., 2011; Tan et al., 2014; Williams et al., 2012) the number of grafts for 
Fuchs endothelial keratoplasty is increasing, and this may lead to more regrafts.(Claesson and Armitage, 2013; 
Keenan et al., 2012) This latter study compared first and regrafts for keratoconus, Fuchs endothelial 
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Figure 9. Kaplan-Meier survival plots of observed penetrating corneal grafts (penetrating) and endokeratoplasties 
(endothelial) performed from 1996 through 2013, stratified by indication for graft. The numbers on the plot represent the 
number of grafts at risk in each stratum. A, Grafts for Fuchs' dystrophy; B, Grafts for pseudophakic bullous keratopathy. The 
differences between the curves in (A) and (B) are significant at P < 0.001 (log-rank test). The insets show the data with all 
grafts that failed within the first post-operative month in each stratum that were removed from analysis. Penetrating grafts 
for Fuchs' dystrophy fared better than did endokeratoplasties for the same indication (P < 0.001), even when early graft 
failures were removed from analysis. Reprinted from Ophthalmology, Vol. 121/5, DJ Coster, MT Lowe, MC Keane, KA 
Williams, A comparison of lamellar and penetrating keratoplasty outcomes: a registry study, pp. 979-987, Copyright 2014, 
with permission from Elsevier. 
 
 
dystrophy and bullous keratopathy in Sweden and demonstrated that not only the risk for failure was 
increased, but also the resulting visual outcome was worse when one needed a regraft for 
keratoconus and Fuchs endothelial dystrophy. One should thus look for ways to reduce the need for 
retransplantations. 
One wonders whether more frequent HLA matching might help to prevent retransplantations. 
Matching is more expensive and cumbersome than the random distribution of corneal grafts. We 
looked at the papers that describe the effect of HLA matching on corneal transplant survival (Table 
1), and while studies before 2000 have shown contradictory results for HLA matching for corneal 
allografts, the overall conclusion from more recent studies favours HLA matching for Class I for high 
risk cases (see below). However, the book has not been closed on the effect of HLA-DR typing and 
matching. (Baggesen et al., 1991; Beekhuis et al., 1991; Ehlers and Kissmeyer-Nielsen, 1979; Foulks et al., 1983; Hargrave et al., 2004; Hoffmann and 
Pahlitzsch, 1989; Reinhard et al., 2003; Stark et al., 1978; The Collaborative Corneal Transplantation Studies Research Group, 1992; Vail et al., 1997; Vannas, 
1975) For example with regard to HLA-DR, the collaborative corneal transplantation studies (CCTS) 
found no beneficial effect of HLA-DR matching,(The Collaborative Corneal Transplantation Studies Research Group, 1992) while 
another study found that HLA-DR matching decreased graft survival.(Vail et al., 1994) A third study on the 
other hand found that matching for HLA-DR could inhibit or even obliterate the effect APCs have in 
initiating immune rejection.(Baggesen et al., 1996) The CCTS study was a major study performed in the USA, 
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and showed no positive effect of HLA-DR typing and matching in corneal allografts for HLA-A and -B 
either. However, when one looks closely at the HLA typing data of the CCTS, the outcome of the CCTS 
study was greatly affected by the lack of repeatability of the HLA typing: in a separate study, 
peripheral blood samples that had been used to determine the different HLA alleles in the CCTS were 
retyped, and it was noticed that there were especially problems with regard to HLA-DR.(Hopkins et al., 1992) 
As there was only 55% concordance between the original result and the outcome of retyping, this 
must clearly have prevented proper matching.(Hopkins et al., 1992; Volker-Dieben et al., 2000) Volker-Dieben et al. 
analyzed the effect of erroneous HLA-DR typing in a study where they determined the beneficial 
effect of HLA-DR typing on corneal allograft survival.(Volker-Dieben et al., 2000) Even with 5% erroneous typing 
results, the effect of matching for HLA-DR was lost. The conclusion of the CCTS study, i.e. that 
matching did not lead to better survival, was therefore based on incorrect typing data, and cases that 
were considered well matched, may well have been badly matched. Apart from the influence of 
erroneous matching, the rather aggressive immunosuppressive regimens used in this study possibly 
prevented any positive findings as well.(Armitage, 2004; The Collaborative Corneal Transplantation Studies Research Group, 1992; 
Volker- Dieben et al., 2000) One may wonder whether proper matching might reduce the amount of 
immunosuppression needed, or whether the use of aggressive immunosuppressive treatment 
overcomes the need for HLA matching in corneal transplantation. As corticosteroids may have many 
side effects, we will ask the question whether other studies support the use of HLA matching in 
corneal transplantation.  
When we take into account the differences between low- and high- risk patient populations with a 
focus on recent findings, a positive effect of serological HLA-matching is certainly found for corneal 
allografting, and is most profound in the high risk patient group. The diversity in the reported results 
can be explained by the fact that in many studies, serological HLA typing was performed, which has 
been reported to be erroneous in 16-35% of the cases, and not the DNA-based HLA typing 
techniques which are much more accurate and came gradually into use around 2000.(Bozon et al., 1997; Yu et 
al., 1997; Zafar et al., 2003) The standardization of HLA typing techniques has been essential in improving 
results. While typing for HLA Class I antigens was well developed around 1978,(Albert et al., 1976; Terasaki et al., 
1978) problems with HLA-DR typing were still encountered in 1992.(Volker-Dieben et al., 2000) 
The application of DNA-methods to determine HLA gene poly-morphisms should be able to produce 
conclusive results on the benefit of HLA matching in corneal grafting. The influence of minor H 
antigens could be another factor explaining the contradictory results.(Nicholls et al., 1991) 
 
3.1. Early studies on HLA matching 
In 1986, a major study was published in the New England Journal of Medicine (Sanfilippo et al., 
1986). This study reported on a prospective masked study at two hospitals, using ABO- compatible, 
crossmatch-negative recipients, matched for HLA-A and -B antigens. Only patients with 
vascularization of two or more quadrants or having a history of prior corneal-graft loss due to 
immune-mediated rejection were included. Post-operatively, topical corticosteroids were applied
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two to three times per day. The well-matched recipients developed a rejection episode in 21% of 
cases, versus 49% in the poorly-matched group. 
According to a report published in 1995,(Beekhuis, 1995) cornea transplant centers in the Eurotransplant 
area (The Netherlands, Germany, Belgium and Austria) used HLA-matched grafts in 19% of cases. 
However, between centers, this percentage varied between 0 and 64%, and there was no 
consistency in the weighing of the importance of the HLA-A and -B versus the HLA-DR antigens. The 
views on what constituted a high-risk cornea for which HLA matching was advantageous were fairly 
consistent: a previous immunological rejection in the same eye, deep stromal vascularization in two 
or more quadrants, and chemical burns. There was no consensus on whether a regraft in the same 
eye after failure without a rejection, or a previous immunological rejection in the fellow eye 
constituted an indication for HLA matching. In Germany, HLA-DR compatibility was considered more 
important than matching for the Class I antigens, while in the Netherlands, only matching for HLA-A 
and -B was applied.(Beekhuis, 1995) 
 
3.2. HLA matching using HLA-A, -B and -DR 
Matching donor and recipient can be performed for HLA Class I only, where two A's and two B's can 
be matched. When also looking at HLA-DR antigens, the total number of potentially-matchable 
antigens goes up to six. In 2000, Volker-Dieben et al. reported on all corneal transplantations 
performed in a single center between 1976 and 1996, that had been matched on the basis of HLA-A 
and -B antigens, and retrospectively typed for HLA-DR (558 cases).(Volker- Dieben et al., 2000) A beneficial 
effect of HLA-A and -B matching was found in both non-vascularized and vascularized cases, and a 
very significant influence was noticed for 0 mismatches for HLA-DR versus 1 or 2 mismatches for HLA-
DR in moderately and severely vascularized recipients. No effect of DR matching on non- vascularized 
cases was noticed. Surprisingly, the paper does not provide information which technique was used 
for HLA-DR typing, serology or PCR. 
Studies performed since 2000, which mostly use modern methods of HLA typing, show a clear 
beneficial effect of HLA matching in (high-risk) patients.(Bartels et al., 2003; Hargrave et al., 2004; Khaireddin et al., 2003; 
Osawa and Streilein, 2005; Reinhard et al., 2003; Volker-Dieben et al., 2000) Khaireddin, using serological HLA typing, observed 
that a donor-recipient match of two or more of the six alleles in HLA-A, -B or -DR reduced the 
rejection rate by at least 10% in low-risk (at 10 years after PKP) cases, and by 40% in high-risk 
patients, at three years after PKP. An analysis at the split antigen level (highly detailed HLA typing) 
showed no improved results. In the low-risk group, matching for either the HLA-B or -DR locus was 
found to reduce the number of rejections, while in the high-risk group matching for any of the loci 
reduced rejections. In 2001, Bartels et al. performed retrospective DNA-based HLA typing of donors 
and of recipients with or without a rejection episode.(Bartels et al., 2001) An increased rejection-free 
survival time of the patients (low- and high risk combined) was observed in graft recipients with one 
or two HLA-A matches, while no difference was observed for HLA-B and -DR. However, when one 
specifically looked at the high-risk group and studied the split level typing (identifying HLA subtypes), 
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less rejection was observed in graft recipients with one or two HLA-DR matches. HLA-B matching had 
no significant effect on graft rejection, which may be due to the low number of HLA-B matches 
observed in this retrospective study (as the B locus is the most polymorphic one).(Bartels et al., 2001) In 
2003, Bartels repeated the study for only HLA-A and -B, looking at the split-level HLA typing in a 
larger group of high-risk patients,(Bartels et al., 2003) taking graft failure instead of graft rejection as end-
point. Still, a better survival was found when there was no or only one split-mismatch for HLA-A/HLA-
B. 
In 2004, Reinhard et al. reported on a study in 418 first keratoplasties with an avascular recipient 
cornea, in which matching took place if a cornea with 0e2 mismatches of the six HLA-A, -B and -DR 
antigens could be found within 6 months.(Reinhard et al., 2004a) If a match had not been found during that 
time period, a graft with 3e6 mismatches was allocated. HLA typing was performed serologically for 
the Class I antigens, and by PCR for Class II; corticosteroids had been given topically as well as 
systemically. Even in these low-risk cases, a clear influence of matching was observed: at 4 years 
postoperatively, 92% of the matched group and 72% of the badly-matched group were rejection free. 
Most of these rejections were reversible; nevertheless, a positive effect on corneal clarity was 
present. Interestingly, Reinhard et al. did not find a clear influence of the number of (mis)matches on 
chronic endothelial cell loss in a study of 223 normal risk transplantations. However, as only first 
PKPs in an avascular host cornea were included in their study, the occurrence of immunological 
responses was limited (although no numbers were reported) and strangely, cases with an identifiable 
immune response during follow up were excluded from the study.(Reinhard et al., 2004b) Bohringer et al. 
reported in a prospective single center study of 545 normal risk corneal transplants, matched for 
HLA-A, and -B at the split level with a HLAMatchmaker algorithm (triplet string matching), that having 
13 or less mismatches led to 85% rejection-free graft survival at 3 years, which significantly differed 
from the 76% rejection free survival when having more than 13 mismatches.(Bohringer et al., 2004) This was 
despite having significantly more HLA-DR mismatches in the first group. Conventional matching for 
HLA-A and -B resulted in 92% rejection-free survival when only having 0e1 mismatches compared to 
76% rejection-free survival when having 3-4 mismatches. Although this last finding was not 
significant, these studies clearly state the benefit of HLA-A and –B matching. An overview of the 
studies found in literature on HLA matching is shown in Tables 1 and 2. 
The unclear effect of HLA-DR may be due to different outcomes in relation to the degree of Class I 
matching: in kidney trans- plantation, HLA-DR matches lead to increased graft survival, but the 
otherwise significant effect of HLA-A and -B matching disappears when HLA-DR is incompatible.(Doxiadis 
et al., 2007; Johnson et al., 2010) 
 
3.3. Approaches to allo-antibodies 
Although cell-mediated immunity is considered the dominant cause of corneal allograft 
rejection,(Boisgerault et al., 2001; Hegde et al., 2005; Krensky et al., 1990; Niederkorn, 2001, 2007) complement-activating allo-
antibodies may also contribute to corneal allograft rejection, especially once sensitization has 
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occurred. In contrast to patients awaiting a renal transplant, patients on the corneal transplant 
waiting list are not routinely screened for the presence of HLA-specific antibodies. Serum of only 
high-risk or retransplant patients is screened for such antibodies, using either the complement-
dependent cytotoxicity assay and Elisa (LAT, One Lambda) or the luminex screening assay (Lifecodes® 
SSO; Immucor, Nijlen, Belgium). Patients with a negative screening result (Panel Reactive Antibodies 
(PRA) 5%) are identified as non-immunized. For corneal transplant patients, pretransplant 
crossmatches are not being performed. In patients that are immunized (PRA >5%), the complement-
dependent cytotoxicity test is used to characterize the specificities of the HLA antibodies. In the few 
immunized patients, one thoroughly looks for acceptable mismatches, first by selecting HLA antigens 
which gave negative results in the complement- dependent cytotoxicity screening and by applying 
the HLA Match-maker program as described by Duquesnoy.(Duuquesnoy, 2002) 
 
3.4. Current strategy for HLA screening and typing 
In the Netherlands, only high-risk recipients (mostly retrans- plants) are typed for the HLA antigens: 
for the LUMC, on average only five patients per year. In contrast, a considerable number of cornea 
donors (around 250 a year) happen to be typed for HLA in the LUMC for other organ donation 
purposes. The HLA class I an- tigens are currently typed using oligonucleotide probes, that pro- vide a 
low resolution result with names that follow the HLA nomenclature that was developed in 2010 by 
the WHO Committee for Factors of the HLA System. HLA-DRB1 and DQB1 are similarly genotyped 
using the sequence-specific oligonucleotide probe (PCR/ SSOP) technique as previously 
described.(Verduyn et al., 1993) 
HLA typing of the donors is used for allocation of these corneas to high risk patients and is done on 
basis of HLA-A, -B and -DR antigen matching, taking broad specificities into account first. 
Furthermore, in immunized patients, unacceptable mismatches are reckoned with and donors are 
selected after exclusion of these HLA mismatches. The allocation rules are ordered on HLA-A, -B, -DR 
broad level, country of the recipient, urgency, and HLA-A, B antigen split level. Currently, 60 Dutch 
patients are on the Dutch waiting list for an HLA-typed cornea, as well as 150 patients from abroad 
(Germany, Belgium, Austria, Italy, and Scandinavia). Around 600 Dutch patients are waiting for a non-
HLA typed cornea. Annually, around 1250 Dutch inhabitants receive a non HLA-typed cornea 
transplant and around 50e60 a HLA-typed cornea transplant (data provided by the Dutch 
Transplantation Society). 
 
3.5. HLA Matchmaker 
HLA Matchmaker is a matching algorithm which was originally introduced to explain why many 
mismatched transplants do well. HLA Matchmaker determines histocompatibility at the epitope 
rather than antigen level in terms of the humoral alloimmune response. An epitope has two 
characteristics namely antigenicity, i.e. the reactivity with antibody, and immunogenicity, i.e. the 
ability of inducing an antibody response. Immunogenicity depends on the structural difference 
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between an immunizing protein and the antibody responder's homologous proteins. Certain 
structural differences lead to immunodominant epitopes whereas others are associated with low 
immunogenicity. The elucidation of three-dimensional molecular structures and amino acid sequence 
differences between HLA antigens made it possible to view each HLA antigen as a string of short 
linear sequences (triplets) involving polymorphic amino acid residues in antibody-accessible 
positions. These triplets are considered key elements of epitopes that can induce the formation of 
specific antibodies. 
The triplet-matching concept has clinical relevance because HLA-A, B mismatched kidney transplants 
that are compatible at the triplet level have practically the same graft survival rates as the zero HLA-
A, B antigen mismatches defined by conventional criteria. Triplet matching has been shown to 
benefit platelet transfusions of refractory thrombocytopenic patients. HLA Matchmaker is also useful 
in the determination of acceptable mismatches for highly-sensitized patients that are considered for 
kidney transplantation. 
Recent studies have led to an updated version of HLA Matchmaker: stereo-chemical modelling of 
crystallized complexes of antibodies with different protein antigens revealed that antigenic proteins 
have functional epitopes consisting of amino acid residues that are about 3 Å apart from each other 
and at least one of them is non-self. The term now used to describe patches of polymorphic residues 
within a radius of 3.0-3.5 Å is “eplet”. By using this updated version of HLA Matchmaker (using 
eplets) a more complete repertoire of structurally-defined HLA epitopes can be made, which also 
provides a more detailed assessment of HLA compatibility. 
Using HLA Matchmaker(Duquesnoy, 2002) to identify the number of mismatched HLA Class I eplets 
(polymorphic amino acid configurations), Bohringer et al. were able to show an additional value of 
the HLAMatchmaker on top of HLA Class I matching in preventing immunorejection after 
keratoplasties.(Bohringer et al., 2010) 
4. Matching minor histocompatibility antigens 
 
Even in fully HLA-matched cases, corneal survival, after excluding the non-immunological causes for 
graft failure, is well below 100%.(Baggesen et al., 1991; Beekhuis et al., 1991; Ehlers and Kissmeyer-Nielsen, 1979; Foulks et al., 1983; 
Hargrave et al., 2004; Hoffmann and Pahlitzsch, 1989; Reinhard et al., 2003; Stark et al., 1978; The Collaborative Corneal Transplantation Studies Research 
Group, 1992; Vail et al., 1997; Vannas, 1975) This indicates that aside from major histocompatibility antigens, minor H 
antigens could play a role. Studies in murine models in the 1990s observed that minor H antigens 
were of higher relevance for alloimmunity leading to corneal graft rejection than HLA antigens.(Nicholls 
et al., 1991; Sano et al., 1996; Sonoda and Streilein, 1992; Yamada and Streilein, 1998) In humans, one study found that 
mismatching for the minor HY antigen, which is only expressed on male cells, seemed not to 
influence graft survival.(Inoue et al., 2000b) However, an influence of HY in this study might well been 
obscured as they did not correct for HLA-antigen mismatches. A more recent clinical study on corneal 
graft survival, with a mean follow up of two years and taking HLA matching into account, showed 
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that mismatches for the minor H antigen HY indeed led to more graft rejection. Mismatches in the 
minor antigen HA-3 also had a negative effect on graft survival, although not significantly.(Bohringer et al., 
2006) 
Since both the HY and HA-3 minor H antigens are expressed on a variety of tissues, including corneal 
tissue, it justifies a potential role for both in corneal transplantation,(de Bueger et al., 1992; Dierselhuis and Goulmy, 
2009; Goulmy et al., 1995) and especially for HY, as larger solid organ transplant studies found increased graft 
loss for HY mismatches;(Gratwohl et al., 2008) gender mismatches are known to be an independent risk 
factor in HLA-matched Stem Cell Transplantations.(Gratwohl et al., 2001; Stern et al., 2006) More research in this 
area is warranted, as we do not yet know which other polymorphic tissue-specific antigens are 
expressed in the cornea, and more specifically, from which proteins these peptides have been 
derived.  
 
5. Other approaches to prevent rejection 
 
5.1. Potential of biologics to prolong human corneal graft survival 
Most of the recent studies indicate that matching donor and recipient for HLA-A and -B antigens may 
improve graft survival in high risk cases, and probably in low risk cases as well. However, when this is 
not possible, one may try to reduce the chance of rejection using a variety of techniques. Knowing 
the degree of mismatching may help to decide on the post-transplant protocol. One of the new 
classes of drugs that may help to improve corneal graft survival is that of the biologics, which have 
especially been applied experimentally, but are increasingly being used clinically. Biologics, which in 
this context are primarily recombinant antibodies or fusion proteins, are an important and widely-
used class of drugs for the treatment of many ocular conditions including in- flammatory eye disease, 
(Durrani et al., 2011; Jap and Chee, 2008) diabetic macular edema,(Ho et al., 2012) and neovascular age-related macular 
degeneration.(Holz et al., 2014) 
The choice of route of administration of biologics is a complex issue that is of direct relevance to 
prevention and treatment of clinical corneal graft rejection. Unmodified protein drugs cannot be 
delivered orally, because they will be rapidly degraded in the gastrointestinal tract. In humans, the 
common routes of administration of biologics for amelioration of eye disease include intravenous 
injection (used for example to deliver infliximab in some cases of Behçet's disease), and intravitreal 
injection (used to deliver eg. bevacizumab, ranibizumab or aflibercept to moderate aberrant 
angiogenesis and reduce macular edema in the posterior segment). 
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Table 2. Overview of clinical studies of HLA-matching and corneal graft survival (outcome) 
Author, year Antigens 
analyzed 
Outcome (n = group size)  
Allansmith et al., 1974 A No effect overall (immunoreaction); no p-value mentioned 
2 matches 14% immunoreaction (n = 7); 1 match 9% immunoreaction (n = 22); 0 matches 0% immunoreaction (n = 14) 
 
NB: effect of confounding factors not mentioned. 
Gibbs et al., 1974 A No effect overall (rejection episode); no p-value mentioned 
2 matches 41% rejection (n = 29); 1 match 52% rejection (n =62); 0 matches 41% rejection (n = 64) 
 
Beneficial severe vascularization (opaque graft with or without rejection); p < 0.05 
2 matches 47% opaque graft (n = 19); 0 matches 76% opaque graft (n = 29) 
 
NB: effect of other confounding factors not mentioned. 
Vannas, 1975 A,B,C Beneficial overall (rejection); no p-value mentioned 
5-6 matches 4% rejection (n = 27); 3-4 matches 21% rejection (n = 19); Untyped 26% rejection (n=34) 
 
Beneficial high risk (rejection); no p-value mentioned 
5-6 matches 8% rejection (n = ?); Untyped 39% rejection (n = ?) 
 
NB: effect of confounding factors not mentioned. 
Batchelor et al., 1976  A, B Beneficial severe vascularization (irreversible immune rejection) 
Two year follow-up (n = 73): 
2 matches 27% rejection (n = 12); 1 match 72% rejection (n = 30); p < 0.05 
2 matches 27% rejection (n = 12); 1 or 0 matches 70% rejection (n = 60); p < 0.01 
 
Confounding factors (unknown whether equally distributed per group): 120 first grafts and 80 regrafts; graft sizes differ 5-10 mm; 
Stark et al., 1978b A, B, C No effect high risk (immunoreaction); no p-value mentioned 
4 matches 0% immunoreaction (n = 1); 3 matches 40% immunoreaction (n = 5); 2 matches 9% immunoreaction (n = 11); 1 match 26% 
immunoreaction (n = 35); 0 matches 27% immunoreaction (n = 51) 
 





Beneficial overall (rejection episode and/or opaque graft); p < 0.005 
2-4 matches 12% rejection (n = 49); 0-1 matches 35% rejection (n = 173) 
 
Confounding factors (having impact on outcome and not corrected for): Transplant indication, p-value unknown. 
Foulks and Sanfilippo, 
1982 
A, B Beneficial high risk (graft failure); trend, no p-value mentioned 
3-4 matches 0% graft failure (n = 7); 0-2 matches 21% graft failure (n = 39) 
 
NB: effect of confounding factors not mentioned. 
Ozdemir, 1986 A, B Beneficial high risk (graft failure): p < 0.05 
Five year follow-up: 
2-3 matches 15% graft failure (n = 20); 0-1 matches 45% graft failure (n = 20) 
 
NB: effect of, or possible confounding factors not mentioned. 
Sanfilippo et al., 1986  A, B  Beneficial high risk (immunoreaction); p < 0.01 (Chi-square Test), p < 0.01 (Multivariate Cox Regression) 
2-3 matches 21% immunoreaction (n = 38); 0-1 matches 49% immunoreaction (n = 59) 
 
Beneficial high risk (irreversible immunoreaction); p < 0.02 (Multivariate Cox Regression) 
For the irreversible immunoreactions, group size and percentage are unknown. 
 
NB: p-values of multivariate analysis adjusting for age and graft size. 
Keyserlingk et al., 1987 A, B, DR Beneficial high risk (graft survival); p = 0.001 
2-4 matches 0% graft failure (n = 7); 0-1 matches 46% graft failure (n = 13) 
 
No data for normal risk (n = 20) 
 
NB: effect of, or possible confounding factors not mentioned. 
Volker-Dieben et al., 1987 A, B /DR A, B 
Beneficial overall (graft clarity); p < 0.001 
2-4 matches (A,B) ± 40% opaque graft (n = 497); Untyped ± 50% opaque graft (n = 721) 
Beneficial high risk (graft clarity); p < 0.001 
2-4 matches (A,B) ± 45% opaque graft (n = 397); Untyped ± 60% opaque graft (n = 343) 
 
DR 
No effect overall (graft clarity); ns 
2 matches (DR) ± 12% opaque graft (n = 45);1 match (DR) ± 25% opaque graft (n = 64); 0 matches (DR) ± 28% opaque graft (n = 14) 
No effect high risk (graft clarity); ns 
2 matches (DR) ± 18% opaque graft (n = 34); 1 match (DR) ± 34% opaque graft (n = 44); 0 matches (DR) ± 30% opaque graft (n = 11) 
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Confounding factors (having influence on graft clarity, but not corrected for): degree of vascularization, p < 0.001; number of regrafts, p < 
0.001; diagnosis, p < 0.001; patient age, p < 0.001; graft diameter, p < 0.001 
NB: unknown whether the 123 DR-typed patients were in the matched or untyped group for A,B. 
Hoffmann and Pahlitzsch, 
1989  
B, DR Beneficial overall (immunoreaction); p < 0.05 
2-4 matches 11% immunoreaction (n = 46) vs. 0-1 matches 29% immunoreaction (n = 91) 
No effect normal risk (immunoreaction); p < 0.10 
2-4 matches 0% immunoreaction (n = 15); 0-1 matches 13% immunoreaction (n = 68) 
Beneficial high risk (immunoreaction); p < 0.01 
2-4 matches 16% immunoreaction (n = 31); 0-1 matches 74% immunoreaction (n = 23) 
 
NB: effect of confounding factors not mentioned. 
Boisjoly et al., 1990 A, B Beneficial overall (immunoreaction); p < 0.001 (multivariate analysis correcting for vascularization, graft diameter, HLA-DR, regrafting, 
and age) 
2-4 matches 19% immunoreaction (n = 174) (0 or 1 mismatch at both loci); 0-2 matches 40% immunoreaction (n = 261) (2 mismatches at 
either loci) 
 
Beneficial overall (graft failure); p = 0.04 (unclear whether corrected for confounders) 
2-4 matches 18% graft failure (n = 174) (0 or 1 mismatch at both loci); 0-2 matches 29% graft failure (n = 261) (2 mismatches at either loci) 
 
Analysis for DR and high risk group had too less power. 
Baggesen et al., 1991  
Study updated (extended) 
in 1996 
DR Beneficial high risk (graft failure); p = 0.003 
18 month follow-up 
1-2 matches 7% graft failure (n = 51); Untyped 50% graft failure (n = 23) 
 
Confounding factors (having influence on outcome, but not corrected for): regrafts, p < 0.01;  
NB: RFLP detected mismatches were serology did not 
Beekhuis et al., 1991 A, B /DR 
 
Unknown, no statistical comparisons made 
NB: More grafts failed from non-immunological reasons than from immunoreactions: 13 out 33 due to immunoreaction 
The Collaborative Corneal 
Transplantation Studies 
Research Group, 1992 
A,B, DR 36 months follow-up: 
A, B 
No effect high risk (graft failure all causes); p = 0.59 
3-4 matches 33% graft failure (n = 137); 0-2 matches 37% graft failure (n = 282) 
No effect high risk (immunoreaction); p = 0.83 
3-4 matches 64% immunoreaction (n = 137); 0-2 matches 66% immunoreaction (n = 282) 
No effect high risk (failure due to immunoreaction); p = 0.66 
3-4 matches 21% failure due to immunoreaction (n = 137); 0-2 matches 26% failure due to immunoreaction (n = 282) 
 
DR 
No effect high risk (graft failure all causes); p = 0.99 
2 matches ± 43% graft failure (n = 199); 0-1 match ± 41% graft failure (n = 220) 
No effect high risk (immunoreaction); p = 0.53 
2 matches ± 69% immunoreaction (n = 199); 0-1 match ± 70% immunoreaction (n = 220) 
 
No effect high risk (failure due to immunoreaction); p = 0.87 
2 matches 25% failure due to immunoreaction (n = 199); 0-1 match 24% failure due to immunoreaction (n = 220) 
Beneficial high risk (failure due to immunoreaction); p = 0.02 
When using only donor-recipient pairs in which four distinct DR antigens were identified. 
 
NB: p-values of multivariate analysis adjusting for ABO, vascularization, and regrafts  
Hoffmann et al., 1994 A,B, DR  A 
No effect normal risk (immunoreaction); ns 
1-2 matches 11% immunoreaction (n = 109); 0 matches 13% immunoreaction (n = 56) 
No effect high risk (immunoreaction); ns 
1-2 matches 56% immunoreaction (n = 59); 0 matches 54% immunoreaction (n = 24) 
 
B 
Beneficial normal risk (immunoreaction); p < 0.01 
1-2 matches 4% immunoreaction (n = 80); 0 matches 19% immunoreaction (n = 85) 
Beneficial high risk (immunoreaction); p < 0.01 
1-2 matches 47% immunoreaction (n = 64); 0 matches 84% immunoreaction (n = 19) 
 
DR 
Beneficial normal risk (immunoreaction); p < 0.05 
1-2 matches 10% immunoreaction (n = 122); 0 matches 16% immunoreaction (n = 43) 
Beneficial high risk (immunoreaction); p < 0.05 
1-2 matches 49% immunoreaction (n = 68);0 matches 87% immunoreaction (n = 15) 
 
NB: postoperative regimen changed during the years 
Vail et al, 1994 A, B, DR A, B 
Beneficial overall (graft failure?); trend, not significant 
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DR 
Bad effect overall (graft failure?); p = 0.02 
 
NB: unclear which groups were compared, no data on amount of immunoreaction/graft failure per HLA loci, DR groups not corrected for 
HLA-A,B differences and visa versa. 
Baggesen et al., 1996 DR  Beneficial high risk (graft failure); p = 0.03 
2 matches 23% graft failure (n = 38); 0-1 matches 42% graft failure (n = 36) 
 
Confounding factors (having influence on outcome, but not corrected for):  
Regrafts, p < 0.05;  
Vail et al., 1997 A, B, DR  
 
At 12 months follow-up: 
A, B 
Beneficial overall (immunoreaction); trend, not significant due to too small groups 
 
DR 
Bad effect overall (immunoreaction); no p-values mentioned 
 
NB: unclear which groups were compared, no data on amount of immunoreaction/graft failure per HLA loci, DR groups not corrected for 
HLA-A,B differences and visa versa. 
Munkhbat et al, 1997  DRB1, 
DQB1, DPB1 
12 months follow-up: 
DRB1, DQB1, DPB1 together 
No effect overall (immunoreaction); ns 
No effect normal risk (immunoreaction); ns 
Beneficial high risk (immunoreaction); p = 0.02 
1-4 matches 17% immunoreaction (n = 23); 0 matches 50% immunoreaction (n = 28) 
 
Separate analysis of the loci for overall, normal, high risk 
DRB1 no effect (immunoreaction), although trend for benefit in high risk group 
DQB1 no effect (immunoreaction), although trend for benefit in high risk group 
DPB1 beneficial high risk (immunoreaction): p = 0.01 
1-2 matches 7% immunoreaction (n = 14); 0 matches 46% immunoreaction (n = 37) 
 
NB: other factors of influence are not mentioned or corrected for. 
Munkhbat et al, 1999  A, B  12 months follow-up: 
A, B 
Beneficial overall; p = 0.03 
1-4 matches 19% immunoreaction (n = 42); 0 matches 41% immunoreaction (n = 37) 
Beneficial high risk; p = 0.008 
1-4 matches 17% immunoreaction (n = 24); 0 matches 52% immunoreaction (n = 25) 
 
A separate 
Beneficial overall; p = 0.001 
1-2 matches ± 12% immunoreaction (n = 26); 0 matches ± 39% immunoreaction (n = 54) 
Beneficial high risk; p = 0.02 
1-2 matches ± 14% immunoreaction (n = 16); 0 matches ± 48% immunoreaction (n = 34) 
 
B separate 
No effect overall; p = 0.60 
1-2 matches ± 25% immunoreaction (n = 24); 0 matches ± 31% immunoreaction (n = 55) 
No effect high risk; p = 0.17 
1-2 matches ± 17% immunoreaction (n = 12); 0 matches ± 40% immunoreaction (n = 37) 
 
NB: other factors of influence are not mentioned or corrected for. 
Volker-Dieben et al, 2000 A, B / DR 
 
A, B 
Beneficial normal risk (immunoreaction); p = 0.05 
2-4 matches 9% immunoreaction (n = 480); 0-1 matches 13% immunoreaction (n = 349) 
Beneficial high risk (immunoreaction); p < 0.001 
2-4 matches 25% immunoreaction (n = 642); 0-1 matches 42% immunoreaction (n = 207) 
Corrected for vascularization status: beneficial: p = 0.01 
 
DR 
No effect normal risk (immunoreaction); p = 0.14 
2 matches 7% immunoreaction (n = 69); 0-1 matches 12% immunoreaction (n = 209) 
Beneficial high risk (immunoreaction); p = 0.02 
2 matches 15% immunoreaction (n = 66); 0-1 matches 29% immunoreaction (n = 214) 
Corrected for vascularization status: beneficial: p = 0.03 
 
Confounding factors (having influence on outcome, but not corrected for): graft size, p = 0.002; organ culture, p = 0.001; gender, p = 0.01; 
HLA-A,B and DR 
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Khaireddin et al, 2003  
(Update on study 
Hoffmann et al., 1994) 
A, B, DR Beneficial normal risk (immunoreaction); p = 0.04 
2-6 matches 12% immunoreaction (n = 249); 0-1 matches 26% immunoreaction (n = 46) 
 
Beneficial high risk (immunoreaction); p < 0.001 
2-6 matches 41% immunoreaction (n = 130); 0-1 matches 92% immunoreaction (n = 13) 
 
NB 1: analysis at split level added no advantage 
NB 2: other factors of influence are not mentioned or corrected for.  
Bartels et al., 2003  A, B Split level analysis 
Beneficial high risk (immunological graft failure); p = 0.002 
3-4 matches ± 15% immunological graft failure (n = 216); 0-2 matches ± 31% immunological graft failure (n = 87) 
 
NB: the beneficial effect remained significant with an odds-ratio of 0.41, after multivariate analysis correcting regrafts and indication for 
transplantation. 
 
Beneficial high risk (overall graft failure); p = 0.04 
Reinhard et al, 2004a A, B, DR Four year follow-up 
A, B, DR 
Beneficial normal risk (immunoreaction); p = 0.048 
4-6 matches 8% immunoreaction (n = 66); 0-3 matches 28% immunoreaction (n = 352) 
 
Beneficial normal risk (rejection-free clear graft); p = 0.03 
4-6 matches 8% no rejection-free/clear graft (n = 66); 0-3 matches 34% no rejection-free/clear graft (n = 352) 
 
Confounding factors (having influence on outcome, but not corrected for): organ storage time, p = 0.03. 
Böhringer et al., 2004 A, B, DR Split level analysis A, B (triplet-string matching) 
Beneficial normal risk (immunoreaction); p < 0.05  
<13 triplet mismatches 15% immunoreaction (n = 147); > 13 triplet mismatches 24% immunoreaction (n = 398) 
 
NB 1: groups differed significantly for DR matches (p = 0.02). 
NB 2: Cox multivariate regression analysis was used, yet it is unknown which confounding factors were included. 
 
Broad level analysis A, B 
No effect normal risk (immunoreaction); p = 0.08  
3-4 matches 8% immunoreaction (n = 57); 0-2 matches 24% immunoreaction (n = 488) 
 
NB: groups differed significantly for DR matches (p < 0.01). 
 
DR 
Analysis not performed due to too small group size.  
   
Minor antigens   
Inoue et al., 2000b H-Y  No effect normal risk (immunoreaction); p = 0.71 
Matched (male-male) ± 25% immunoreaction (n = 175); Mismatched (male-female) ± 27% immunoreaction (n = 53) 
 
No effect high risk (immunoreaction); p = 0.70 
Matched (male-male) ± 40% immunoreaction (n = 127); Mismatched (male-female) ± 40% immunoreaction (n = 41) 
 
NB: no assessment or correction for possible confounding effect of HLA type. 
Reinhard et al, 2004a H-Y No effect normal risk (immunoreaction); ns 
Matched (male-male) (n = 291); Mismatched (male-female) (n = 418)  
No other data mentioned except relative risk of 1.1. 
 
NB: no data provided on possible confounding effect of HLA type. 
Böhringer et al., 2006 
(Reinhards group)  
H-Y, HA-3 H-Y 
Beneficial overall (immunoreaction); p = 0.02  
Matched 12% immunoreaction (n = 148); Mismatched 23% immunoreaction (n = 81) 
 
H-Y 
No effect overall (immunoreaction); p = 0.52 
Matched 15% immunoreaction (n = 148); Mismatched 27% immunoreaction (n = 81) 
 
NB 1: p-values are of multivariate analysis adjusting for risk group, HLA-A1 mismatch and patient age. 
NB 2: no assessment or correction for possible confounding effect of HLA type (although data was available). 
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Reports on the systemic use of immunomodulatory biologics for the prophylaxis and treatment of 
human corneal graft rejection are relatively few. In a small study reported in the German-language 
literature, basiliximab (a chimaeric monoclonal antibody with specificity for CD25) in combination 
with corticosteroids was found to be moderately effective for the prophylaxis of corneal graft 
rejection.(Birnbaum et al., 2008) Alemtuzumab, originally known as Campath-1 (a humanized monoclonal 
antibody with specificity for CD52) was used systemically to reverse corticosteroid-resistant corneal 
allograft rejection in several recipients, with some success.(Dick et al., 2000; Newman et al., 1995) However, 
administration of these specific biologics is not without risk in either the short or long term and their 
side-effects profiles, and need for continuous monitoring by non-ophthalmologists together with 
their limited efficacy, probably explain why neither has as yet found widespread favour as an 
immunosuppressant for keratoplasty. 
In recent times, the use of topical or subconjunctival administration of biologics to target the cornea 
has generated some interest. Large biologics of the size of intact antibody molecules will not pass 
across the human ocular surface over any reasonable time-frame,(Allansmith et al., 1979) although it is 
possible to enhance the penetration of engineered small antibody fragments into the cornea.(Thiel et al., 
2002, 2013) However, topical administration of a biologic for the successful prophylaxis or treatment of 
human corneal graft rejection has not yet been achieved. Subconjunctival administration is a well-
established method for producing a depot of a drug that may influence disease processes in the 
cornea and anterior segment. The application of anti-vascular endothelial growth factor (VEGF) 
biologics delivered by subconjunctival injection is actively being examined as a means to limit corneal 
neo-vascularization in humans, especially in cases of trauma or infection. Aside from reducing the 
direct consequences of vascularization upon vision, the rationale is to increase the chances of 
success of a corneal graft (should one subsequently be required), given that neovascularization is a 
well-established risk factor for rejection-mediated corneal graft failure.(Coster and Williams, 2005) 
Cursiefen and co-workers have demonstrated the importance of lymph vessels in corneal 
transplantation. Immunohistochemistry was applied to human corneas to determine the presence of 
LYVE-1 and podoplanin- (two markers of lymphangiogenesis) positive vessels. About 8% of vessels in 
vascularized corneas were lymph vessels. There was a strong correlation between the presence of 
lymphatic vessels and hemangiogenesis.(Cursiefen et al., 2002) Anti-angiogenesis treatments that decreased 
both blood and lymph vessel ingrowth were able to restore the immune privilege. VEGF inhibitors 
such as bevacizumab were found to effectively block corneal angiogenesis as well as lymphangio- 
genesis.(Bock et al., 2007) Blocking lymph- and hemangiogenesis with an inhibitor of VEGF (VEGF Trap 
(R1R2)) greatly improved corneal transplant survival (Cursiefen et al., 2004). Similarly, blocking VEGF-
A or VEGFR-3 post-transplantationally resulted in less vessels and subsequently less APC trafficking, 
ending in improved graft survival in an experimental model.(Bachmann et al., 2008; Chen et al., 2004; Niederkorn and Larkin, 
2010) A recent randomized, placebo-controlled clinical trial of three subconjunctival injections of 2.5 
mg bevacizumab for new-onset corneal neovascularization demonstrated a significant reduction in 
the area of corneal vessels in the treated group, compared with an increase in the area of new 
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vessels in the control group, at 3 months after initiation of treatment (Petsoglou et al., 2013). The 
intervention was reportedly well tolerated, with no major safety concerns, and could as such provide 
a good measure to reduce the risk of corneal graft rejection. Another approach may be the inhibition 
of the VEGF-receptor related kinases, such as VEGFR-tyrosine kinase. Application of a VEGFR-tyrosine 
kinase inhibitor led to improved survival of corneal transplants in a murine model.(Hos et al., 2008) 
As antigens from the AC drain to preauricular and submandibular lymph nodes,(Camelo et al., 2005) local 
lymphadenectomy in mice helped to prevent antigens from reaching the local lymphoid tissue, and 
prolonged corneal graft survival.(Plskova et al., 2004; Yamagami and Dana, 2001) One may also attack the lymph 
vessels: CD11b+ macrophages express LYVE-1 and Prox-1 under inflamed conditions in the murine 
cornea, and these cells were able to form vessel-like structures in vivo. Blocking such cells may help 
in preventing (lymph)angiogenesis.(Maruyama et al., 2005) 
Depletion of antigen-presenting cells may be an alternative for HLA Class II matching. This may 
effectively block antigen-presentation by APC depletion. It has been shown that blocking corneal and 
conjunctival antigen-presenting cells by local depletion with clodronate-containing liposomes 
completely inhibited graft rejection in a murine model.(Slegers et al., 2000) A problem with this approach is 
the simultaneous blocking of local innate immune protection against pathogens, such as 
Acanthamoeba.(Van Klink et al., 1996) On the other hand, this approach is inherent to using grafts that have 
been kept in culture for a while: reduction of HLA Class II expression was found in corneas stored for 
two weeks in organ culture.(Al-Fakih et al., 2012; Mayer et al., 2007) However, time and type of storage may 
influence the quality of the graft. A disadvantage of storing corneas for a longer time is that it may 
adversely affect reepithelialization, even if storage in Optisol-GS lasted less than 14 day.(Lam et al., 2013) 
Other immunological treatments such as blocking of CD4+ T cells will, unless topically applicable, 
likely result in significant systemic immunosuppression, which is therefore unlikely to be used 
clinically as preventive treatment in clinical corneal transplantation. Many different 
immunomodulatory biologics have been examined for their efficacy in prolonging corneal graft 
survival in experimental animals. Because mice and rats have open lymphatics in the peritoneal 
cavity, intraperitoneal injection has been the favoured means of delivery in these species, but such 
administration is clearly not applicable for humans. Furthermore, the immune systems of mice and 
men differ substantially in many respects.(Mestas and Hughes, 2004) Ophthalmologists have naturally had 
reservations about administering any of these potent immunosuppressants systemically to their 
patients with corneal grafts, without a great deal more evidence of efficacy. Corneal graft rejection is 
a so-called “orphan disease”,(Aronson, 2006) so that large pharmaceutical companies are unlikely to 
expend resources on the discovery of new biologic drugs for this relatively rare condition. The role of 
biologics in the future is thus likely to be restricted to agents that have already been licensed for use 
in other, more common diseases. In such instances, the safety profile at least will already be 
reasonably well-established, as was the case with bevacizumab, licensed initially for use in colon 
cancer. 
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5.2. Potential of gene therapy to prolong human corneal graft survival 
The potential of gene therapy to modulate corneal diseases in general and corneal graft rejection in 
particular has been extensively - even exhaustively - studied and reviewed over the past 15 years. 
(Borras, 2003; George et al., 2000; Jun and Larkin, 2003; Kampik et al., 2012; Mohan et al., 2005; Parker et al., 2009; Qazi and Hamrah, 2013; Ritter et al., 2013; 
Williams et al., 2004) The usual approach is to modify the donor corneal endothelium ex vivo, prior to 
transplantation, with a transgene designed to influence the afferent or efferent arm of the allograft 
response. This is a clinically-relevant scenario, as donor corneas are preserved in the eye bank for 
varying periods prior to release for keratoplasty. 
Increasing the expression of the factors that mediate immune privilege by gene transfer of 
immunomodulatory molecules such as TNF-receptor, TGF-beta, IL-10, IL-12, and NGF (Nerve Growth 
Factor), may increase or restore corneal immune privilege and prolong graft survival. This has been 
investigated in several animal models;(Beutelspacher et al., 2006; Comer et al., 2002; Gong et al., 2007; Klebe et al., 2001a, 2005; Rayner 
et al., 2001; Ritter et al., 2007) however, most factors were not able to prolong corneal survival when applied 
alone, with the exception of NGF.(Gong et al., 2007) 
The choice of the animal model is especially important in studying ex vivo gene transfer to corneal 
endothelium, because unlike the situation in humans and larger mammals, the endothelial cells of 
small rodents can replicate.(Tuft et al., 1986) A positive outcome in a small animal model thus demands 
confirmation in a larger, preferably outbred animal model, several of which are available.(Klebe et al., 
2001b; Nicholls et al., 2012) Despite a number of partial successes, overall outcomes have thus far been 
somewhat underwhelming. Indefinite and biologically-significant, long-term prolongation of corneal 
graft survival has seldom been achieved in the majority of animals tested, a likely requirement of the 
gene technology regulators before permission would be forthcoming for any clinical trial. Not 
surprisingly, then, ex vivo gene therapy directed at a donor cornea prior to clinical transplantation, 
with the ultimate goal of prolonging the survival of that graft, has not been reported. This is in stark 
contrast to success in the use of gene therapy for inherited monogenic retinal disorders such as 
Leber's congenital amaurosis.(Bainbridge et al., 2008; Maguire et al., 2008) One likely reason lies in the remarkable 
degree of redundancy that is evident in the immune response to an allograft. Possibly not one 
transgene will prove sufficiently broad-acting enough on its own to modulate the immune response 
to a corneal graft completely. Whether a combinatorial approach will be more successful has yet to 
be thoroughly tested. Topical, rather than systemic therapies, and lamellar keratoplasty, are the 
current approaches that are being applied to reduce corneal allograft rejection. The most successful 
future therapies would be those that target more than one pathway. 
 
5.3. Cellular suppression 
A potential new approach to prevent or treat rejection may be found in the use of mesenchymal 
stem cells. Bone marrow-derived mesenchymal stem cells (MSCs) are non-hematopoietic cells, that 
are capable of a range of anti-inflammatory functions, and can reduce corneal rejections in mouse 
and rat transplantation models,(Lan et al., 2012; Oh et al., 2012) reviewed by Li and Zhao (2014).(Li and Zhao, 2014) 
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They have been found to stimulate tissue repair(Lan et al., 2012) by increasing the expression of anti-
inflammatory cytokines such as TGF-beta and IL-1Ra. Intravenously injected MSCs home to damaged 
(inflamed) tissues, including a cornea that has undergone a corneal transplant.(Omoto et al., 2014) When 
injected at the time of a corneal transplantation in mice, these cells are able to bring down the 
number of APCs in the cornea and draining lymph nodes, as well as the number of induced Th1 cells, 
while improving graft survival. Earlier, Oh et al.(Oh et al., 2012) reported that injection of MSCs at the time 
of corneal transplantation in mice would reduce rejection. On day 7 post-transplantation, the 
number of dendritic cells and macrophages was reduced in corneas of mice that had received MSCs. 
The injection of MSCs reduced not only the aspecific early inflammation induced by surgery but also 
the allo-specific response observed on day 28 post transplantation. The production of a soluble 
factor, tumor necrosis factor-alfa stimulated gene/protein 6 (TSG6) was involved and infusion of 
recombinant TSG6 was also capable of reducing rejection rate, by reducing the local corneal immune 
response. Using an immunosuppressive factor would make the use of cells redundant. However, if 
cells would be more efficient, it raises the question whether the MSCs need to be compatible with 
the cornea donor. Obtaining donor-derived human MSCs or cells derived from other sources such as 




Corneal transplantation is considered one of the most successful form of transplantation in humans. 
Long-term survival rates in low-risk non HLA-matched patients are higher than those seen in HLA-
matched solid organ transplants.(Cecka, 2010; Claas et al., 2005; Coster and Williams, 2005; Gondos et al., 2013; Ing et al., 1998; Inoue et al., 
2000a; Thompson et al., 2003; Williams et al., 1997) A prospective study on PKPs for normal risk cases with a median 
follow-up of 18 months showed rejection episodes in 11% of the grafts in the first 18 months. Risk 
factors for rejection were atopic dermatitis, clinically-manifest tear insufficiency and short storage of 
the graft.(Kuchle et al., 2002) This shows that in normal risk cases, graft rejection can occur, but is not 
common. Next to penetrating keratoplasty, other allografting methods such as ALK and deep-ALK for 
anterior corneal disease are more frequently applied, improving the survival rates even further by 
leaving the endothelium intact. Lamellar transplants are usually performed in diseases where 
vascularization is absent. A survival rate of 99% over 9 years has been reported in deep-ALK 
performed for stromal disease.(Sarnicola et al., 2012) The group of 806 eyes consisted of keratoconus (74%), 
postherpetic keratitis scarring (15%), and other stromal opacities. This excellent success is mainly 
attributed to the dimin- ished endothelial cell loss for deep-ALK compared to PK.(Borderie et al., 2012; Kubaloglu 
et al., 2012) However, one should take into account that ALK is especially used in keratoconus, a disease 
that consists of thinning and malformation of the cornea, usually without inflammation or blood 
vessel formation, which would also have excellent survival in perforating grafts. PKPs performed in 
keratoconus are hardly ever rejected, so it is logical that laminar grafts for this disease are also not 
prone to rejection.(Thompson et al., 2003) The influence of ALKs on the overall corneal survival rates to date 
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is minimal as 81-94% of the corneal allografts still replace the endothelium.(Konijn-Janssen et al., 2011; Lichtinger et 
al., 2012; Williams et al., 2012) In the posterior transplants, one either replaces Descemet's membrane with a 
new Descemet membrane together with the endothelial cells, or with a combination of Descemet's 
with endothelium and an additional thin layer of corneal stroma.(Melles et al., 2000, 2008) In both cases, the 
target of endothelial rejections is the donor tissue; although long-term results remain to be 
determined, the first prospective studies are reporting 5-year survival rates around 72.5% for DLEK 
(Deep Lamellar Endothelial Keratoplasty),(Mashor et al., 2010) and 89% for DSEK (Descemet's Stripping 
Endothelial Keratoplasty),(Anshu et al., 2012a) while the 5-year survival for full thickness grafts for Fuchs' 
dystrophy is 83-87%.(Cheng et al., 2013; Fasolo et al., 2011; Thompson et al., 2003) Although these grafts are especially 
performed for corneas with primary or secondary Fuchs' dystrophy, a fast loss of endothelial cells 
may also occur following the transplantation, independent of the technique applied.(Chan et al., 2012) A 
study that compared DMEK (Descemet's Membrane Endothelial Keratoplasty, n = 141), DSEK (n = 
598) and PK (n = 30) in patients with similar demographics and indications for surgery, showed a 2-
year survival rate of 99% for DMEM, 88% for DSEK, and 82% for PK.(Anshu et al., 2012b) However, recent 
data from the Australian Corneal Graft Registry Study, comparing the graft survival of 1643 lamellar 
and 9875 penetrating keratoplasties between 1996 and 2013, showed that the survival of DALKs 
(deep anterior lamellar keratoplasty) and endokeratoplasties is worse than the survival of 
penetrating keratoplasties performed for the same indications (mostly keratoconus for DALK, and 
mostly Fuchs' dystrophy or pseudophakic bullous keratopathy for endokeratoplasties).(Coster et al., 2014) 
When focusing on irreversible rejection as the reason for graft failure, PK was the least favourable 
with 30% (635/2094) of the failures due to irreversible rejection, compared to only 2% (1/53) for 
DALK and 12% (37/318) for endokeratoplasty. Rejection can thus still occur, although at a lower rate, 
but the current results show a lot of failures due to other causes. When focusing on DALK for 
keratoconus, the rejection rate for anterior lamellae was very low. Overall survival was better for 
DALK at three years, but when early failures were excluded, survival was similar.(Jones et al., 2009) 
Despite (technical) advances, immunological rejection remains a major reason for graft failure in all 
types of grafts, both in low- and high-risk patients. Strikingly, for the high-risk patients, the prognosis 
of corneal graft survival is similar to that of solid organ transplants,(Cecka, 2010; Claas et al., 2005; Thompson et al., 
2003; Williams et al., 1997) and patients may receive systemic treatments to prevent their corneal graft from 
being rejected.(Joseph et al., 2007; Nguyen et al., 2010) Considering this, it seems that transplanted corneas are 
‘forgotten grafts’ with regard to the number of adequate studies investigating the reasons leading to 
corneal allograft rejections.(George and Larkin, 2004) Furthermore, notwithstanding that in corneal 
allografting, HLA typing and proper allocation is generally assumed to be unnecessary, most studies 
show that outcomes in high risk cases are better for increasingly-matched grafts and best for those 
grafts which have no HLA differences with the recipient at all. Obviously, finding a good match can be 
difficult due to the high polymorphism of the HLA system. In solid organ transplantation where the 
benefit of HLA matching is evident, there is not always time to wait for a completely compatible 
donor, as waiting might prove fatal to the patient. Corneal transplantation however, is performed to 
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restore or improve sight and not to save life, and with the exception of emergency transplants, this 
often provides the valuable time needed to find a compatible donor. With longer cornea storage 
times, possibly up to one year,(He et al., 2012) even more time will be available for proper matching. 
Worldwide, a great shortage exists in the number of grafts available, and this is even the case in 
countries with a long tradition of cornea banking. With the increasing number of elderly patients, 
more corneas will be necessary, and the lower the number of necessary re-grafts, the more patients 
can be helped. Therefore, it would be a waste not to invest in studies to determine properly the 
benefit of matching corneal allografts for HLA minors in addition to HLA Class I antigens. 
From an immunological point of view, studies on the effect of HLA matching should ideally take 
immunological rejection, not necessary leading to graft failure, as end point. This would help to 
better differentiate between the causes of graft failure, and thus help to develop preventive 
measures. Comparing this graft rejection-free survival time is more appropriate than using graft 
failure-free survival and might give more adequate results, even more so when DNA-based HLA 
matching at broad or split-level is used instead of the less accurate serological matching. A system 
identifying acceptable HLA mismatches and only matching for the most relevant and significant HLA 
alleles, could be a valuable, and time-and money-saving approach.(Claas et al., 2005, 2009; Opelz and Dohler, 2007) 
Currently, the FANCY trial (Functional Antigen Matching in Corneal Transplantation, NCT00810472), 
running from 2009, is investigating the results of HLA matching in a blind randomized study. Patients 
are being matched using the HLAMatchmaker algorithm, identifying acceptable mismatches for 
sensitized patients, and the end-point is first endothelial graft rejection. In the UK, the CTFS 
II/Corneal Transplant follow-up Study II is a multi-center study that was commenced in 1998 (ISRCTN 
25094892). In this study, a waiting list of HLA-typed patients was established, to maximize the 
chances of patients getting a matched graft. This study should provide information on the role of 
HLA-DR in graft survival. Efforts to improve corneal graft rejection-free survival need also take into 
account the effect of minor H antigens, as in mice these seem to be able to negate the MHC 
matching effect. The advantage of better matching is a better graft survival without side effects, 
which is not going to be the case for medical interventions. 
An interesting question is whether the genetic make-up of the recipient influences the rate of 
rejection: the CTFSII study in the UK also investigates the role of different gene polymorphisms that 
may influence the outcome of cornea transplants. The genotypes of different cytokine genes were 
determined in 384 patients undergoing a full-thickness transplant, and related to the occurrence of 
rejection during the first three years after transplantation. Specific haplotypes of the TNFalfa gene 
were either associated with a reduced or an increased risk of rejection.(Winton et al., 2014a) Similar results 
were reported for polymorphisms in VEGF-A and the IL-17F gene, which together with a specific 
TNFalfa polymorphism seem to make up a “high inflammatory haplotype”, that leads to a higher 
chance of rejection.(Winton et al., 2014b) It is fascinating that these genes are located on chromosome 6. It 
does however mean, that a determination of the genetic make-up of the recipient, independent of 
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the corneal recipient status, may be used to assess the risk of rejection, and therefore the need to 
perform HLA matching or not. 
The cost-effectiveness of HLA matching for keratoplasties also plays a role in the decision to perform 
HLA matching. Baumler et al. performed a retrospective analysis and used information that typing 
donor and recipient cost 1200 euro, and came to the conclusion that proper matching would give a 
prolonged rejection/failure-free survival of more than 1000 days.(Baumler et al., 2014) The incremental cost 
of HLA matching would than range from 2.10 euro to 6.71 euro per additional day of graft survival, 
which is very acceptable given the high cost of regrafting and the shortage of corneal donors 
worldwide. 
 
7. Conclusion and future directions 
 
Despite controversial results of the effect of HLA matching on corneal allograft survival in older 
studies, we should not ignore that recent studies, using more accurate typing methods, provide 
consistent evidence that HLA matching is beneficial to corneal allograft survival in general and even 
more in high-risk allografts. The corneal transplantation field can take advantage of the results 
coming from solid organ HLA matching, as once the immune privilege has been compromised, the 
same immunological mechanisms apply. Obviously, and especially from a patient's view, successful 
prevention of immune rejection, rather than immune suppression by post-transplantation 
treatments or immune-modifying treatments, such as gene therapy, remains the best primary 
approach. Combining HLA matching with other preventive immunological therapies, thus targeting 
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 132 Chapter 5 
Abstract 
 
Purpose: Human leukocyte antigen (HLA) polymorphisms have been associated with the 
development of autoimmune diseases. In uveal melanoma, a high expression of HLA classes I and II, 
and infiltration with lymphocytes and macrophages are associated with a bad prognosis. 
Inflammation has an important role in this malignancy. The goal of our study was to determine 
whether specific HLA alleles are associated with increased inflammation. 
 
Methods: Records were analyzed of 45 patients who underwent enucleation for uveal melanoma. 
HLA typing, tumor HLA expression and tumor macrophage infiltration were determined in each case. 
 
Results: Before correction for multiple testing, macrophage infiltration was less in HLA-A2 positive 
patients. Patients with HLA-DR6 had a higher tumor cell expression of HLA-DR. After correction for 
the number of analyses, no associations remained statistically significant. 
 
Conclusion: The results before correction suggest that the HLA genotype may influence inflammation 
as indicated by HLA expression and macrophage infiltration in uveal melanoma. However, after 
correction this association did not prove significant.  
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Introduction 
 
Mechanisms by which tumor cells evade the immune system have an important role in tumor 
growth, as emphasized by the cancer immunosurveillance theory.1 Among these escape mechanisms, 
alterations in the expression of classical and non-classical human leukocyte antigen (HLA) classes I 
and II antigens on tumor cells are of a particular interest. These antigens have a crucial role in the 
induction of specific immune responses, and can modulate the interactions of natural killer (NK) cells 
and T cell subpopulations with their target cells.2–4 The clinical relevance of HLA class I expression in 
oncology is evident from the finding that a reduced expression often correlates with a worse 
prognosis,5–10 while the relevance of HLA class II expression in cancer remains ambivalent.1,11,12 
Unlike most tumors, in uveal melanoma a high HLA class I expression is considered to be a bad 
prognostic sign.13–16 This observation may be explained by the role of NK cells. Tumors with high HLA 
class I expression are more resistant to destruction by NK cells, as these cells specifically kill cells that 
lack certain HLA class I antigens.16–18 Metastases of primary uveal melanoma show a high HLA-A and 
B expression,19 thus suggesting evasion of NK cells by the tumor is necessary in the development of 
metastases. In uveal melanoma, a high expression of HLA class II also is related to a bad prognosis.15 
A small, but growing number of studies have indicated that, apart from HLA expression, HLA 
polymorphisms mediate susceptibility to certain neoplastic diseases.20,21 In several uveal melanoma 
studies an increased incidence of HLA-A32 has been found,22–25 and another study revealed that 
patients with HLA-B40 died more often from metastases.26 Nevertheless, a study on 235 cases could 
not confirm this association between HLA- B40 and metastasis; however, the study did find an 
association between HLA-B44 and metastasis before correction. Therefore, a role for HLA genotype 
in prognosis is not excluded.27 
Other important immunological parameters associated with prognosis in uveal melanoma are 
lymphocyte28 and macrophage29 infiltration. High numbers of tumor-infiltrating CD68+ and CD163+ 
macrophages are associated with an unfavorable prognosis,29–31 and CD68+ macrophages have been 
associated with increased HLA classes I and II expression as well.32 Several specific associations are 
known between HLA antigens and ocular diseases. It may well be that certain local immune 
responses may protect against the development of uveal melanoma by providing a local 
immunosurveillance system, for example against aberrant melanocytes. Choroidal auto-immune 
responses are noticed in birdshot chorioretinopathy (BCR), which is characterized by multiple 
hypopigmented chorioretinal lesions, and is associated with HLA-A29.33 In Vogt-Koyanagi-Harada 
syndrome (VKH), a bilateral, chronic, diffuse panuveitis with late stage depigmentation of the fundus 
occurs, with a genetic association with primarily HLA-DR4.34 Finally, uveitis in relation to autoimmune 
diseases has been related to HLA-B27.35,36 Therefore, we investigated whether the most common as 
well as these specific HLA genotypes are related to the level of HLA expression on tumor cells and 
intra-tumoral macrophage infiltration, which can be regarded as parameters of inflammation in uveal 
melanoma. 
 134 Chapter 5 
Material and Methods 
Study Population and Data Set 
Records were analyzed of 50 patients with uveal melanoma who underwent enucleation between 
1999 and 2004 at the Leiden University Medical Center in the Netherlands. 
 








 (n = 50) (n = 45) (n = 38) 
Males (mean age) 23 (60 y) 22 (59 y) 19 (60 y) 
Females (mean age) 27 (61 y) 23 (62 y) 19 (62 y) 
Stage I 10% 9% 5% 
Stage IIA 22% 22% 21% 
Stage IIB 28% 24% 26% 
Stage IIIA 34% 38% 40% 
Stage IIIB 6% 7% 8% 





For 45 patients, the HLA genotype was available. Information on the presence or absence of one 
chromosome 3 in the tumor was available for all 45 cases.37 The research protocol followed the 
tenets of the Declaration of Helsinki (World Medical Association Declaration of Helsinki 1964, ethical 
principles for medical research involving human subjects). All patients signed an informed consent 
form. 
 
Collection of Specific Data 
The specific HLA genotype of each patient had been determined previously27 and was retrieved from 
the patients’ chart. All results of DNA-based techniques were transformed to the serological 
classification to obtain unified data, usable for statistical analysis. 
Immunostaining of tumor cells of these patients for expression of HLA-A, HLA-B and HLA-DR had 
been performed previously and described by Maat et al.,32 using the monoclonal antibodies (mAbs) 
HCA2, which stains exclusively HLA-A, and HC10, which binds to HLA-B and HLA-C.38,39 Both 
antibodies were obtained from the Dutch Cancer Institute (Amsterdam, The Netherlands). For HLA-
DR staining Tal.1B5 was used, obtained from DakoCytomation (Glostrup, Denmark). 
Phenotypic characterization of macrophages and digital counting were performed previously by 
Bronkhorst et al.31 using immunofluorescence double-staining with mAbs against CD68 and CD163. 
The amount of positive staining was calculated as pixels per mm2. 
Comparison of Data 
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To minimize loss of significance after correction for the number of tests performed, only common 
and well-defined HLA alleles with the highest frequency in 2440 healthy Dutch blood donors were 
selected for statistical analysis.40 In detail, we selected three alleles for HLA-A (A1, A2, A3) and the 
two major grouping alleles for HLA-B (Bw4, Bw6), while for HLA-DR two alleles (DR4 associated with 
VKH, DR6) were used. Additionally, we selected alleles associated previously with uveal melanoma 
and bad prognosis (HLA-B40 and -B44), and two alleles associated with ocular autoimmune diseases 
(HLA-A29 and HLA-B27). 
All statistical analyses were performed with a statistical software program (SPSS for Microsoft 
Windows, version 17.0.2; SPSS Inc., Chicago, IL). The hypothesis was tested with the Mann-Whitney 
U test (Wilcoxon rank test) for non-normal distribution for each specific HLA allele. For the 
comparison of each HLA allele with chromosome 3 status, the v2 test was used. Statistical significance 
was assumed for a P value <0.05. Correction for multiple testing was performed according to the 





The HLA genotype of 45 patients was collected. Tissue specimens for macrophage staining were 
available for 38 patients. Tumor staging according to the pathologic TNM staging of the 7th edition of 
the American Joint Committee on Cancer International Union on Cancer (AJCC-UICC),41 and sex and 
age distribution of these patients is shown in Table 1. The frequencies of the studied HLA alleles in 
patients with uveal melanoma were compared to those of healthy Dutch blood donors and showed a 
comparable distribution (Table 2). 
The VKH-associated HLA-A29 was present only in four cases, while the autoimmune uveitis-related 
HLA allele B27 was not present in the population being studied. HLA-B40, associated previously with 
bad prognosis in uveal melanoma, is now split into B60 and B61. Only five patients carried B60, while 
no patients were positive for HLA-B61. Therefore, the relationship between these alleles and the 
degree of HLA expression or macrophage infiltration was not determined. 
 
Expression of HLA I and II Molecules 
Sections of uveal melanoma stained with HCA2 (HLA-A), HC10 (HLA-B and HLA-C) and Tal.1B5 (HLA-
DR) had been analyzed previously. Figure 1 shows an example of a section stained with HCA2. The 
percentage of cells that reacted positively with the anti-HLA class I antibodies HC10 and HCA2 varied 
widely, with a mean of 43% for HCA2 (SD 29%) and 37% for HC10 (SD 31%). The mean percentage of 
HLA-DR-positive cells was 20% (SD 23%). 
Staining for HCA2 correlated positively with HC10 staining (P < 0.001). Staining for Tal.1B5 was 
correlated with HCA2 and HC10 staining (P = 0.01 and P = 0.005, respectively, Spearman test). 
 

























Expression of HLA I and II Molecules 
Sections of uveal melanoma stained with HCA2 (HLA-A), HC10 (HLA-B and HLA-C) and Tal.1B5 (HLA-
DR) had been analyzed previously. Figure 1 shows an example of a section stained with HCA2. The 
percentage of cells that reacted positively with the anti-HLA class I antibodies HC10 and HCA2 varied 
Table 2. Distribution of the Selected HLA Alleles in the Study Group and a Dutch Blood Donor Database 
 Study Group (n = 45)  Dutch Blood Donors (n = 2440)*  
HLA Allele Positive (n) Positive (%)  Positive (n) Positive (%) P Value 
A1 14 31  747 31 0.94 
A2 24 53  1284 53 0.93 
A3 16 36  700 29 0.31 
A29 4 9  119 5 0.22 
B27 0 0  157 6 0.11† 
B44 10 22  586 24 0.78 
B60 (B40) 5 11  361 15 0.49 
B61 (B40) 0 0  73 3 0.64 
Bw4 23 51  1346 55 0.59 
Bw6 38 84  2143 88 0.49 
DR4 13 29  679 28 0.88 
DR6 14 31  796 34 0.83 





†Fisher’s exact test was used due to zero positive cases in the study group. 
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widely, with a mean of 43% for HCA2 (SD 29%) and 37% for HC10 (SD 31%). The mean percentage of 
HLA-DR-positive cells was 20% (SD 23%). 
Staining for HCA2 correlated positively with HC10 staining (P < 0.001). Staining for Tal.1B5 was 
correlated with HCA2 and HC10 staining (P = 0.01 and P = 0.005, respectively, Spearman test). 
 
HLA Allele versus HLA Expression 
As in autoimmune diseases some HLA alleles are associated with increased inflammation, we 
wondered if this were the case in uveal melanoma. Therefore, we compared staining of uveal 
melanoma cells for HCA2, HC10 and Tal.1B5 with the presence of frequently-occurring HLA alleles in 
45 patients, as well as with alleles associated previously with prognosis in uveal melanoma, and 
alleles well-known for their association with ocular auto-immune diseases. HLA-A29 was present in 
only four cases, HLA-B27 in none, and HLA-B60 in five, and comparisons, therefore, were not 
feasible. HLA-B44 was present in 10 cases, but showed no correlation with HLA expression. 
HLA-DR4 was associated almost significantly with a decreased expression of HLA-DR (P = 0.06), 
while HLA-DR6 was associated with a higher HLA-DR expression (P = 0.04). Significance was lost after 
correction for the total number of tests. An overview of HLA alleles versus HLA expression is shown 
in Table 3. 
 
Macrophage Infiltration 
Infiltration of macrophages had been assessed previously using immunofluorescence staining on 
paraffin-embedded sections of uveal melanomas from 38 patients. An example of this staining is 
shown in Figure 2. The presence of positive cells was measured as total amount of staining per 
section. The area of CD163+CD68+ double-staining associated with the area of CD68+ (Spearman test, 
P < 0.001). 
 
 
Figure 2. Immunofluorescence staining of macrophages in uveal melanoma using two antibodies directed 
against CD68 or CD163. Fluorescent staining of CD68 is shown as green and of CD163 as red. Overlay of both 
stainings showing double-positive cells are visualized in yellow. 250x magnification. 
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A comparison of CD68+ cells with HLA expression showed that an increased density of 
macrophages was associated with an increased number of cells positive for staining with mAbs 
HCA2, HC10, and Tal1.B5 (respectively, P = 0.02, P < 0.001, and P < 0.001, Spearman test). 
 
HLA Allele versus Macrophage Infiltration 
The most common HLA alleles together with HLA B44 were compared with macrophage infiltration 
and phenotype. Of the class I HLA alleles, only where the HLA-A2 allele was present, less 
CD68+staining (P = 0.03) as well as less CD68+CD163+ staining (P = 0.02) was observed. With regard to 
HLA-DR4 and -DR6, there was no increased or decreased macrophage infiltration compared to other 
alleles. When corrected for the total number of tests, significance was lost for all associations 
between HLA genotype and macrophage infiltration. An overview of the distribution of macrophage 
infiltration per HLA allele is shown in Figures 3 and 4, and the P values are displayed in Table 3. 
 
HLA Allele versus Monosomy 3 
Since we had shown previously that an inflammatory phenotype is associated with loss of one 
chromosome 3 in uveal melanoma tissue, we performed a comparison between the presence of HLA 
alleles and monosomy 3 in these 45 cases. No significant associations were found between any of 





Certain HLA polymorphisms predispose to immunological and neoplastic diseases. The frequencies of 
HLA alleles found in our study group correlated well with known data of HLA frequencies in the 
Caucasian population.40,42–44 We analyzed the most common HLA alleles, as well as HLA alleles that 
were associated previously with bad prognosis in uveal melanoma, and some alleles that have a 
known association with ocular inflammation. Individuals with local autoimmune disease might be 
protected against the development of melanoma due to local immunosurveillance. However, the 
alleles HLA-A29 and HLA-B40 were very infrequent, and HLA-B27 was absent in the 45 patients 
studied. Patients positive for HLA-DR4 (a gene with an association with VKH) had a trend toward a 
lower HLA-DR expression on their tumor cells, while the presence of the HLA-DR6 allele was 
associated with a higher HLA-DR expression on uveal melanoma tumor cells. With regard to 
macrophage infiltration, only the presence of the HLA-A2 allele correlated with less macrophage 
infiltration. After correction for the number of analyses, statistical significance was no longer present. 
Our study was performed to determine a possible relationship between HLA genotype and the level 
of HLA expression, and the amount of macrophage infiltration or loss of chromosome 3 in uveal 
melanoma. To study these relationships, we analyzed common alleles, as the results otherwise most 
likely would be insignificant due to necessary corrections for the number of analyses. Focusing on a  
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limited number of frequently-occurring alleles would reveal population-relevant correlations. 
The relationship that we observed between the HLA-DR4 and the HLA-DR6 allele, and level of HLA-
DR expression could suggest that certain HLA genotypes influence the expression of HLA on tumor 
cells. Since we know that a high expression of HLA classes I and II are prognostic factors for 
metastasis in uveal melanoma,13,15 this would be expected. However, the tendency to a lower 
expression associated with HLA-DR4 is surprising, as this gene is associated with inflammation 









Figure 4. Distribution of CD68 and CD163 positive staining, representing the M2 macrophages, for the most 
common HLA alleles. Error bars represent the SD of the mean. 
 
 
It is known that different mechanisms lead to HLA down regulation, which may be allele specific or 
haplotype specific.45 While mutations in the β2-microglobulin (β2M) gene can be responsible for lack 
of HLA class I expression in colon carcinoma and cutaneous malignant melanoma,46–48 in uveal 
melanoma no complete loss of β2M has been found, although a significantly decreased expression of 
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β2M has been described15 and is associated with a favorable outcome.49 Loss of chromosome 
material due to defective chromosome segregation or mitotic recombination may be another 
mechanism for loss of HLA expression. However, a study on the presence of loss of heterozygosity 
(LOH) in the area on chromosome 6 that codes for the HLA class I genes did not find a correlation of 
LOH with HLA-A or -B expression.50 Up regulation of HLA classes I and II expression also is mediated 
by cytokines, such as interferon-alpha and –gamma,45,51 which are released in the presence of an 
inflammatory infiltrate. Inflammation often is found in uveal melanoma and is associated with a 
worse prognosis.18,52 
The observed correlation between HLA-A2 and fewer infiltrating macrophages in uveal melanoma 
is difficult to interpret. Less macrophage infiltration is associated with a better prognosis.29–31 Thus, 
the association between being positive for the HLA-A2 allele and fewer infiltrating macrophages 
pleads for a protective function of the HLA-A2 allele in uveal melanoma. However, studies have 
shown that a direct association for HLA-A2 with survival in uveal melanoma does not exist.26,27 This 
does not exclude any influence of HLA-A2 on macrophage infiltration and, to prove this, studies with 
a larger patient population should be undertaken. 
No cases were positive for HLA-B27, which is known for its association with several autoimmune 
diseases, that is ankylosing spondylitis and anterior uveitis. This most likely is due to the relatively 
small study group, as a previous association study showed that 7% of 235 uveal melanoma patients 
were positive for HLA-B27.27 We also looked at HLA-A29 because of its association with VKH, and at 
the HLA-B alleles B44 and B40 (now B60 and B61), as earlier studies showed an increased risk for 
metastases with these alelles,26,27 although no association with an increased susceptibility to uveal 
melanoma was seen.53 However, most of these alleles occurred with a frequency that was too low 
for a useful comparison. Where possible, we did analyze relations with these alleles, and did not find 
a correlation with HLA expression and macrophage infiltration or chromosome 3 status. 
Understanding the pathological mechanism of HLA expression and macrophage infiltration in 
uveal melanoma is important, since both are related to prognosis. Our study shows that with the 
possible exception of an association between HLA-A2 and fewer infiltrating macrophages, and 
between HLA-DR6 and increased HLA-DR expression, HLA genotype does not determine the amount 
of HLA expression and macrophage infiltration or chromosome 3 status in uveal melanoma. It is 
important to look at these findings in the light of multiple testing, as these associations were 
observed before correction of the P value because of the number of tests performed. A second study 
with larger patient population, analyzing HLA genotypes with HLA expression and macrophage 
infiltration, will be essential to determine whether the associations we observed were valid. 
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Introduction: Uveal melanoma (UM) with an inflammatory phenotype, characterized by infiltrating 
leukocytes and increased human leukocyte antigen (HLA) expression, carry an increased risk of death 
due to metastases. These tumors should be ideal for T-cell based therapies, yet it is not clear why 
prognostically-infaust tumors have a high HLA expression. We set out to determine whether the level 
of HLA molecules in UM is associated with other genetic factors, HLA transcriptional regulators, or 
microenvironmental factors. 
 
Methods: 28 enucleated UM were used to study HLA class I and II expression, and several regulators 
of HLA by immunohistochemistry, PCR microarray, qPCR and chromosome SNP-array. Fresh tumor 
samples of eight primary UM and four metastases were compared to their corresponding xenograft 
in SCID mice, using a PCR microarray and SNP array. 
 
Results: Increased expression levels of HLA class I and II showed no dosage effect of chromosome 
6p, but, as expected, were associated with monosomy of chromosome 3. Increased HLA class I and 
II protein levels were positively associated with their gene expression and with raised levels of the 
peptide-loading gene TAP1, and HLA transcriptional regulators IRF1, IRF8, CIITA, and NLRC5, 
revealing a higher transcriptional activity in prognostically-bad tumors. Implantation of fresh 
human tumor samples into SCID mice led to a loss of infiltrating leukocytes, and to a decreased 
expression of HLA class I and II genes, and their regulators. 
 
Conclusion: Our data provides evidence for a proper functioning HLA regulatory system in UM, 
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Introduction 
 
Uveal melanoma (UM) is the most common primary intraocular tumor in adults with an incidence 
of 5.1 per million.1 Metastases develop in up to 50% of patients,2 and there is still no effective cure 
for metastatic disease. Once the tumor has metastasized, the median patient survival is 
approximately one year, and survival has remained largely unaltered during the last 
40 years.1 A patient’s individual prognosis is easily predictable, as during the last three decades 
several reliable prognostic markers have been found for UM and tests predicting patient survival 
have been developed. These include gene-expression profiling (GEP),3 and chromosome testing: 
patients that have lost one copy of chromosome 3 (monosomy 3) are at high risk to die from 
metastatic disease.4,5 Other chromosomal aberrations which modulate the risk of metastasis are 6p 
gain6,7 and 8q gain.8-10 Gain of 6p is only rarely observed in the same tumor as monosomy 3, and is 
associated with a favorable prognosis, while gain of 8q is often associated with monosomy of 
chromosome 3 and associated with a bad prognosis.6,7 
Inflammation is another prognostic marker for the development of metastatic disease,4,11 and is 
associated with monosomy 3.4,12 Inflammation has been established as one of the hallmarks of 
cancer,13 and despite the fact that the eye is an immune-privileged site, inflammation can be 
present within the intraocular tumor. The inflammatory phenotype seen in UM is characterized by 
an increased number of tumor-infiltrating lymphocytes and macrophages, as well as an increased 
expression on UM cells of Human Leukocyte Antigens (HLA) class I and II.4 Several studies already 
showed that, in contrast with many other malignancies, a high expression of the HLA class I and II 
antigens is associated with a poor prognosis.15-16 The sensitivity of UM to natural killer (NK)-cell 
mediated lysis was shown to be inversely correlated to this HLA protein expression:15,17 UM cells 
with a high HLA class I expression gave rise to higher numbers of metastases in mice, which 
suggests that the tumor cells are able to escape from NK-cell mediated lysis. As especially UM with 
a high HLA expression give rise to metastases in patients, this possible escape mechanism may also 
be present in humans.18 
The genes encoding both the HLA class I and II antigens are located on chromosome 6p. This 
faces us with an intriguing paradox because in general, chromosomal gain tends to lead to an 
increased gene expression in tumors.19,20 While in UM, 6p gain is associated with a good prognosis, 
an increase in HLA expression of both classes is associated with a poor prognosis. This made us 
wonder what exactly regulates HLA expression levels in UM: chromosomal dose effects (gain or loss 
of chromosome 6), an intrinsic genetic regulation, or external influences. We know that occasionally 
specific HLA alleles are not expressed.21 Therefore we looked in a previous study at the association 
between HLA expression and LOH (Loss of Heterozygosity) of chromosome 6.22 However, no 
relation between LOH and lack of expression was observed at the time, suggesting that a low HLA 
expression was not caused by loss of chromosome 6 material. Furthermore, several studies have 
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shown that the more malignant UM are not characterized by a downregulation, but by an 
upregulation of HLA class I and II antigens.14-16 
While expression at the cell surface depends on a properly-functioning peptide-loading system, 
regulation at the gene level depends on a set of different genes, which includes NLRC5 and CIITA. 
NLRC5 plays a crucial role in the transcriptional regulation of HLA class I genes,23 and CIITA in the 
transcriptional regulation of the HLA class II genes,24 while it is also involved in HLA class I 
transcriptional activation.25 The promoters NLRC5 and CIITA are on their turn under the influence 
of, amongst others, the interferon-regulatory factor 1 (IRF1).26 Furthermore, Holling et al., using UM 
cell lines, reported that HLA class II could be induced in half of their UM cell lines, and showed that 
the lack of HLA class II expression in one particular cell line was caused by epigenetic silencing of the 
gene encoding CIITA. Silencing of CIITA was mediated through EZH2 (Enhancer of Zeste Homologue 
2, a Polycomb Repressive Complex 2 subunit; chr7q), which triple methylates lysine 27 in histone 
H3.27 That not only transcriptional regulators influence HLA class I and II expression, but also 
external influences, was also shown using UM cell lines where interferon-gamma (IFNG) stimulation 
led to increased levels of HLA class I and II.27,28 Additionally, downregulation could be induced by 
tumor growth factor beta (TGFB).17,28 However, all of these studies regarding the regulation of HLA 
expression were performed on a limited number of available cell lines. As IFNG induces 
upregulation of HLA molecules in cell lines in vitro, IFNG produced by tumor-infiltrating leukocytes 
may have a similar effect in vivo in high-risk UM. HLA expression is of great importance for T-cell 
based therapies, because without HLA-molecules, T-cells cannot react to and subsequently destroy 
their target cells.29 Therefore it is important to determine whether HLA expression in UM cells 
functions properly, and how it is regulated. 
We here investigate whether chromosomal dose effects or specific known regulators influence 
HLA gene or protein expression in UM, this time studying primary enucleated tumors and not cell 
lines. We analyze the relationship between HLA class I and II RNA and protein levels, and genes 
involved in the regulation of (HLA) transcription, genes of the peptide-loading system, such as the 
TAP molecules, and the influence of the absence or presence of one chromosome 3 or 6p. 
Additionally, we assess the association and influence of the microenvironment on HLA gene 
expression by comparing expression levels in human primary or metastatic UM with their 





Tumor tissue was obtained from 28 eyes that underwent primary enucleation for UM between 1999 
and 2004 at the LUMC in Leiden, the Netherlands. Patient records and survival were updated from 
the patient’s charts and through the Dutch National Registry; the last update was in November 2013. 
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The current study population has previously been described,30 but only cases with mate rial 
suitable for gene-analysis were included; each tumor sample was processed for conven tional 
histopathological evaluation, including cell type assessment according to the modified Callender 
classification. The mean age at enucleation of the 28 patients was 62 years (median 68, range 28–
84 years) and median follow up was 72 months (median 76, range 14–145 months). At the time of 
the study, 13 patients were alive, 13 had died due to UM metastases, and in two cases, the cause 
of death was unknown. The mean time to metastasis was 37 months (median 30, range 14–96 
months). 
 
SNP and gene expression 
A genome wide micro-array analysis on single-nucleotide polymorphisms (SNPs) was performed 
with the Affymetrix 250K Nsp array (Affymetrix, Santa Clara, CA, US) to acquire a highly detailed 
image of the chromosome copy numbers. The average number of copies of all genes lying on the 
short (p) or long arm (q) of chromosome was used to determine gain or loss of that arm. For 
chromosome 6p we focused on gain or loss of the HLA region on that arm. 
Gene-expression profiling was performed with the Illumina HT12 v4 array (Illumina, Inc., San 
Diego, CA, US) for the HLA genes (HLA-A, -B, beta-2-microglobulin, HLA-DR [HLA- DRA, HLA-DRB1, 
HLA-DRB3, HLA-DRB6] and HLA-DQ [HLA-DQA1, HLA-DQB1]), the genes encoding HLA 
transcriptional regulators (NLRC5,25,26,31 CIITA,25,26,31 IRF8, IRF1, IRF2and genes of the peptide-
loading machinery (TAP1, TAP2, PDIA3, Tapasin, Calreticulin). Beta-2-microglobulin(B2M) is a 
component of the HLA class I complex at the cell surface, and should theoretically be upregulated 
when there are more HLA-molecules on the cell surface. However, the B2M gene is located on a 
different chromosome (15q21). HLA-C was not analyzed, as it has a tenfold-lower expression at the 
protein level than HLA-A and –B.32,33 As the peptide-loading mac hinery is needed to get a functional 
HLA class I molecule expressed at the cell surface, we looked at several of these genes. In cases 
where Illumina provided multiple probes for the same gene, the mean value of these probes was 
used for further analysis. One of four probes for HLA-A (ILMN_2165753) was omitted because of 
discordancy with the values of the other three HLA-A probes. 
The Illumina array data discussed in this publication have been deposited in NCBI's Gene 




Quantitative polymerase chain reaction (qPCR) was performed, as described previously,35 in 
duplicate on the selected genes for HLA and HLA-regulation activators, as a validation of the 
results found with gene-expression profiling. 
In short, RNA was extracted from the fresh frozen primary tumors using an RNeasy Mini Kit 
(Qiagen). Complementary DNA (cDNA) was synthesized with the iScript cDNA synthesis kit (Bio-
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Rad). Beacon Designer (Biosoft) was used for primer design. Primers for ACTB (β- actin; OMIM 
102630), GAPDH (OMIM 138400), RPL13 (OMIM 113703), and RSP11 (OMIM 180471) were 
included for selecting suitable reference genes. Gene expression was calculated by normalizing the 
C-value of each marker to the reference genes. Reference genes were selected based on their 
stable expression in the tissue, which was measured with the geNorm Software.36 
In the material studied, RPL13 and RPS11 were stably expressed, and the genes of interest 
were corrected for the geometric mean of these two reference genes as described previously.37 
For a overview of the primers used, see the supplements (S1 Table). 
 
Immunohistochemistry 
Immunohistochemical staining for HLA class I (HLA-A, -B) and II (HLA-DR) was previously performed 
as described.4 In short, immunohistochemical staining was carried out using the mouse monoclonal 
antibodies HCA2 (Produced by the Netherlands Cancer Institute, Amsterdam, the Netherlands) 
exclusively staining HLA-A heavy chains, HC10 (Produced by The Netherlands Cancer Institute, 
Amsterdam, the Netherlands) which binds to HLA-B and -C heavy chains,38,39 and Tal.1B5 
(DakoCytomation, Glostrup, Denmark) reacting with HLA-DR alpha chains. The number of tumor 
cells positive for each marker was counted at 100X magnification and expressed as percentage of 
the total number of tumor cells (S2 Table). 
Immunofluorescence staining for infiltrating macrophages was performed and described 
previously, with antibodies against CD68 (clone 514H12; Abcam, Cambridge, UK) and CD163 (clone 
10D6; Novocastra, Newcastle-upon-Tyne, UK), and expressed as pixels per millimeter squared.40 T 
cells were identified and scored previously using an anti-CD3 antibody (ab828; Abcam), and 
expressed as numbers of cells per millimeter squared.12 
 
Xenografts 
Fresh intraocular or metastatic human tumor samples were acquired with informed consent at the 
Institut Curie (Paris, France), and immediately transplanted into the interscapular fat pad of two to 
four non-preirradiated immunodeficient female SCID mice, and considered to be stable xenografts 
for characterization after three consecutive mouse-to-mouse passages.41 
Total RNA was isolated from frozen material of the fresh intraocular and metastatic human tumor 
samples, and from frozen material of the corresponding xenografts, and subsequently analyzed 
with GeneChip Human Exon 1.0 ST microarrays (Affymetrix).42 
Of these tumors, eight of primary and four of metastatic origin were included in our study and 
expression on the microarray was analyzed for HLA-A, HLA-B, HLA-DR (HLA-DRA), and HLA-DQ (HLA-
DQA1, HLA-DQA2), and markers of infiltrating T cells: CD3 (CD3D, CD3E), CD4), and CD8 (CD8A, 
CD8B), and macrophages: CD68, and CD163. 
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Statistics 
Data analysis of the material obtained at the LUMC in Leiden was performed with the statistical 
programming language R version 3.0.1 (R: A Language and Environment for Statistical Computing, R 
Core Team, R foundation for Statistical Computing, Vienna, Austria, 2014, http://www.R-
project.org), supplemented with specialized packages for SNP and RNA analysis. The main package 
used for SNP analysis was aroma.affymetrix,43-45 supported by ‘DNA-copy’ (Venkatraman E. Seshan 
and Adam Olshen, DNAcopy: DNA copy number data analysis. R package version 1.34.0), ‘sfit’ 
(Henrik Bengtsson and Pratyaksha Wirapati (2013), sfit: Multidimensional simplex fitting. R package 
version 0.3.0/r185, http://R-Forge.R-project.org/ projects/matrixstats/), and ‘R.utils’ (Henrik 
Bengtsson (2014), R.utils: Various programming utilities, R package version 1.29.8, http://CRAN.R-
project.org/package=R.utils). Data of eighty-four healthy controls served as reference set, obtained 
with the same Affymetrix 250K Nsp chip (Affymetrix, Santa Clara, CA, USA) by the Department of 
Human Genetics at our center. The ‘Aroma.Affymetrix’ package made it possible to use these SNP 
microarrays to determine copy number values.43-45 The packages used for RNA microarray analysis 
were ‘limma’ version 3.16.8 and the specific packages for Illumina microarrays: ‘lumi’ version 2.12.0, 
‘annotate’ (R. Gentleman, annotate: Annotation for microarrays, R package version 1.38.0), and 
‘illuminaHumanv4.db’ (Mark Dunning, Andy Lynch and Matthew Eldridge, illuminaHumanv4.db: 
Illumina HumanHT12v4 annotation data (chip illuminaHumanv4), R package version 1.18.0). 
Data of the xenografts and corresponding original human tumors were analyzed at the Institut 
Curie (Paris, France) with R software (version 2.12) at gene level using custom Brain array Chip 
Description Files (CDF) based on Entrez Gene database (version 13) as described in detail by Laurent 
et al.42 For this study, a paired sub-analysis was made at the Institut Curie with regard to the genes 
of our interest. 
All other statistical analysis was performed with SPSS 20.0.1 (IBM SPSS Statistics, IBM 
Corporation, Armonk, NY, US). Cumulative survival was calculated with Kaplan-Meier and its 
significance analyzed with the log rank test. Hazards ratios (HR) were measured with Univariate Cox 
regression models. Associations for clinical categorical variables with gene expression were 
determined using the Mann-Whitney U test (Wilcoxon rank sum test) for non-parametric analysis. 
Statistical correlation between two continuous variables was calculated with the Spearman’s rank 
test. For survival analysis with Kaplan-Meier, the linear variables were dichotomized at 50% cut off, 
unless mentioned otherwise. Statistical significance was assumed for a p-value <0.05. 
 
Study approval 
The collection of material and the research performed with it for this study has been agreed upon 
by the Medical Ethics Committee of the LUMC (Leiden University Medical Center, Leiden, the 
Netherlands). The research protocol adhered to Dutch law and the current version of the tenets of 
the Declaration of Helsinki (World Medical Association of Declaration 1964; ethical principles for 
medical research involving human subjects). Patients were informed about the use of their 
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enucleated eyes for research, and signed an informed consent prior to the enucleation. The 
performance of the xenograft study was in accordance with the French Ehtics Committee (Ministère 
de l'Alimentation, de l'Agriculture et de la Pêche, Direction de la Santé et de la Protection Animale, 
Paris, France). Both studies were thus specifically approved by the Ethics Committee of the 
respective centers, the first one being the Medical Ethics Committee of the LUMC (Leiden University 
Medical Center, Leiden, the Netherlands) and the second one being the just mentioned French 
Ethics Committee (Ministère de l'Alimentation, de l'Agriculture et de la Pêche, Direction de la Santé 




HLA gene expression and HLA immunohistochemistry 
We wondered whether differences that were noticed in HLA gene-expression assays correlated with 
previous immunohistochemical staining results on tumor cells and observed that the gene-
expression of HLA-A and -B was significantly correlated with the percentage of tumor cells being, 
respectively, positive for HCA2 (HLA-A) and HC10 (HLA-B/C) (Table 1). B2M gene-expression 
correlated positively with HCA2 and HC10 staining too, although not significant for HCA2. Gene-
expression of HLA-DR failed to correlate with monocolonal antibody Tal.1B5. Gene-expression levels 
of the HLA molecules in the Illumina test correlated with death due to metastases (S3 Table). When 
comparing clinical and histopathological parameters, gene expression of HLA-A, HLA-B, B2M, and 
HLA-DR was positively associated with age at enucleation and with the largest basal diameter of the 
tumor, a well-known adverse parameter. 
The genes that code for the HLA class I and II antigens are located on chromosome 6p, which has 
prognostic importance in UM. In order to determine whether the level of HLA class I and II antigens 
was influenced by a gene-dosage effect, we determined the presence of chromosome 6 by SNP 
array, and compared HLA and B2M gene expression levels with chromo- some dosage. Additionally, 
we examined the gene-dose effect of chromosome 3, as a previous study from our laboratory had 
indicated an association between loss of chromosome 3 and increased HLA expression levels on 
primary UM(8). An overview of the clinical, chromosomal, gene-expression, and histological data is 
provided in S4 Table. 
 
Aberrations of chromosome 3 and 6p 
Aberrations of chromosome 3 and 6p were analyzed with a SNP micro-array in 28 UMs. Monosomy 
3 was present in fourteen (50%) cases and associated with death due to metastases (Kaplan-Meier, 
p < 0.001). 
Gain of the HLA region of chromosome 6p was present in eight cases (29%), and associated with 
good survival (Kaplan-Meier: p = 0.049). Gain of 6p co-occurred with monosomy 3 in only one 
case. 
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Gene-expression (Illumina) r p r p r p   
HLA-A .434 0.02 .545 0.003 .161 0.41   
HLA-B .488 0.01 .609 0.001 .286 0.14  
B2M .346 0.07 .508 0.006 .279 0.15  
        
HLA-DR .242 0.21 .332 0.08 .225 0.25  
HLA-DQ .301 0.12 .400 0.04 .172 0.38   
Correlation of HLA gene-expression, as determined with the Illumina array, with the results of HLA 
immunohistochemical staining in 28 cases of UM. r = two-tailed Spearman correlation coefficient. p = p-value. 
 
 
To determine a possible dose effect of chromosome 6 on HLA expression levels in UM, we 
investigated whether there was an association of chromosome 6p dose and gene or protein 
expression of HLA. Monosomy of chromosome 3 was associated with an increased gene 
expression of HLA class I and B2M but not of HLA class II. Gain of 6p occurred almost exclusively in 
tumors without monosomy 3, and when looking at all tumors, an association was observed 
between 6p gain and less HLA-B expression (p = 0.049). Expression of HLA class I and II as 
determined by immunohistochemistry was not associated with 6p gain (HLA-A p = 0.12; HLA-B/C p 
= 0.26; HLA-DR p = 0.24). 
However, the effect of the loss of one copy of chromosome 3 may have overshadowed that of 
chromosome 6p. Therefore we separated monosomy 3 and disomy 3 tumors into those with or 
without gain of 6p. As the group with monosomy 3 with gain of 6p consisted of only one tumor, we 
did not use this case for analysis. As expected, monosomy 3 tumors showed a higher expression of 
HLA class I than disomy 3 tumors, at the gene-expression as well as the protein- expression level (Fig 
1A and 1B). When looking at the effect of 6p gain in disomy 3 tumors, no significant differences in 
gene and protein expression were observed between tumors with a normal 6p (n = 7) or a gain of 6p 
(n = 7). Similarly, HLA class II gene and protein expression was not different as well. We can conclude 
that there is no clear dose effect of chromosome 6p on HLA class I and II expression. 
 
Peptide-loading genes and HLA transcriptional regulators 
As chromosomal gain of 6p had no influence on the expression levels of HLA genes, we questioned 
whether HLA expression was influenced by the peptide-loading machinery or any of the known 
HLA regulators. 
We compared expression levels of the HLA class I subtypes with expression of the genes 
encoding the main molecules of the peptide-loading machinery, eg. with TAP1, TAP2, tapasin and  
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Figure 1. Chromosomal aberrations and HLA expression. Comparison between chromosomal aberrations and 
the expression of HLA class I and II antigens in a set of 27 primary UM. Tumors are divided according to their 
chromosome 3 and 6 status (disomy or monosomy of chromosome 3, and disomy of chromosome 6 or gain of 
6p). HLA gene expression was determined using an Illumina microarray (A) and protein expression by 
immunohistochemistry (B) in UM. Additionally, HLA gene expression was determined using qPCR, which served 
to validate the Illumina findings (C). Four data points of the qPCR that are outside the axis limits (> 11 and < 24) 
are not shown (HLA-A, D3D6p: 17; HLA-B, D3D6p: 24, and M3D6p: 12; B2M, D3D6p: 13). Only significant p-
values are shown, all other comparisons between the groups were not significant (p-values not shown). Error-
bars represent the interquartile range. Results were obtained using the Mann-Whitney U tests. 
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calreticulin. TAP1-gene expression correlated positively with the gene-expression levels of HLA 
class-I and B2M, while TAP2 in general showed a similar correlation, although this was not 
significant for all comparisons (Table 2). The other antigen-presenting machinery molecules were 
not co-regulated with HLA antigen expression. 
We subsequently focused on the influence of known regulators of HLA gene expression. NLRC5 
is a regulator for HLA class I and not for HLA class II genes, while CIITA is essential for the 
transcriptional regulation of HLA class II genes. In contrast to NLRC5, CIITA also plays an ancillary 
function in the transcriptional regulation of HLA class I genes. Other known HLA regulators, 
influencing both class I and II, are IRF1, IRF2, and IRF8. When we compared expression of these 
HLA transcriptional regulators with HLA expression in tissue of human uveal melanoma, we 
observed that the gene-expression levels of the HLA transcriptional activators IRF1 and IRF8 
correlated positively with HLA class I and B2M, NLRC5 with HLA-B and B2M expression, and CIITA 
with HLA-B as well as with B2M (Table 2). Additionally, the gene-expression levels of IRF1, IRF8, 
NLRC5 and CIITA correlated positively with the expression levels of both HLA class II subtypes, i.e. 
HLA-DR and HLA-DQ. IRF1 and IRF8 exert their function on HLA class II genes via their 
involvement in CIITA transcription. 
 
 
Table 2. Correlation between HLA- gene expression and the expression of the genes encoding the HLA 
transcriptional regulators and peptide-loading machinery 
 
HLA-A HLA-B B2M 
    
Peptide loading 
machinery r p r p r p 
        
TAP1 .859 <0.001 .809 <0.001 .814 <0.001        
TAP2 .367 0.06 .350 0.07 .465 0.01     
PDIA3 .204 0.30 .184 0.35 .159 0.42     
Tapasin .171 0.38 .135 0.50 -.038 0.85     
Calreticulin -.036 0.86 .031 0.88 -.218 0.27         
           
 
HLA-A HLA-B B2M HLA-DR HLA-DQ 
HLA transcriptional 
regulators r p r p r p r p r p 
CIITA .276 0.16 .407 0.03 .408 0.03 .415 0.03 .465 0.01 
NLRC5 .280 0.15 .470 0.01 .389 0.04 .557 0.002 .492 0.01 
IRF1 .758 <0.001 .854 <0.001 .853 <0.001 .828 <0.001 .852 <0.001 
IRF2 .137 0.49 .096 0.63 .179 0.36 .032 0.87 -.085 0.67 
IRF8 .578 0.001 .679 <0.001 .689 <0.001 .937 <0.001 .916 <0.001 
Correlations based on Illumina array data. r = two-tailed Spearman correlation coefficient. p = p-value.  
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Only an increased gene-expression level of IRF1 was associated with monosomy 3, expression 
levels of IRF2, IRF8, NLRC5, and CIITA were not associated (S1 Fig). 
A high expression of TAP1 and of IRF1 was associated with death due to metastases (TAP1: 
Univariate Cox regression: HR = 1.6, p = 0.004, and Kaplan-Meier: p < 0.001; IRF1: Univariate Cox 
regression: HR = 1.4, p = 0.06, and Kaplan-Meier: p = 0.007). NLRC5, CIITA, IRF2, and IRF8 displayed 
no association with survival. 
 
Validation 
Quantitative polymerase chain reaction (qPCR) on the same 28 UMs was performed to validate our 
findings based on the gene-expression values obtained with Illumina HT12 v4 array for HLA class 1 
genes (Fig 1C). Unfortunately, a suitable primer pair for qPCR could not be developed for IRF8. qPCR 
confirmed most of the correlations between the HLA genes and TAP1, CIITA, IRF1, and NLRC5 
(Spearman correlations, S5 Table). Using qPCR data, TAP2 was significantly correlated with the HLA 
genes. 
 
Tumor-infiltrating immune cells 
Expression of several HLA class 1 and 2 molecules, regulators of the antigen-presenting machinery, 
as well as several of the transcriptional regulators, are thus co-regulated in human UM samples, and 
the presence of most of these, showed an association with loss of one chromosome 3. We noticed 
that all of these molecules are part of the interferon-regulated pathway. As infiltrating cells are 
considered important sources of interferon and infiltrating leukocytes are also an important part of 
the inflammatory phenotype of UM, we compared HLA expression with infiltrating leukocyte 
density, using the Illumina HLA expression data. We looked at the presence of macrophages and 
CD3+ T-cells, as markers of the presence of an immune infiltrate. We separated the tumors into two 
groups, with a low or high infiltration, and compared expression levels of HLA-A, HLA-B, B2M, TAP1, 
IRF1, IRF8 and NLRC5 between these two groups. Overall, a high infiltrate was associated with 
increased expression of the genes related to HLA class I (Fig 2A and 2B). 
 
Xenografts 
The clear association between the presence of infiltrating leukocytes and HLA-A, HLA-B, TAP1, as 
well as the HLA regulator genes suggests that the presence of leukocytes is associated with the 
level of expression of all HLA-associated molecules. However, it may be that a high HLA expression 
attracts leukocytes to the site of inflammation, or it may be that the HLA expression is upregulated 
by cytokine production from the leukocytes. These two options can be tested by comparing 
intraocular UM with xenografts from the same tumors in mice. When human tumors are placed as 
xenografts into SCID mice, they loose their infiltrating human leukocytes over time due to their 
limited timespan,46 and any environmental effect caused by these leukocytes disappears. If the HLA 
expression is upregulated due to leukocyte-produced interferon, its expression should go down in a 
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xenograft. Twelve xenografts, consisting of eight primary tumors and four metastases of UM, were 
analyzed and their gene expression levels were compared with the original human tumor tissue. 
This allowed us to compare the effect of the absence of infiltrating human leukocytes on the 
expression of the genes of our interest (Fig 3). Indeed, a decrease in infiltrating T cells was 
observed (Cd3E p < 0.001, Cd3D p <0.001, Cd4 p < 0.001, Cd8A p = 0.001, Cd8b p = 0.34). Also, the 
markers for macrophages, Cd68 (p < 0.001) and Cd163 (p < 0.001), were decreased in xenografts. In 
parallel, the xenografts showed a decrease of the HLA genes investigated, as well as of most of the 





Figure 2. Tumor infiltrating immune cells. Association between a low or high density of tumor-infiltrating 
CD3+ (A), and CD68+ (B)cells and several HLA and HLA-related genes (Illumina array) in primary UM. CD3 





We found that the immune infiltrate was associated with an increased HLA-gene expression in UM. 
Immune infiltrate is associated with monosomy 3,4,12 and loss of infiltrating human leukocytes from 
the xenografts in SCID mice resulted in a lower HLA class I and II gene expression. Many of the 
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studies on UM focus on markers predicting prognosis.3,5,7,18,40 Predicting prognosis, important as it 
is, does not explain why and how these markers are related to an altered life expectancy. We first 
compared the relationship between the expression of HLA genes and aberrations of chromosome 3 




Figure 3. Effect of the absence of human leukocytes. Gene-expression (log 2 intensity values) of HLA-B, 
HLA-DRA, CD3D (as marker for T-cells), and CD163 (as marker for macrophages), of the original tumors 
(patient) compared to the xenografts (xeno). MP’s are primary tumors; MM’s are metasisis. 
 
 
We observed that for the HLA class I and II genes, an increased number of copies of 
chromosome 6p led not to a higher HLA expression, showing that UM deviate from the general 
rule that gain of gene copy number leads to a higher expression of those genes (Fig 1). Following 
the line of HLA production from the presence of its complexes on the cell membrane downwards 
to the amount of RNA (gene-expression) and finally to the genes located in the nuclei, two patterns 
could be discerned: HLA class I gene and protein levels were not related to the dose effect of 
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chromosome 6p, yet they were clearly and inversely associated with the dose of chromosome 3. 
This not only affected the HLA class I and II antigens, but also transporter molecules, such as B2M 
located on a different chromosome than 6, as well as HLA expression regulators. In our earlier 
work on the same tumors,4,12,22 we had used karyograms and FISH analysis on isolated nuclei for 
determining the presence of monosomy 3, while in the current study we used the more precise 
SNP array. We here show that loss of one chromosome 3 is associated with an increased leukocytic 
infiltrate, and increased expression of not only the HLA class I and II molecules, but also of 
molecules related to the peptide-loading machinery and transcriptional regulators. 
The apparently intact HLA protein production tree in UM directed us to look outside the cell for 
factors influencing HLA expression. The HLA transcriptional regulators are under the influence of 
IFNG, a cytokine often produced by lymphocytes.47 IFNG can activate Janus kinase 1 and 2 (JAK1 and 
JAK2), which causes activation of STAT1 (signal transducer and activator of transcription 1) and IRF1, 
leading to induction of CIITA.26 With regard to HLA class I expression, NLRC5 has been identified as 
the key transcriptional regulator at this level in human cells of different origin (embryonic kidney 
cells, HeLa cells, and Jurkat T cells).23 Our current findings have been obtained on a set of 28 primary 
UM, and show that not only TAP1 is being upregulated together with HLA, but that HLA class I is 
upregulated together with TAP1, IRF1, IRF8, NLRC5 and CIITA, and HLA class II together with CIITA 
and IRF1, which agrees with the previous results obtained using cell lines.27 
It was previously reported that EZH2 (also known as KMTase Enhancer of Zeste Homolog 2), a 
member of the polycomb repressive complex 2 (PRC2), is involved in blocking IFNG-induced 
upregulation of CIITA in a UM cell line.27 Monosomy 3 in uveal melanoma is associated with loss of 
BAP1 (BRCA1 associated protein-1; chr3p),8,48 which is connected to PRC2 (of which EZH2 is a 
member) through ASXL1(additional sex combs-like transcriptional regulator 1).49,50 This could 
represent a possible connection between BAP1 and expression of HLA in uveal melanoma, as study in 
mice showed that loss of BAP1 leads to increased levels of EZH2 (and PRC2) with repressed 
expression of its targets,51 including thus CIITA, leading ultimately to less HLA class II expression. 
However, this is not what we found in uveal melanoma, where BAP1 loss seemed to be associated 
with increased HLA expression.52 The general picture that emerges from the Illumina array was 
validated with the qPCR (Fig 2). HLA class I and HLA II are upregulated in monosomy 3 tumors, and 
the upregulation of HLA class I genes is positively correlated to IRF1, CIITA, and TAP1 (and TAP2), 
while HLA class II is upregulated together with IRF1, CIITA and NLRC5. NLRC5 is located on the same 
chromosome as CIITA (chromosome 16). Since both of these transcriptional regulators belong to the 
NOD-like receptor family of proteins and share some regulatory elements in their promoters, it could 
therefore be a co-regulatory effect that explains this finding for NLRC5. Some UM are known to loose 
copies of Chromosome,16,53 so likely here is no gene dose effect. 
As we were not finding clues indicating that the regulation of HLA expression was internally 
deranged in these UM, we aimed to find the origin of the elevated HLA expression by factors 
outside the UM cells. The most well-known factor is IFNG, which has previously
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been shown to stimulate HLA expression in UM cell lines,28 IFNG is predominantly secreted by CD4+ 
T helper 1 cells (Th1), CD8+ cytotoxic T cells, and NK cells, although it is also to a lower degree 
produced by professional antigen-presenting cells (APCs), including macrophages, and B-cells. Our 
data confirmed that indeed a high leukocyte infiltration of CD68+ and CD3+ leukocytes, was 
associated with an increase in gene expression of HLA, B2M, TAP1, and IRF1. Some of these markers 
may be more highly expressed at the RNA level due to the presence of leukocytes in the RNA that 
was used for the array and qPCR. One may suggest that the PCR data identified HLA antigens on 
infiltrating cells, however all original studies were performed using immunohistochemistry on tumor 
sections, analyzing melanoma-cell specific HLA class I and II and B2M expression. We can thus 
conclude that we are really looking at the HLA expression of the tumor cells themselves. 
Using SCID-mice (lacking T and B cells) into which freshly-obtained UM were grafted, we 
observed that xenografts obtained from tumors that originally showed a high HLA class I and II 
expression, showed a much lower HLA class I and II expression than their original counterpart (Fig 
3). The original tumors (primary and metastatic) were usually monosomic for chromosome 3 and 
exhibited high gene-expression levels of CD3, CD4, CD8 (T-cell markers), and CD68 and CD163 
(macrophages markers), as well as a high HLA class I and II gene expression. The average 
expression of all of these genes decreased in the xenografts, although the tumors continued to 
show monosomy of chromosome 3. This means that the tumor-infiltrating lymphocytes (TILs), 
and especially the T cells as main producers of IFNG, are the ones triggering the increased HLA 
expression in UM. Jehs et al. observed that UM cell lines are not producing IFNG themselves, and 
that upon co-culture with IFNG-secreting T cells, the UM cells were responding by synthesizing 
chemokines that create a tumor-promoting environment with increased HLA expression and 
attraction of M2 type macrophages.54 Indeed, the T cell-containing primary UMs as well as the 
xenografts contained high numbers of macrophages. Following xenografting, a decrease in gene-
expression of CD68 was observed. 
Although the question remains how these T cells are exactly recruited to the tumor, and 
whether they do or do not recognize the peptides presented in the HLA molecules, all these data 
together indicate that the presence of an infiltrate is a bad prognostic parameter in uveal 
melanoma. Several studies have shown that UM contain Foxp3-positive regulator cells, which may 
inhibit effective CTL function.12,55 An interesting option is to specifically deplete these regulator T 
cells. A recent study in a mouse model showed that attacking a T-reg specific kinase may help bring 
back CTLs, which subsequently kill the tumor cells.56 As T cells may produce factors that bring in 
macrophages,54 T-cell depletion may also reduce macrophages density, and this may subsequently 
influence the development of the primary tumor or metastases, as the presence of macrophages is 
related to angiogenesis and most of the macrophages in UM are of the pro-angiogenic M2 type.40 
This and other T-cell based therapies will only work when there is a proper functioning HLA system 
present, which we have shown here to be the case. 
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Figure 4. Schematic illustration of tumor characteristics and infiltrate. UM with monosomy 3 attract an 
infiltrate, producing different cytokines, including Interferon-gamma. The tumor cell (UM cell) responds by 
increasing HLA class I and II levels, as well as rendering the infiltrating immune cells ineffective (immune 
suppression) and creating a tumor-favorable environment, with amongst others, stimulation of angiogenesis. 
 
 
In summary, we show that in primary UM, there is no gene-dose effect of chromosome 6p with 
regard to HLA expression nor a general abnormal internal regulation of HLA expression. We provide 
evidence for a co-regulated upregulation of genes encoding for HLA transcrip tional regulators, 
peptide-loading machinery, and HLA proteins on the cell surface, which we attribute to the 
presence of tumor-infiltrating T cells, secreting IFNG (Fig 4). This indicates a proper function 
antigen presenting system, which one would not expect, as likely the most common method a 
tumor deploys for immune evasion is reducing their antigen expression by down regulation of HLA 
molecules,57,58 or altering the subtypes of HLA molecules expressed.59 In earlier work we also 
showed that this latter is not the case.30 Together, our data indicates that UM contain a proper 
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S1 Figure. Chromosome 3 status and gene-expression (Illumina array data) of several HLA regulators. Only 
significant p-values are shown, all other comparisons between the groups were not significant (p-values not 
shown). Error-bars represent the interquartile range. Results were obtained using the Mann-Whitney U tests.  
 
 
S1 Table. An overview of the primers used for the validation with qPCR. 
Primers Forward Reverse  
Beta-Actin CGGGACCTGACTGACTACCTC CTCCTTAATGTCACGCACGATTTC  
GAPDH  GCACAGCCCACAGGTTTC CAGGCGGAGGACAGGATG  
RPL13 GTACGCTGTGAAGGCATCAAC GGTTGGTGTTCATCCGCTTG  
RPS11 AAGCAGCCGACCATCTTTCA CGGGAGCTTCTCCTTGCC  
HLA-A TGTGTTCGTGTAGGCATA TTGAGACAGAGATGGAGAC  
HLA-B  CTCCATCTCTGTCTCAACTT CATCAACCTCTCATAGCA  
B2M TGCTGTCTCCATGTTTGATGTATCT TCTCTGCTCCCCACCTCTAAGT  
HLA-DR CAAAGAAGGAGACGGTCTGG GGCTCTCTCAGTTCCACAGG  
HLA-DQ TGATGGAGATGAGCAGTTC GCAGCGGTAGAGTTGTAG  
CIITA(-PIII) GCTGGGATTCCTACACAATGC TCTCCAGCCAGGTCCATCTG  
IRF1 TCACCAAGAACCAGAGAA TCCATCAGAGAAGGTATCAG  
NLRC5 CTGGAGGAGTTGATGCTT GATGGCTGAATGGTAGGT  
TAP1 CGAAGCCCAGAAGTTTAG CCACCAATGTAGAGGATTC  
TAP2 CTATTCTGGTCGTGTGATTG CTGTCTTAGTCTCCTGGAA  
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S2 Table. Percentage of tumor cells staining positive for the monoclonal antibodies for 
HLA-A, HLA-B or HLA-DR. 
Tumor nr. mAb HCA2 (HLA-A) mAb HC10 (HLA-B/C) mAb Tal.1B5 (HLA-DR) 
01-042 0 5 10 
01-074 40 25 60 
01-091 50 60 10 
01-129 80 100 30 
01-131 50 60 20 
02-158 0 0 5 
02-167 70 90 15 
02-174 20 70 5 
02-199 30 10 15 
03-086 30 5 25 
03-087 5 0 5 
03-120 50 70 100 
03-129 60 5 10 
04-018 20 10 15 
04-035 80 70 15 
04-074 5 5 10 
04-075 60 50 25 
04-103 20 10 5 
04-112 50 40 10 
20-005 90 60 10 
20-042 25 25 5 
20-125 10 0 5 
20-128 50 40 50 
20-173 40 5 80 
20-178 25 10 35 
99-184 5 10 20 
99-187 5 0 10 
99-239 95 80 30 
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S3 Table. Hazard ratio’s (Univariate Cox-regression) of death due to metastasis for HLA 
gene expression as determined by the Illumina array.  
Gene-expression array log2 
intensity values (n=28) 
Mean 
(median) ±SD HR (p-value) 
 95% conf. 
interval 
 
HLA-A 11.3 (11.4) 0.8 2.7 (0.003) 1.4-5.2  
HLA-B  10.7 (10.8) 1.2 1.7 (0.004) 1.2-2.4  
B2M 12.2 (12.2) 0.9 2.1 (0.01) 1.2-3.7  
      
HLA-DR 9.0 (8.9) 0.9 1.4 (0.16) 0.9-2.4  
HLA-DQ  7.3 (7.1) 1.0 1.3 (0.21) 0.9-1.9  






S4 Table. Characteristiscs of study population, with hazard ratio’s (HR) for death due to metastasis. 
 
Baseline Data  
 
Associations with gene-expr. (mean) 
Categorical 






HLA-A HLA-B B2M HLA-DR HLA-DQ 
Patient gender                
  Male 15 54 0.7 (0.60) 0.3-2.2 
 
11.3 10.8 12.1 9.1. 7.5 
  Female 13 46 1.3 (0.60) 0.4-4.0 
 
11.3 10.7 12.3 8.8 7.1 
p-values      1.00 0.72 0.50 0.47 0.41 
Prognostic groups                
  Stage I & IIA 8 28 - 
  
11.1 10.6 11.9 8.9 7.3 
  Stage IIB 10 36 4.4 (0.18) 0.5-30.6 
 
11.3 10.6 12.2 9.0 7.3 
  Stage IIIA 8 29 14.1 (0.01) 1.7-117.9 
 
11.6 11.3 12.7 9.1 7.2 
  Stage IIIB 2 7 5.1 (0.25) 0.3-82.8 
 
11.1 10.2 12.0 9.2 7.7 
p-values      0.33 0.43 0.25 0.76 0.60 
Cell type                
  Spindle 10 36 0.2 (0.44) 01-1.0 
 
11.0 10.3 11.9 8.9 7.2 
 Mixed/Epithelioid 18 64 4.7 (0.44) 1.0-21.6 
 
11.5 11.0 12.4 9.0 7.4 
p-values      0.09 0.13 0.21 0.91 0.83 
Chromosome 3                 
  Normal 14 50 0.04 (0.003) 0.01-0.35 
 
10.1 10.1 11.8 8.9 7.2 
  Loss 14 50 22.6 (0.003) 2.9-176.1 
 
11.7 11.4 12.6 9.1 7.4 
p-values       0.002 0.001 0.01 0.35 0.23 
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Chromosome 6p 
(HLA loci)                
  Normal 20 71 6.0 (0.09) 0.8-46.4 
 
11.4 11.0 12.4 9.1 7.4 
  Gain 8 29 0.2 (0.09) 0.02-1.3 
 
11.2 10.1 11.7 8.7 7.0 
p-values       0.47 0.049 0.09 0.38 0.47 
      














62 (68) 15 1.0 (0.26) 1.0-1.1 
 
0.046 0.008 0.001 0.02 0.15 
LBD (mm) (n=28) 14 (15) 3 1.4 (0.01) 1.1-1.7 
 
0.03 0.04 0.01 0.02 0.01 
Prominence (mm) 
(n=28) 
7 (7) 3 1.1 (0.58) 0.9-1.3 
 
0.99 0.62 0.77 0.86 0.89 
Baseline characteristics of patients and histological of 28 cases of primary UM, obtained by enucleation. The 
gene expression values of the indicated genes were determined by the Illumina array.  
Tumor size (Largest Basal Diameter and Prominence) has been an important prognostic factor for a long time. 
LBD = Largest Basal Diameter; HR = hazard ratio (Univariate cox regression). 
Wilcoxon rank sum test (Mann-Whitney U) was used for comparing two categories, and the Kruskal Wallis Test 
was used for comparing more than two categories. P-values for associations with numerical data were 




S5 Table. qPCR confirmation of the correlations found with the Illumina data, between expression values of HLA 
regulator genes and TAP1/TAP2, with HLA genes.  
  HLA-A HLA-B B2M HLA-DR HLA-DQ 
HLA transcriptional 
regulators r p r p r p r p r p 
CIITA .437 0.02 .626 <0.001 .461 0.02 .615 <0.001 .430 0.02 
IRF1 .527 0.001 .440 0.02 .591 0.001 .819 <0.001 .601 0.001 
NLRC5 .331 0.09 .177 0.37 .363 0.06 .544 0.003 .539 0.003 
        
 HLA-A HLA-B B2M     
Peptide loading machinery r p r p r p     
TAP1 .824 <0.001 .744 <0.001 .878 <0.001     
TAP2 .537 0.003 .446 0.02 .536 0.003     
Underlined values confirmed the IIllumina-array results. r = two-tailed Spearman correlation coefficient. p = p-value. 
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S6 Table. Changes in mean expression of gene expression levels for markers identifying infiltrating cells, HLA 












CD3D 6.39 5.05 1.35 1.12 0.22 < 0.001 
CD3E 5.84 4.57 1.27 1.07 0.15 < 0.001 
CD4 7.14 5.90 1.24 0.75 1.09 < 0.001 
CD8A 7.52 6.61 0.91 0.84 0.16 0.001 
CD8B 5.30 5.17 0.13 0.26 0.11 0.34 
CD68 10.62 9.22 1.39 0.60 1.05 < 0.001 
CD163 6.08 4.60 1.48 0.75 0.14 < 0.001 
HLA-A 11.54 10.54 1.0 0.59 1.15 0.005 
HLA-B 12.44 10.45 1.99 0.77 1.76 < 0.001 
B2M 10.98 9.68 1.30 0.72 0.92 0.004 
HLA-DRA 10.44 4.94 5.50 1.45 0.15 < 0.001 
HLA-DQA1 7.25 4.18 3.07 2.09 0.19 < 0.001 
HLA-DQA2 5.41 4.82 0.59 0.41 0.23 0.002 
IRF1 7.61 6.38 1.23 0.87 0.23 < 0.001 
IRF2 9.21 8.85 0.36 0.37 0.38 0.046 
IRF8 7.09 5.43 1.66 0.84 0.17 < 0.001 
CIITA 7.46 6.24 1.22 0.77 0.22 < 0.001 
NLRC5 7.80 6.89 0.90 0.67 0.36 0.002 
PDIA3 7.02 7.03 -0.01 0.25 0.22 0.93 
TAP1 10.13 8.76 1.36 1.04 0.99 0.005 
TAP2 8.88 8.13 0.75 0.74 0.52 0.02 
Tapasin 10.30 9.58 0.72 0.49 0.56 0.004 
Calreticulin 10.78 10.83 -0.05 0.16 0.17 0.54 
IFNG 4.11 3.85 0.26 0.29 0.11 0.005 
CCL2 7.87 5.93 1.94 1.33 0.81 < 0.001 
TGFB1 7.84 6.91 0.92 0.54 0.63 < 0.001 
TGFB2 6.96 6.77 0.19 0.78 1.41 0.14 
TGFB3 7.04 6.55 0.49 0.77 0.41 0.08 
TNF 5.79 5.71 0.08 0.35 0.17 0.40 
The gene-expression was determined with the Affymetrix array in 12 primary human uveal 
melanoma/metastases and their corresponding xenograft in a mouse. 






 169 Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes 
References 
1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. 
Ophthalmology 2011 Sep; 118(9):1881–5. doi: 10.1016/j.ophtha.2011.01.040 PMID: 21704381 
2.   Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest 
Ophthalmol Vis Sci 2003 Nov; 44(11):4651–9. PMID: 14578381 
3. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two 
molecular classes and predicts metastatic death. Cancer Res 2004 Oct 15; 64(20):7205–9. doi: 
10.1158/0008-5472.CAN-04-1750 PMID: 15492234 
4. Maat W, Ly LV, Jordanova ES, De Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ. Monosomy of 
chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol 
Vis Sci 2008 Feb; 49(2):505–10. doi: 10.1167/iovs.07-0786 PMID: 18234992 
5. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: 
correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003 Mar; 44 
(3):1008–11. PMID: 12601021 
6. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic 
abnormalities with the outcome of patients with uveal melanoma. Cancer 1998 Jul 15; 83(2):354–9. 
PMID:9669819 
7. Harbour JW. Molecular prognostic testing and individualized patient care in uveal melanoma. Am J 
Ophthalmol 2009 Dec; 148(6):823–9. doi: 10.1016/j.ajo.2009.07.004 PMID: 19800609 
8.   Coupland SE, Lake SL, Zeschnigk M, Damato BE. Molecular pathology of uveal melanoma. Eye (Lond) 
2013 Feb; 27(2):230–42. 
9. van Beek JG, Koopmans AE, Vaarwater J, de Rooi JJ, Paridaens D, Naus NC, et al. The prognostic value of 
extraocular extension in relation to monosomy 3 and gain of chromosome 8q in uveal melanoma. Invest 
Ophthalmol Vis Sci 2014; 55(3):1284–91. doi: 10.1167/iovs.13-13670 PMID: 24508790 
10.  Versluis M, de Lange MJ, van Pelt SI, Ruivenkamp CA, Kroes WG, Cao J, et al. Digital PCR validates 8q 
dosage as prognostic tool in uveal melanoma. PLoS One 2015; 10(3):e0116371. doi: 
10.1371/journal.pone.0116371 PMID: 25764247 
11.  Niederkorn JY, Wang S. Immunology of intraocular tumors. Ocul Immunol Inflamm 2005 Feb; 13 
(1):105–10. PMID: 15835077 
12.  Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH, Jager MJ. Different subsets of tumor-infiltrating 
lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol 
Vis Sci 2012 Aug; 53(9):5370–8. doi: 10.1167/iovs.11-9280 PMID: 22743317 
13.  Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh 
hallmark of cancer: links to genetic instability. Carcinogenesis 2009 Jul; 30(7):1073–81. doi: 10.1093/ 
carcin/bgp127 PMID: 19468060 
14.  Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, et al. Association of HLA class I 
and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci 2001 Sep; 
42(10):2153–6. PMID: 11527924 
15.  Jager MJ, Hurks HM, Levitskaya J, Kiessling R. HLA expression in uveal melanoma: there is no rule 
without some exception. Hum Immunol 2002 Jun; 63(6):444–51. PMID: 12039519 
 170 Chapter 6 
16.  Blom DJ, Schurmans LR, de Waard-Siebinga I, De Wolff-Rouendaal D, Keunen JE, Jager MJ. HLA 
expression in a primary uveal melanoma, its cell line, and four of its metastases. Br J Ophthalmol 1997 
Nov; 81(11):989–93. PMID: 9505825 
17.  Ma D, Niederkorn JY. Transforming growth factor-beta down-regulates major histocompatibility complex 
class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-
mediated cytolysis. Immunology 1995 Oct; 86(2):263–9. PMID: 7490128 
18.  Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I 
expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci 1997 Aug; 38 
(9):1865–72. PMID: 9286277 
19. Mine KL, Shulzhenko N, Yambartsev A, Rochman M, Sanson GF, Lando M, et al. Gene network 
reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer. Nat Commun 
2013; 4:1806. doi: 10.1038/ncomms2693 PMID: 23651994 
20.  Aure MR, Steinfeld I, Baumbusch LO, Liestol K, Lipson D, Nyberg S, et al. Identifying in-trans process 
associated genes in breast cancer by integrated analysis of copy number and expression data. PLoS One 
2013; 8(1):e53014. doi: 10.1371/journal.pone.0053014 PMID: 23382830 
21. Hurks HM, Metzelaar-Blok JA, Mulder A, Claas FH, Jager MJ. High frequency of allele-specific 
downregulation of HLA class I expression in uveal melanoma cell lines. Int J Cancer 2000 Mar 1; 
85(5):697– 702. PMID: 10699951 
22.  Metzelaar-Blok JA, Jager MJ, Moghaddam PH, van der Slik AR, Giphart MJ. Frequent loss of hetero- 
zygosity on chromosome 6p in uveal melanoma. Hum Immunol 1999 Oct; 60(10):962–9. PMID: 
10566596 
23.  Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, et al. NLR family member NLRC5 is a transcriptional 
regulator of MHC class I genes. Proc Natl Acad Sci USA 2010 Aug 3; 107(31):13794–9. doi: 10. 
1073/pnas.1008684107 PMID: 20639463 
24.  Chang CH, Guerder S, Hong SC, van EW, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) 
show tissue-specific impairment of MHC class II expression. Immunity 1996 Feb; 4(2):167–78. PMID: 
8624807 
25.  Gobin SJ, Peijnenburg A, Keijsers V, van den Elsen PJ. Site alpha is crucial for two routes of IFN gamma-
induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. 
Immunity 1997 May; 6(5):601–11. PMID: 9175838 
26.  Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune 
responses. Nat Rev Immunol 2012 Dec; 12(12):813–20. doi: 10.1038/nri3339 PMID: 23175229 
27.  Holling TM, Bergevoet MW, Wilson L, van Eggermond MC, Schooten E, Steenbergen RD, et al. A role for 
EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol 2007 Oct 
15; 179(8):5317–25. PMID: 17911618 
28.  de Waard-Siebinga I, Creyghton WM, Kool J, Jager MJ. Effects of interferon alfa and gamma on 
human uveal melanoma cells in vitro. Br J Ophthalmol 1995 Sep; 79(9):847–55. PMID: 7488605 
29.  McMichael AJ. Lymphocytes. 1. Function. Genetic restrictions in the immune response. J Clin Pathol 
Suppl (R Coll Pathol) 1979; 13:30–8. 
30.  van Essen TH, Bronkhorst IH, Maat W, Verduyn W, Roelen DL, Luyten GP, et al. A comparison of HLA 
genotype with inflammation in uveal melanoma. Invest Ophthalmol Vis Sci 2012 May; 53(6):2640–6. doi: 
10.1167/iovs.11-8901 PMID: 22447860 
 171 Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes 
31.  van den Elsen PJ. Expression regulation of major histocompatibility complex class I and class II encoding 
genes. Front Immunol 2011; 2:48. doi: 10.3389/fimmu.2011.00048 PMID: 22566838 
32.  McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P. Low HLA-C expression at cell surfaces 
correlates with increased turnover of heavy chain mRNA. J Exp Med 1995 Jun 1; 181(6):2085–95. 
PMID: 7760000 
33.  Bunce M, Welsh KI. Rapid DNA typing for HLA-C using sequence-specific primers (PCR-SSP): identification 
of serological and non-serologically defined HLA-C alleles including several new alleles. Tissue Antigens 
1994 Jan; 43(1):7–17. PMID: 7912861 
34.  Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization 
array data repository. Nucleic Acids Res 2002 Jan 1; 30(1):207–10. PMID: 11752295 
35.  El Filali M, Homminga I, Maat W, van der Velden PA, Jager MJ. Triamcinolone acetonide and anecortave 
acetate do not stimulate uveal melanoma cell growth. Mol Vis 2008; 14:1752–9. PMID: 18836566 
36.  Goossens K, Van Poucke M, Van Soom A, Vandesompele J, Van Zeveren A, Peelman LJ. Selection of 
reference genes for quantitative real-time PCR in bovine preimplantation embryos. BMC Dev Biol 2005; 
5:27. doi: 10.1186/1471-213X-5-27 PMID: 16324220 
37.  Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of 
real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome 
Biol 2002 Jun 18; 3(7):RESEARCH0034. PMID: 12184808 
38.  Seitz C, Uchanska-Ziegler B, Zank A, Ziegler A. The monoclonal antibody HCA2 recognises a broadly shared 
epitope on selected classical as well as several non-classical HLA class I molecules. Mol Immunol 1998 
Sep; 35(13):819–27. PMID: 9839550 
39.  Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains 
permit biochemical characterization of certain HLA-C locus products. J Immunol 1986 Oct 1; 
137(7):2299–306. PMID: 3760563 
40.  Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP, et al. Detection of M2-macrophages 
in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 2011 Feb; 52(2):643– 50. doi: 
10.1167/iovs.10-5979 PMID: 20811059 
41.  Nemati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and 
characterization of a panel of human uveal melanoma xenografts derived from primary and/or 
metastatic tumors. Clin Cancer Res 2010 Apr 15; 16(8):2352–62. doi: 10.1158/1078-0432.CCR-09-3066 
PMID: 20371695 
42.  Laurent C, Gentien D, Piperno-Neumann S, Nemati F, Nicolas A, Tesson B, et al. Patient-derived 
xenografts recapitulate molecular features of human uveal melanomas. Mol Oncol 2013 Jun; 7 
(3):625–36. doi: 10.1016/j.molonc.2013.02.004 PMID: 23478236 
43.  Bengtsson H, Simpson K, Bullard J, Hansen K. aroma.affymetrix: A generic framework in R for analyzing 
small to very large Affymetrix data sets in bounded memory. Tech Report #745, Department of Statistics, 
University of California, Berkeley 2012 Feb. 
44.  Bengtsson H, Irizarry R, Carvalho B, Speed TP. Estimation and assessment of raw copy numbers at the 
single locus level. Bioinformatics 2008 Mar 15; 24(6):759–67. doi: 10.1093/bioinformatics/btn016 
PMID: 18204055 
 172 Chapter 6 
45.  Bengtsson H, Wirapati P, Speed TP. A single-array preprocessing method for estimating full-resolution raw 
copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 
2009 Sep 1; 25(17):2149–56. doi: 10.1093/bioinformatics/btp371 PMID: 19535535 
46.  Daniels VG, Wheater PR, Burkitt HG. Functional histology: A text and colour atlas. Edinburgh: Churchill 
Livingstone; 1979. 
47.  Seliger B. Different regulation of MHC class I antigen processing components in human tumors. J 
Immunotoxicol 2008 Oct; 5(4):361–7. doi: 10.1080/15476910802482870 PMID: 19404870 
48.  Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in 
metastasizing uveal melanomas. Science 2010 Dec 3; 330(6009):1410–3. doi: 10.1126/science. 1194472 
PMID: 21051595 
49.  Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone 
H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010 May 13; 
465(7295):243–7. doi: 10.1038/nature08966 PMID: 20436459 
50.  Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer 2013 Mar; 
13(3):153–9. PMID: 23550303 
51.  LaFave LM, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to 
EZH2-dependent transformation. Nat Med 2015 Nov; 21(11):1344–9. doi: 10.1038/nm.3947 PMID: 
26437366 
52.  van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, et al. Prognostic 
parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol 2014 Dec; 
98(12):1738–43. doi: 10.1136/bjophthalmol-2014-305047 PMID: 25147369 
53.  Kilic E, van GW, Lodder E, Beverloo HB, van Til ME, Mooy CM, et al. Clinical and cytogenetic analyses in 
uveal melanoma. Invest Ophthalmol Vis Sci 2006 Sep; 47(9):3703–7. doi: 10.1167/iovs.06-0101 PMID: 
16936076 
54. Jehs T, Faber C, Juel HB, Bronkhorst IH, Jager MJ, Nissen MH. Inflammation-induced chemokine 
expression in uveal melanoma cell lines stimulates monocyte chemotaxis. Invest Ophthalmol Vis Sci 
2014 Aug; 55(8):5169–75. doi: 10.1167/iovs.14-14394 PMID: 25074768 
55.  Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, Larsson O, et al. Intratumoral 
forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal 
melanoma. Cancer 2010 May 1; 116(9):2224–33. doi: 10.1002/cncr.24999 PMID: 20209608 
56.   Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110delta breaks 
regulatory T-cell-mediated immune tolerance to cancer. Nature 2014 Jun 19; 509(7505):407–11. 
57.  Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing 
apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz) 2006 Sep; 54(5):323–33. 
58.  Cavallo F, De GC, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol 
Immunother 2011 Mar; 60(3):319–26. doi: 10.1007/s00262-010-0968-0 PMID: 21267721 
59.  Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J 










Prognostic parameters in uveal melanoma and their association 
with BAP1 expression 
 
T. Huibertus van Essen, Sake I. van Pelt, Mieke Versluis, Inge H.G. Bronkhorst, Sjoerd G. van 
Duinen, Marina Marinkovic, Wilma G.M. Kroes, Claudia A.L. Ruivenkamp, Shruti Shukla, 
Annelies de Klein, Emine Kiliç, J. William Harbour, Gregorius P.M. Luyten, Pieter A. van der 
Velden, Rob M. Verdijk, Martine J. Jager 
 





 176 Chapter 7 
Abstract 
 
Aim: To determine whether BAP1 gene and protein expression associates with different prognostic 
parameters in uveal melanoma and whether BAP1 expression correctly identifies patients as being at 
risk for metastases, following enucleation of the primary tumour.  
 
Methods: Thirty cases of uveal melanoma obtained by enucleation between 1999 and 2004 were 
analysed for a variety of prognostic markers, including histological characteristics, chromosome 
aberrations obtained by fluorescence in situ hybridisation (FISH) and single nucleotide polymorphism 
(SNP) analysis and gene expression profiling. These parameters were compared with BAP1 gene 
expression and BAP1 immunostaining.  
 
Results: The presence of monosomy of chromosome 3 as identified by the different chromosome 3 
tests showed significantly increased HRs (FISH on isolated nuclei cut-off 30%: HR 11.6, p=0.002; SNP 
analysis: HR 20.3, p=0.004) for death due to metastasis. The gene expression profile class 2, based on 
the 15-gene expression profile, similarly provided a significantly increased HR for a poor outcome (HR 
8.5, p=0.005). Lower BAP1 gene expression and negative BAP1 immunostaining (50% of 28 tumours 
were immunonegative) were both associated with these markers for prognostication: FISH cut-off 
30% monosomy 3 (BAP1 gene expression: p=0.037; BAP1 immunostaining: p=0.001), SNP-monosomy 
3 (BAP1 gene expression: p=0.008; BAP1 immunostaining: p=0.002) and class 2 profile (BAP1 gene 
expression: p<0.001; BAP1 immunostaining: p=0.001) and were themselves associated with an 
increased risk of death due to metastasis (BAP1 gene expression dichotomised: HR 8.7, p=0.006; 
BAP1 immunostaining: HR 4.0, p=0.010).  
 
Conclusions: Loss of BAP1 expression associated well with all of the methods currently used for 
prognostication and was itself predictive of death due to metastasis in uveal melanoma after 
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Introduction 
 
Uveal melanoma is a rare primary malignancy of the eye. Up to 50% of the patients may develop 
metastases, which are fatal in almost all cases.1 A correct risk assessment is necessary in order to 
effectively select patients for inclusion in clinical trials, now that more effective drugs are being 
developed. An analysis of 8033 uveal melanomas showed a 10-year metastasis rate of 12% for small 
tumours (up to 3 mm thick) and 49% for large tumours (>8 mm thick).2 It is therefore especially 
important to properly assess this risk in individuals with large tumours, such as those that need 
enucleation. Prognostic factors include histological factors such as cell type, involvement of the 
ciliary body, extrascleral extension and several chromosomal aberrations.1 The parameter size, ciliary 
body involvement and extrascleral extension are often combined into one parameter used in the 
TNM classification, which provides a better prognostic value than any of these parameters 
individually.3 Different techniques such as fluorescence in situ hybridisation (FISH) on tumour 
sections or isolated nuclei, or chromosome analysis techniques can be used to assess the tumour’s 
chromosome status.4–6 originally, loss of one chromosome 3 was identified as an important marker of 
poor prognosis, and this has been substantiated in many studies. However, later studies have also 
identified the importance of other chromosomes: gain of chromosome 8q is also correlated with 
death due to metastases,5–14 while an extra chromosome 6p is associated with a better survival.8,10, 15–
18 In separate studies, gene expression profiling has also been identified as a reliable method for 
prognostication.19, 20 
The pathophysiology of the importance of chromosome 3 loss was demonstrated by Harbour et al, 
who observed that loss of one copy of chromosome 3 together with inactivating mutations in the 
metastasis-suppressor gene encoding for BRCA1-asssociated protein 1 (BAP1) on the remaining copy 
of chromosome 3 was associated with the development of metastases. BAP1 is a deubiquitinating 
enzyme that is a member of the polycomb group proteins of transcriptional repressors and exhibits 
tumour suppressive activity.21–23 Inactivation of BAP1 at the chromosome level may be the driving 
force for the development of metastases, and BAP1 levels may therefore influence survival.7, 24–26 
For early detection of metastases and for studies on adjuvant treatment, it is important to know 
which techniques accurately predict the patient’s prognosis. As loss of chromosome 3 is an essential 
step in the inactivation of BAP1,27 we decided to compare BAP1 gene and protein expression in 30 
cases of enucleated uveal melanoma of at least 8-year follow-up, with the results of a variety of 
techniques assessing chromosome aberrations, and with gene expression profiling based on the 15-
gene classification assay described by Onken et al.20, 24, 28 
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Materials and Methods 
 
Study population 
Fresh-frozen material and formalin-fixed, paraffin-embedded specimens were obtained from the 30 
uveal melanoma of which enough frozen material was left and good quality DNA was available. All 30 
uveal melanomas had been enucleated at the Leiden University Medical Center (LUMC), Leiden, The 
Netherlands, between 1999 and 2004. Following enucleation, fresh tumour material was obtained 
immediately after the bulbus had been opened. Survival data and information on cause of death 
were obtained from the patient’s charts and from the Dutch National Registry, and updated in 
November 2013. Each tumour sample was processed for conventional histopathological evaluation, 
including cell-type assessment according to the modified Callender classification at that time.29 The 
collection of material for research had been agreed upon by the Medical Ethics Committee of the 
LUMC and the research protocol adhered to Dutch law and the current version of the tenets of the 
Declaration of Helsinki (World Medical Association of Declaration 1964; ethical principles for medical 
research involving human subjects). 
 
Chromosome aberrations and gene expression 
Three different techniques were applied to determine the presence of aberrations of chromosomes 3 
and 8: FISH on isolated nuclei (for chromosome 3) and single nucleotide polymorphism (SNP) 
analysis. FISH analysis on isolated nuclei was performed as described before.30, 31 
DNA and RNA were isolated from fresh-frozen tissue. DNA for SNP analysis was extracted with the 
QIAmp DNA Mini kit and RNA for gene expression profiling with the RNeasy mini Kit (both from 
Qiagen, Venlo, the Netherlands). SNP analysis was performed with the Affymetrix 250K_NSP 
microarray chip (Affymetrix, Santa Clara, California, USA) on all 30 uveal melanomas. Gene 
expression analysis on BAP1 was carried out on RNA of 28 tumours using the Illumina HT-12v4 chip 
(Illumina, San Diego, California, USA). RNA obtained from frozen material from all 30 uveal 
melanomas was tested in the 15-gene classification assay as described by Onken et al.28 and results 
sent to the Department of Ophthalmology and Visual Sciences of Washington University School of 
Medicine (St. Louis, Missouri, USA) for class assignment. 
 
BAP1 immunohistochemistry 
Immunohistochemical staining was performed for 28 patients from whom enough tumour material 
was available using the Ventana Benchmark ULTRA fully automated staining system (Ventana 
Medical Systems Inc, Tucson, Arizona, USA) with an alkaline phosphatase red detection kit.32 In short, 
sections were deparaffinised and then heated using Heat-induced Epitope Retrieval for 64 min at 
97C°. The sections were then incubated for 32 min at 37C° with the primary BAP1 antibody (sc-
28383, concentration 1:50, Santa Cruz Biotechnology, Dallas, Texas, USA). Target amplification was 
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performed and then followed by incubation with haematoxylin II counterstain for 8 min. An 
additional counterstain was performed with blueing reagent (Ventana Medical Systems Inc.). 
Liver, tonsil, breast and surrounding non-malignant tissue, as well as intratumoral vessels and 
inflammatory cells, were used as positive controls. As negative control sections without antibody 
were used.32 Tumours were scored either negative or positive for the BAP1 nuclear staining. 
 
Statistical analysis 
For data analysis, we used the statistical programming language R V.3.0.1 (R: A Language and 
Environment for Statistical Computing, R Core Team, R foundation for Statistical Computing, Vienna, 
Austria, 2014, http://www.R-project.org) supplemented with specialised packages for SNP and RNA 
analysis. The main package used for SNP analysis was aroma.affymetrix,33–35 supported by ‘DNAcopy’ 
(Venkatraman E. Seshan and Adam Olshen, DNAcopy: DNA copy number data analysis. R package 
V.1.34.0), ‘sfit’ (Henrik Bengtsson and Pratyaksha Wirapati (2013), sfit: Multidimensional simplex 
fitting. R package V.0.3.0/r185, http://R-Forge.R-project.org/projects/ matrixstats/) and ‘R.utils’ 
(Henrik Bengtsson (2014), R.utils: Various programming utilities, R package V.1.29.8, http:// CRAN.R-
project.org/package=R.utils). As reference set, we used the data of 84 healthy controls obtained with 
the same Affymetrix 250K Nsp chip (Affymetrix, Santa Clara, California, USA) by the Department of 
Human Genetics at our centre. The ‘Aroma.Affymetrix’ package made it possible to use these SNP 
microarrays to determine copy number values.33–35 The packages used for RNA microarray analysis 
were ‘limma’ V.3.16.836 and the specific packages for Illumina microarrays: ‘lumi’ V.2.12.0,37–40 
‘annotate’ (R. Gentleman, annotate: Annotation for microarrays, R package V.1.38.0), and the 
database package ‘illuminaHumanv4.db’ (Mark Dunning, Andy Lynch and Matthew Eldridge, 
illuminaHumanv4.db: Illumina HumanHT12v4 annotation data (chip illuminaHumanv4), R package 
V.1.18.0). 
Mann–Whitney U test for non-parametric analysis was used to assess differences in the amount of 
BAP1 gene expression, and χ2 tests for comparing the prognostic parameters with the BAP1 staining 
on immunohistochemistry (IHC). Univariate Cox regression was applied with events determined as 
‘death due to UM’ and right censoring. Cases of which the cause of death was unknown were 
censored as well. To calculate the respective HRs of the different parameters, the BAP1 gene 
expression was dichotomised at the median to create two equal groups. All analyses were performed 





We studied a group of 30 uveal melanoma patients, consisting of 13 men and 17 women with an 
average age at the time of enucleation of 61.7 years (range 28–84 years; median 66.5 years) and a 
mean follow-up of 77.5 months (range 14–155 months). Of these patients, 14 had died of uveal 
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melanoma metastases (mean survival 36.7 months; range 14–96 months) and 3 of unknown causes 
(mean survival 85.0 months; range 63–126 months), while no patient has been lost to follow-up. The 
mean largest basal tumour diameter was 13.7 mm (range 8–18 mm; median 13.5 mm), with an 
average prominence of 7.3 mm (range 2–12 mm; median 7.0 mm). The pathological TNM stages 
showed stage I in 4, stage IIA in 5, stage IIB in 10, stage IIIA in 9 and stage IIIB in 2 cases.41 The ciliary 
body was involved in 13 cases. The histological cell type was spindle in 11, mixed in 14 and 
epithelioid in 5 cases. Immunohistochemical staining for BAP1 (figure 1) was positive in 14 of the 28 
patients who could be tested. BAP1 staining was either present on more than 95% of the tumour 
cells or almost completely absent. An overview of all variables per patient is available (see online 
supplementary table S1). 
 
 
Figure 1. Examples of a BAP1-immunopositive (A) and a BAP1-immunonegative (B) tumour. 
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Table 1. Comparison of different prognostic parameters with survival in 30 uveal melanoma patients 
 
 
Univariate analysis – unknown cases attributed 
to death due to other causes 
 
 
 95% confidence 
interval 
  
Parameters n HR Lower Upper  p-value 
       
Standard clinical/histological parameters       
Gender       
  Male 17 - - -  - 
  Female 13 1.3 0.5 3.7  0.63 
Ciliary Body involvement       
  No 17 - - -  - 
  Yes 13 6.3 1.9 21.0  0.002 
Stage group       
  Stage I & IIA 9 - - -  - 
  Stage IIB 10 5.0 0.6 45.0  0.14 
  Stage IIIA 9 16.9 2.1 138.8  0.009 
  Stage IIIB 2 5.8 0.4 92.6  0.22 
Age at enucleation (years; low to high; 
continuous) 
30 1.0 1.0 1.1  0.26 
Largest basal diameter (mm; low to high; 
continuous) 
30 1.4 1.1 1.7   0.008 
       
Chromosomal aberrations       
FISH on isolated nuclei, cut-off at 5%       
  Disomy chromosome 3 11 - - -  - 
  Monosomy chromosome 3 19 12.1 1.6 93.2  0.017 
FISH on isolated nuclei, cut-off at 30%       
  Disomy chromosome 3 15 - - -  - 
  Monosomy chromosome 3 15 11.6 2.5 52.5  0.002 
SNP on tumour DNA       
  Disomy chromosome 3 14 - - -  - 
  Monosomy chromosome 3 16 20.3 2.6 156.7  0.004 
  Disomy chromosome 8q  11 - - -  - 
  Gain chromosome 8q 19 11.7 1.5 89.7  0.018 
  Disomy chrom 3 + disomy chrom 8q  10 - - -  - 
  Monosomy chrom 3 + gain chrom 8q 15 8.9 2.0 40.4  0.004 
       
Gene expression       
15-gene expression assay class       
  Class 1 14 - - -  - 
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  Class 2 14 8.5 1.9 38.3  0.005 
BAP1 gene expression (dichotomized at 
median) 
      
  High 14 - - -  - 
  Low 14 8.7 1.9 39.7  0.006 
 BAP1 gene expression (high to low; 
continuous) 
28 
4.0 1.5 10.6  
0.006 
       
Immunohistochemistry        
Positive BAP1 immunostaining 14 - - -  - 
Negative BAP1 immunostaining 14 5.5 1.5 20.1  0.010 
An univariate Cox regression analysis was performed. 
FISH, fluorescence in situ hybridization; SNP, single nucleotide polymorphism. 
 
 
Figure 2. Kaplan–Meier (log-rank test) survival graphs for single nucleotide polymorphism data on chromosome 
3 status (A), BAP1 gene expression dichotomised at the median (B), and for BAP1 negative and positive staining 




FISH analysis of chromosome 3 on isolated nuclei with a cut-off value of 5% indicated 19 cases of 
monosomy of chromosome 3, while a cut-off value of 30% identified 15 cases. 
SNP analysis revealed 16 cases with monosomy of chromosome 3, and one case with a partial 
deletion from 3q28 till the end of the chromosome. With this technique, 15 out of the 16 monosomy 
3 tumours had a gain of the long arm of chromosome 8 (8q) compared with four of the disomy 3 
tumours. 
 
Gene expression profiling 
The 15-gene expression assay of Onken et al, performed on all 30 tumours, classified 14 of the 
tumours as class 1 (good prognosis) and 16 as class 2 ( poor prognosis) uveal melanoma. Associations 
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A univariate Cox regression analysis was performed to compare the impact of all clinical, histological, 
chromosomal and gene expression data on death due to metastases. All categorical variables fulfilled 
the proportional hazards assumption. All parameters, except gender and age at enucleation, were 
associated with increased risk of death due to metastasis, with the chromosomal aberration 
 
 
Figure 3. Median BAP1 gene expression compared with the immunohistochemistry of BAP1 and different 
parameters used for prognostication. (A, B), and a bar graph showing the distribution of BAP1 immunopositive 
tumours with regards to disomy and monosomy of chromosome 3 (C). 
p Values were calculated with Mann–Whitney U test and corrected for multiple comparisons (Benjamini–
Hochberg; n=7) for A and B, and with the χ2 test for C. GEP, gene expression profiling; D3, disomy of 
chromosome 3; M3, monosomy of chromosome 3; D8q, disomy of chromosome 8q. 
 
 
s analysed with SNP, and the stage groups having relatively wide CIs (table 1). When the cases for 
which the cause of death was unknown were attributed to death due to metastasis, the results were 
similar (see online supplementary table S2). Multivariate analysis of all parameters led to results 
containing one in the 95% CI, or having infinite as upper limit, or both (data not shown). 
Loss of chromosome 3 was associated with death due to metastasis (figure 2A). Dividing the tumors 
in two groups based on chromsome 3 and 8q (either both disomic or both altered: loss of 
chromosome 3 together 8q gain), as determined by SNP analysis, associated with the 15-gene 
expression classes of Harbour (χ2 test p<0.001; one cell, had an expected count less than 5). 
The Kaplan–Meier survival graphs showed a discriminative function for BAP1 gene expression and 
the BAP1 immunostainings with regards to death due to metastasis (figure 2B, C). 
Low BAP1 gene expression (RNA) was associated with lack of immunohistochemical staining of BAP1 
on uveal melanoma cells (p<0.001 for dichotomised data, χ2 test; p<0.001 for continuous data, 
independent t test). When the RNA expression values of BAP1 were compared with the 15-gene 
expression assay classes, and the different methods assessing chromosome 3 aberrations, significant 
associations were seen for all comparisons, with lower RNA values for the gene expression class and 
the aberrations that were associated with poor prognosis (figure 3A, B). Especially the strong 
association between the RNA values of BAP1 and the 15 gene expression profile is striking. 
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The BAP1 immunostaining corresponded to the expected Harbour gene expression class in 23 of the 
28 cases. Similar to the findings at the RNA level, loss of chromosome 3 as seen by the two different 




The different methods that identify monosomy of chromosome 3 as well as the gene expression-
based classifications had increased HRs for death due to metastasis. These parameters were all 
associated with lower RNA levels of BAP1 and negative immunohistochemical staining for BAP1, and 
moreover, these BAP1 expression levels themselves were predictive for death due to metastasis of 
uveal melanoma ( p=0.01). 
Harbour et al.27 identified an important role in the development of metastases in uveal melanomas 
for a specific gene on chromosome 3, that is, BAP1, and suggested that loss of one copy of 
chromosome 3 may unmask inactivating mutations in the metastasis-suppressor gene BAP1 on the 
remaining copy of chromosome 3. We were able to classify uveal melanoma easily into two groups 
using gene expression profiling (15-gene expression profile classification), as has already previously 
been shown by Tschentscher, Onken and van Gils.19, 20, 42 In our study, the loss of one copy of 
chromosome 3 together with gain of chromosome 8q was highly correlated to the 15 gene 
expression profile class 2, while we had only enough tumour material to perform a gene expression 
analysis in 28 of the 30 tumours and our number of samples was relatively small. 
Interestingly, one case was staged as stage IIA and still alive after 9 years’ follow-up, despite having a 
monosomy of chromosome 3 together with gain of chromosome 8q and being a class 2 tumour (15-
gene expression assay). In this case, the BAP1 immunostaining scored negative as well. 
In large tumours, strong positive associations have been described between the prognostically poor 
15-gene expression profile known as class 2 and the presence of epithelioid cells, the extracellular 
matrix pattern known as networks and largest basal tumour diameter, all of which associations have 
also been described to be related to monosomy of chromosome 3.19, 20, 43, 44 As we observed an 
almost perfect association between the presence of monosomy of chromosome 3 plus 8q gain and 
the 15 gene expression profile class 2, we hypothesised that both should associate with loss of BAP1. 
We indeed noted a significant association for lower BAP1 gene expression (dichotomised and 
continuous data) and negative BAP1 immunostaining, with the combined presence of monosomy of 
chromosome 3 and chromosome 8q gain, as well as with the 15 gene expression prolife class 2. This 
is identical to the results published by Harbour et al.27 
Our data show that BAP1 gene expression correlated with the findings of the BAP1 
immunohistochemistry. Previously Harbour et al.27 showed this for six tumour samples. The 
association between RNA and immunohistochemistry suggests that a cut-off value of the BAP1 gene 
expression, for example, measured with a quantitative PCR, could be made to predict loss of BAP1 
immunoreaction. Shah et al.45 and members of our group32 have shown that immunohistochemistry 
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for BAP1 protein expression might be an easy way to discriminate between long and short survival, 
and may even replace mutation analysis of BAP1 in uveal melanoma patients. In large uveal 
melanoma, loss of one copy of chromosome 3, together with gain of chromosome 8q, clearly leads to 
this specific gene expression profile known as class 2, which is associated with loss of BAP1 gene 
expression, and with metastases formation.20, 27 This loss of BAP1 plays an important role in 
developing malignant tumour behaviour,27 and it may also be involved in the development of an 
inflammatory phenotype, as this was previously found to be associated with monosomy of 
chromosome 3.46 Although Harbour’s group originally reported a strong association between the 
presence of the 15-gene expression profile class 2 and monosomy of chromosome 3, they stated in 
their most recent papers that monosomy 3 is not a good prognostic marker.47 This was based on the 
use of different tests on material obtained from enucleated uveal melanoma as well as on biopsies.47 
However, the small amount of material obtained from biopsies may not have been sufficient for the 
specific SNP assay that they used, or small tumours may not represent the same profile in all parts of 
the tumours. 
Now that several prognostication techniques have been developed that work accurately in the 
highest risk patients, that is, those that undergo enucleation, the next challenge is to determine the 
exact way how these inactivation mutations in BAP1 lead to metastasis formation. 
In summary, our results show that monosomy 3/8q gain and the class 2 gene expression profile are 
both highly associated with lower BAP1 gene expression and negative BAP1 immunostaining, and 
that both methods for assessing BAP1 levels are predictive for death due to metastasis in uveal 
melanoma after enucleation. This emphasises the importance of further research on the role of BAP1 
in the development of the inflammatory phenotype and the pathophysiology of the role of BAP1 in 
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Ocular Immunology 
The immunological characteristics of the eye are intriguing and characterized by immune-privilege 
and immune deviation. Because of its avascularity, the cornea has already a higher threshold before 
immune responses take place. Directly behind the cornea is the anterior chamber where immune 
responses are influenced by an active system of immunosuppression, known as ACAID (Anterior 
Chamber Associated Immune Deviation).1 This immunoregulatory system raises an additional 
threshold for any immune response. In this complex system, we aim to place the artificial cornea 
made out of fish collagen, which should ideally not elicit an immune response.  
 
Fish Scale-derived Collagen Matrix 
The Fish Scale-derived Collagen Matrix (FSCM) represents a new approach to replace human donor 
corneas.  We need an alternative to human donor corneas as there is a worldwide donor shortage, 
even in the developed world. This is tragic, as cornea transplantation is the most successful form of 
organ transplantation, largely attributable to the immune privilege that the cornea exhibits.2, 3  
The make-up of the FSCM is similar to the biosynthetic artificial cornea, used already in a phase one 
clinical study, with respect to being an acellular collagen scaffold.4  The FSCM differs by being of 
natural (fish) origin and not being artificially constructed: its natural origin should ideally lead to a 
cheaper fabrication process. The challenge is to keep the modification process after harvesting the 
scales as simple and straightforward as possible. This could give some difficulties as the FSCM differs 
from batch to batch and also individually, as every scale has different dimensions and is not uniform 
with regard to thickness. However, technical modifications may help to overcome this. 
The most well-known alternative to normal human donor cornea transplantation is the Boston 
Keratoprosthesis (Kpro),5 which is used in cases where regular cornea transplantation would not 
suffice. The Boston Kpro consists of a central optical cylinder, a titanium back plate and a locking ring, 
with a donor cornea in the middle. This Boston Kpro is a good solution for cases where cornea 
transplantations have failed, however, it does not reduce the shortage of human donor corneas, as it 
still needs a donor cornea sandwiched between the optical cylinder and the back plate. Alternatives 
to the donor cornea for the Boston Kpro are being investigated.6  The FSCM has the features needed 
to serve as an alternative for human donor corneas. This collagen scaffold has the same arrangement 
of collagen fibers, although a bit denser, and facilitates the regrowth of human corneal epithelial cells 
and adhesion of keratocytes (corneal fibroblasts) in vitro. The regrowth of corneal epithelial cells is 
comparable for human epithelial cell lines or primary cultured human corneal epithelial cells. The 
anterior surface of the initial FSCM is not smooth; it exhibits a micropattern that differs from location 
to location. Yet the growth of human corneal epithelial cells is not hampered by these different 
surfaces. The keratocytes adhere to the FSCM, which we proved by the positive staining for integrin-
α6 and –β1. No infiltration of keratocytes was observed during the relatively short follow-up periods 
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(maximal 2.5 months). The results were similar to those with  the biosynthetic artificial cornea used 
in a phase 1 clinical trial, where the first signs of keratocyte immigration were seen after 6 months at 
the skirts, anchoring it in place, and where signs of repopulation were seen in 7 out of 10 patients at 
12 months.4  
The FSMC is highly permeable for oxygen and glucose, at an even higher permeability rate than the 
human cornea.7, 8  This is important in order to maintain a vital epithelial layer. The technical aspects 
allow suturing of the FSCM into place into the recipient corneal bed. As with all ocular tissues, subtle 
handling is advised, as the FSCM can tear upon too brisk manipulation. This could prove itself a 
cumbersome threshold to overcome, as tearing during surgery is a serious problem, needing the 
FSCM to be replaced. The FSCM is a bit tougher than the human cornea, which provides advantages 
and disadvantages. One of the advantages is that the curvature of the FSCM will be maintained, 
however, its disadvantage is that a reasonable adequate curvature with regard to refraction should 
already be achieved during the production process. The smoothness of the FSCM’s rim depends on 
the cutting procedure; in case of irregularities at the edge, a softer FSCM is more forgiving then a 
brisk version.  
The FSCM facilitates a similar direct light transmission in the visible spectrum as the human cornea 
(90% versus 91%). This high rate of light transmission is not directly correlated with a good visual 
acuity, as for this the curvature and, to a lesser amount, the light scatter of the scaffold are 
important as well. The required curvature is individually based and furthermore largely influenced by 
sutures and in a lesser way by corneal swelling, which is also the case with human donor corneal 
transplants. The light scattering of the first versions of the FSCM with the pattern still on top was 
equal to early to moderate cataract with log(s) = 1.62. This does not necessarily influence visual 
acuity,9, 10  but could produce some haze and lead to decreased contrast vision. Unpublished data of 
experiments using the FSCM with the micro-pattern removed, revealed improved light scatter values.  
As far as we know, no forward light scatter values for the biosynthetic artificial cornea have been 
published. The optical properties of Boston Kpro have been extensively investigated, but we could 
not find a comparison with the human cornea with regard to forward light scatter.11  
Most importantly, our animal studies in which we implanted the FSCM in non-immunoprivileged 
locations show that the FSCM has an excellent biocompatibility, with similar immune responses as 
sham-surgery and no sensitization of the immune system upon subcutaneous implantation. When 
there is no specific immune response triggered when the FSCM is implanted subcutaneously, it is 
reasonable to expect that such an immune response is also absent in an avascular tissue such as the 
cornea.  
Upon intra-stromal introduction into the cornea of rabbits, the FSCM maintained its transparency, 
and elicited neither corneal melting, neovascularization nor any immune response, during the six 
weeks we left it in place. This confirms that the FSCM transmits enough oxygen and nutrients to keep 
the overlaying epithelium vital and that the FSCM is biocompatible with the cornea. Studies on the 
biosynthetic artificial cornea showed already that repopulation by epithelial cells is feasible.4   
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There are a few features of the FSCM that require some adjustment and further research.  We know 
that human corneal epithelial cells can repopulate the FSCM surface in vitro, but we need to confirm 
this in vivo.  Are we going to use the FSCM for anterior lamellar keratoplasty only, thus leaving the 
recipient’s corneal endothelium intact, or are we aiming for penetrating keratoplasty as well? Before 
we can make such decisions, we need to know first whether the FSCM and the overlaying epithelium 
remain stable without an endothelial layer on its posterior surface. Secondly, we need to know how 
strong the interaction is between the corneal fibroblast and the FSCM. Will the connection between 
the FSCM and the rest of the cornea be strong enough to compete with the insertion of a human 
donor cornea? 
Long term animal-studies are needed to determine the long term compatibility of the FSCM, 
especially with regard to the stability of the scaffold and its interaction with the cornea fibroblasts  
Currently, the research focusses on making the FSCM less brisk and to produce a smoother surface 
and on its use as an emergency patch at the time of corneal perforation. A clinical study to determine 
its applicability is ongoing. 
 
Uveal Melanoma 
While the ocular immune privilege allows acceptance of foreign tissue in the cornea, it also allows 
growth of intraocular tumors. We looked into the immunology of Uveal Melanoma (UM) because we 
want to control or cure this malignancy. The tumor is located in the ciliary body and choroid, which 
are richly vascularized, and lie outside the blood-retina-barrier. These tissues contain the rich 
networks of innate immune cells (bone marrow-derived resident macrophages and dendritic cells). 
These cells, together with the parenchymal cells, secrete immune mediators, that support immune-
privilege.12  Several studies show that the immune system is active at the tumor site, yet it is 
apparently not doing its job effectively in halting and destroying the tumor. We showed that higher 
HLA protein expression on the tumor surface is associated with shorter patient survival.13  14  It could 
be that certain HLA-alleles are predisposing for this, as we know for example that several 
autoimmune diseases have HLA-associations such as with HLA-B27, and there are specific regulators 
that influence the level of class I expression. However, our research revealed no association for a 
specific HLA-genotype predisposing to an increased HLA protein expression in uveal melanoma.  
We know that in most tumors, HLA expression is downregulated or skewed towards the non-classical 
HLA types.15  In contrast, in uveal melanoma, classical HLA expression is upregulated. What drives 
this increased HLA class I expression? Is this directly influenced by tumor genetics or indirectly by the 
immune infiltrate? Based on the analysis of data from 28 enucleated eyes with uveal melanoma, we 
found that there was no dosage effect of chromosome 6p, on which the genes encoding the HLA 
antigens are located. We confirmed the known association between a higher expression and 
monosomy of chromosome 3. The protein levels of the HLA Class I and II molecules were positively 
associated with their mRNA gene expression, which is to be expected. The genes encoding the 
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peptide-loading molecules had similarly raised levels. These peptide-loading molecules are needed 
and responsible for putting the peptides in the groove of the HLA molecules before they are 
presented on the cell’s outer surface. The HLA molecules are not functional without them. 
Altogether, this indicates that expression of the HLA antigens is not impaired.  
We confirmed that an increased amount of tumor-infiltrating immune cells was associated with 
increased levels of HLA on the tumor cell surface. This was as expected, based on previous 
research.16 . What is new in uveal melanoma is that we show that when the human immune cells are 
absent, the amount of HLA allele expression subsequently indeed decreases. We demonstrated this 
by analyzing xenografts of the human tumor in immunodeficient female SCID mice. This finding 
proves our earlier statement that the increased HLA levels are not directly influenced by the genetics 
of the tumor, but that the HLA expression level is under the influence of the immunological triggers 
in its direct environment. We can therefore assume that in uveal melanoma the HLA-system 
responds normally to the input of the immune system and is not under direct influence of the tumor. 
Knowing this, the next question to be answered will be whether the tumor will be attacked and 
removed by the lymphocytes when implanted in mice with a patent immune system, or whether the 
uveal melanoma will still be able to create an environment which renders the mouse’s immune 
system ineffective? 
 
Which factors of the immune response in uveal melanoma are responsible for triggering the 
increased HLA expression? It could very well be that the increased HLA expression in uveal melanoma 
is under influence of interferon-gamma (IFNγ), as the tumor-infiltrating lymphocytes and 
macrophages produce IFNγ which activates HLA transcriptional regulators. 17, 18  IFNγ is 
predominantly secreted by CD4+ T helper 1 cells (Th1), CD8+ cytotoxic T cells, and NK cells, and to a 
lower degree by the professional antigen-presenting cells (APCs) including macrophages, and lastly 
also by B-cells.  
We previously showed that IFNγ stimulation resulted in an increased expression of HLA Class I and 
Class II molecules in uveal melanoma cell lines.19, 20  Those studies were done on a limited number of 
available cell lines, yet demonstrated that in vitro the HLA regulation is not aberrant. The UM cell 
lines  during co-culture with IFNγ-secreting T cells, synthesize chemokines such as CXCL8-11, CCL2 
and CCL5, VEGF and ICAM1 that create a tumor-promoting environment by attracting monocytes, 
including M2 type macrophages. M2 macrophages are known to promote angiogenesis.21   
Normally, the presence of classical HLA-alleles together with infiltration of a tumor by immune cells 
should lead to the destruction of the tumor. In uveal melanoma, it does not. This could be due to an 
increase in PD-L1 levels in response to IFNγ exposure, which makes UM cells resistant to lysis by 
cytotoxic T-cells.22  Overall, it is clear that the tumor’s immune response is skewed towards 
angiogenesis and growth factors,23  instead of tumor cell lysis.   
A recent study treating metastatic uveal melanoma patients with an adoptive transfer of autologous 
tumor-infiltrating lymphocytes showed objective tumor regression in 35% of these patients. The 
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tumor infiltrating lymphocytes were selected based on tumor reactivity and subsequently expanded 
in cell culture, prior to their transfer.24  This study demonstrates that tumor infiltrating lymphocytes 
do exist in metastases of uveal melanoma and can be triggered to act against their autologous tumor 
during in vitro culture, which leads to our hypothesis that the HLA alleles in uveal melanoma mostly, 
but not only, present peptides that are not recognized as pathogenic  
Recently, Gezgin et al. showed that tumors with many infiltrating lymphocytes have a loss of BAP1 
expression. In this thesis, we show that monosomy of chromosome 3 and the gene-expression profile 
class 2, are associated with loss of BAP1: 25  both prognostic factors are associated with a lower BAP1 
gene expression and a negative BAP1 immunostaining. We also confirm that on its own, BAP1 gene-
expression and BAP1 immunostaining are predictive of death due to metastasis. This was recently 
again confirmed by the TCGA study (2017). Gezgin’s subsequent work shows that it is possible that 
BAP1 is an inflammatory regulator in uveal melanoma. It may be that BAP1 by itself promoted the 
secretion of regulators of a pro-angiogenesis environment, or that it promotes the influx of cytokine-
producing T cells or macrophages. 
Further research should be directed at finding peptides that are being presented as stimulators of 
anti-uveal melanoma T cells. Another option is to aimed at expanding possible therapies based at 
peptides that can be recognized such as PRAME, which has been demonstrated to be expressed in 
uveal melanoma.26, 27 Another research focus could be aimed at counteracting the skewing of the 
immune response towards angiogenesis and growth factors. 
 
Conclusion 
We used the corneal immunosuppressive environment to test the possibility of inserting a Fish Scale-
Derived Collagen Matrix in a corneal pocket, and the excellent results and lack of primary and 
secondary immune responses led to a clinical trial, which is currently underway.  
The immunosuppressive environment of the eye allows the growth of malignant melanocytes which 
leads to the formation of uveal melanoma. The association between increased numbers of 
macrophages and lymphocytes in uveal melanoma and an increased development of uveal 
melanoma metastases suggest an influence of pro-angiogenic macrophages, The relation between 
loss of BAP1 expression and a very bad prognosis and the influx of leukocytes into the primary tumor, 
suggests that BAP1 functions as a regulator of inflammation. Further research will focus on the role 
of BAP1 in the regulation of inflammation in the uveal melanoma microenvironment.   
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